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Over the past decades, transition-metal-catalyzed cross-coupling reactions have witnessed 
considerable growth and emerged as a powerful tool for the construction of carbon-carbon 
bonds. These reactions have found numerous applications in assembling structurally complex 
molecules ranging from medicines to materials. While the C(sp2)-C(sp2) cross-coupling 
reactions have seen a tremendous development, less effort has been devoted to the more 
challenging C(sp2)-C(sp3) couplings. 
The selectivity control in the palladium(0)-catalyzed cross-coupling of alkyl nucleophiles is 
an important topic of research in the Baudoin group. Both direct and migrative 
cross-couplings can be achieved by simply switching the ligand involved. 
Following the long-standing interest in this field, we firstly extended the migrative 
cross-coupling reactions to simple and easily available secondary alkyl bromides under 
Barbier conditions. Moreover, the terminal-selective functionalization of simple alkanes could 
be achieved when this reaction was coupled to a non-selective radical monobromination 
process. 
On the other hand, a series of azole-based bulky phosphine ligands was designed and applied 
to direct C(sp2)-C(sp3) Barbier-Negishi cross-coupling reactions, successfully preventing the 
β-hydride elimination process while favouring the direct reductive elimination. 
Finally, the ‘‘ligand-controlled selectivity’’ strategy was applied to the divergent synthesis of 
enantioenriched β-amino acid derivatives. 
Keywords: Negishi cross-couplings, palladium, C(sp2)-C(sp3) bond formation, 
ligand-controlled, secondary alkyl bromides, Barbier conditions, enantiodivergence, β-amino 
acids 
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dba Dibenzylidene acetone 
DCM Dichloromethane 
DFT Density functional theory 
DMAP 4-Dimethylaminopyridine 
DMF Dimethyl formamide 
DMSO Dimethyl sulfoxide 
d.r. Diastereoisomeric ratio 
ee Enantiomeric excess 
e.g. Exempli gratia 
Et Ethyl 
e.r. Enantiomeric ratio 
e.q.                     equivalent 
ESI                     Electron spray ionization 
FG                     Functional group 
GC-MS              Gas chromatography mass spectrometry 
h                         hours 
HPLC                High pressure liquid chromatography 
HR-MS             High resolution mass spectrometry 
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i-Pr                     iso-propyl 
t-Bu                    tert-butyl
IR                      Infrared spectroscopy 
L                       Ligand 
Me                    Methyl 
MeCN                Acetonitrile 
NBS                  N-bromosuccinimide 
n-BuLi               n-butyllithium 
s-BuLi               sec-butyllithium 
t-BuLi               tert-butyllithium 
NMR                 Nuclear magnetic resonance 
Ph                      Phenyl 
PEPPSI             Pyridine-enhanced precatalyst preparation, stabilization, and 
initiation 
RT                     Room temperature 
sat.                     Saturated
SM                    Starting material 
Nf                     Nonaflyl
NHCs               N-heterocyclic carbenes 
THF                  Tetrahydrofuran 
TLC                  Thin layer chromatography 
TMEDA               N,N-tetramethylethylenediamine 
Piv                    Pivaloyl
Pr                   Propyl 
Py                     Pyridine 
TBDPS                 tert-Butyldiphenylsilyl 
Tf                     Triflyl 
Pd0/L                  Palladium (0) bearing a ligand 
rac                     Racemate 
RuPhos                 2-Dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl 
UV                  Ultraviolet 
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1. Overview of metal-catalyzed cross-coupling reactions 
1.1 Discoveries and developments 
A coupling reaction is a general term for a variety of reactions where two hydrocarbon 
fragments are coupled with the aid of a metal catalyst. Historically, the first reported 
metal-catalyzed coupling reaction could date back to the 19th century, when Glaser discovered 
the homocoupling of aromatic acetylides in the presence of stoichiometric amounts of copper 
salts (Scheme 1.1a).1 Following the development of C(sp)-C(sp) homocoupling, this method 
was extended to C(sp2)-C(sp2) bond formation. In 1901, Ullmann described the dimerization 
of 2-bromonitrobenzene promoted by excess copper (Scheme 1.1b).2 Although harsh 
conditions were usually required for the early copper-mediated reactions, these discoveries 
paved the way for later developments.  
 
Scheme 1.1. Glaser and Ullmann couplings 
Over the past decades, metal-catalyzed cross-couplings, especially palladium-mediated 
transformations, have been developed rapidly and advances in recent years have greatly 
increased their scope and practicality. These findings revolutionized the way chemists 
construct molecules and provided new methods for previously impossible, but highly 
desirable carbon-carbon and carbon-heteroatom bond forming processes. Due to their great 
contribution to palladium-catalyzed cross-coupling reactions, Richard Heck, Ei-ichi Negishi 
and Akira Suzuki shared the Nobel Prize in chemistry in 2010.3 
Since then, these discoveries inspired chemists to develop a broad range of additional 
cross-coupling reactions, such as C-H activation and decarboxylative couplings.4 It is also 
noteworthy that a great deal of progress has been made on the development of asymmetric 
versions of cross-couplings.5 In addition, “green” cross-coupling reactions are another 
17 
 
interesting research field. This includes the use of catalysts based on cheap and abundant 
transition metals,6 as well as using water or ionic liquids as the reaction medium.7 Given their 
essential role in carbon-carbon/heteroatom bond formation processes, cross-coupling 
reactions continue to attract attention from both the academic and industrial communities. 
1.2 Applications in organic synthesis 
Due to their mild conditions associated with the reactions, together with their tolerance of a 
wide range of functional groups, cross-coupling reactions have had a great impact on 
synthetic organic chemistry and have found many applications in target-oriented synthesis. 
Among them, palladium-catalyzed cross-coupling reactions are the most prominent.8 
Quadrigemine C is representative of the higher-order members of the pyrrolidinoindoline 
alkaloid family.9 First described in 1987, quadrigemine C is reported to exhibit significant 
antibacterial and analgesic activities, and behave as a weak antagonist of the SRIF 
(somatostatin) receptor.10 Therefore, the total synthesis of such a molecule is highly 
interesting and desirable. In 2002, the Overman group described an elegant synthetic route to 
the enantioselective total synthesis of quadrigemine C 1-11, in which sequential tandem Stille 
couplings and catalytic asymmetric intramolecular Heck cyclizations were employed as the 
key steps (Scheme 1.2).11 
Scheme 1.2. Sequential tandem Stille couplings and asymmetric intramolecular Heck reactions in the 
enantioselective synthesis of (-)-quadrigemine C 
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An impressive example of application of Negishi couplings in total synthesis is the novel and 
general synthetic route to the β-carotenoids reported by the Negishi group. As shown in 
Scheme 1.3, these remarkable carbon-carbon bonds forming processes, each of which 
involved four different organometallic intermediates and three transmetallation steps 
(ZrAlZnPd), proceed well with remarkable overall efficiency and stereoselectivity, 
affording the target molecule 1-20 in more than 99% stereoisomeric purity.12 
 
Scheme 1.3. Application of Negishi coupling reaction in the total synthesis of β-carotene 
In addition, the impact of palladium-catalyzed coupling reactions has been witnessed beyond 
academic field, particularly in the pharmaceutical industry.13 One example is the synthesis of 
Crizotinib, a potent and selective Mesenchymal epithelial transition factor/Anaplastic 
lymphoma kinase (c-Met/ALK) inhibitor that is currently in phase III clinical trials. In 2011, 
Koning and co-workers from Pfizer reported a robust six-step process for the synthesis of 
Crizotinib, in which the highly selective Suzuki-Miyaura coupling could be conducted on a 50 
kg scale (Scheme 1.4).14 
Scheme 1.4. Application of the Suzuki-Miyaura coupling in industrial process 
2. Palladium-catalyzed Negishi cross-couplings 
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Negishi and co-workers originally studied the cross-coupling of organoaluminum reagents in 
1976 employing palladium and nickel catalysts.15 Later, they reported that organozinc 
compounds could be readily participated in Ni- or Pd-catalyzed cross-coupling reactions, 
providing a general and mild protocol for the preparation of unsymmetrical biaryls and 
diarylmethanes. It is noteworthy that the described reaction features high chemo- and 
regioselectivity as well as high cross-/homo-coupling ratios.16 Although organozincs are air- 
and moisture-sensitive, a fact that has hindered their use compared to other cross-coupling 
reactions, their fast transmetallation to palladium compared to boronic acids allows the 
investigators to achieve Negishi cross-couplings between a wide range of unsaturated halides 
and organozincs under very mild conditions (Scheme 1.5). In addition, the low toxicity and 
easy preparation of organozinc compounds, as well as the increasing number of commercially 
available zinc reagents have greatly promoted the development and application of Negishi 
cross-coupling reactions in numerous fields.17 
Palladium is the most often used transition-metal in Negishi cross-coupling reactions, but in 
some cases, palladium-based catalyst systems can also be replaced by alternative metals, such 
as Ni, Fe, Co, or Cu.17 Considering the length of the bibliographic part and the focus of this 
thesis, mainly palladium catalysis will be discussed here. 
 
Scheme 1.5. General scheme for Negishi couplings 
2.1 Palladium-catalyzed Negishi cross-couplings of alkylzinc reagents 
In general, transition-metal-catalyzed cross-coupling reactions undergo three consecutive 





Scheme 1.6. General catalytic cycle for palladium-catalyzed cross-coupling reactions 
Due to the presence of an empty low-lying p orbital of zinc, the alkylzinc reagents exhibit an 
excellent ability to undergo transmetalation. Therefore, palladium-catalyzed Negishi 
cross-coupling reactions of alkylzincs have demonstrated to be powerful tools in numerous 
areas of synthesis. 
However, the use of C(sp3) organozincs in Negishi cross-coupling reactions has suffered from 
several serious problems. Consequently, although the Negishi protocol has been extensively 
studied using various coupling partners, such as alkynyl, aryl, alkenyl, allyl, and benzylzinc 
reagents, the frequent use of more challenging alkylzinc reagents containing β-hydrogen(s) as 
coupling partners has only attracted attention and been investigated more recently.18 
2.2 Mechanistic studies on palladium-mediated Negishi cross-couplings 
In light of the importance of Negishi cross-coupling reactions in synthetic organic chemistry, 
the study of their mechanism has been the subject of extensive investigation. In 2010, 
Knochel and Mayr groups studied the influence of the structures of both aryl halides and 
arylzinc reagents on the rate of various steps.19 Competition experiments were conducted to 
determine these structure-reactivity relationships. The cross-couplings were found to be 
accelerated by electron acceptors on the aryl bromides and the accelerating effect decreases in 
the order para > meta > ortho. On the other hand, the presence of electron-acceptors on the 
arylzinc species diminished the reaction rate. Hammett correlations showed that substituents 
on the aryl bromides have a larger impact than the substituent variations on the arylzinc 
reagents (ρ = +2.5 VS. ρ = -0.98). 
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Espinet and co-workers reported a detailed study on the Negishi cross-coupling reaction of 
ArI (Ar = 2-CO2EtC6H4) and Et2Zn in the presence of two different palladium catalysts: 
conventional phosphine ligands (e.g. PPh3) and hydride phosphine-electron-withdrawing 
olefin (P-EWO) ligands.20 Their research provided useful insights into the two competitive 
pathways: reductive elimination giving rise to the cross-coupling product versus β-H 
elimination leading to the reduction product after subsequent reductive elimination (Scheme 
1.7). With P-EWO ligands, the β-H elimination from the palladium complex is slow 
compared to the fast reductive elimination, thus favouring the formation of the cross-coupling 
product. However, in the presence of traditional phosphine ligands, the formation of reduction 
product is always a big problem. 
 
Scheme 1.7. Cross-coupling VS. reduction 
Additionally, halide salts were reported to have a remarkable effect on Negishi cross-coupling 
reactions. In this regard, Organ and co-workers studied the charged zinc species that are 
formed upon addition of LiBr to n-BuZnBr in different solvents.21 They disclosed that less 
polar solvents, like THF, do not allow the formation of n-BuZnBr3
2- and the Schlenk 
equilibrium shifts toward n-Bu2Zn, which is not the active transmetallation species in Negishi 
cross-couplings (Scheme 1.8b). On the contrary, in a mixed solvent system (THF/DMI 2/1), 
the Schlenk equilibrium tends to form a highly charged organozinc species n-BuZnBr3
2- 
(Scheme 1.8a). Based on these studies, they proposed the following catalytic cycle as 
described in Scheme 1.9 for the alkyl–alkyl Negishi reaction. On the other hand, the Clyburne 
group developed a method to prepare and identify RZnX3
2- species, which allowed the 




Scheme 1.8. Schlenk equilibrium involved in Negishi cross-couplings 
 
Scheme 1.9. Proposed catalytic cycle for the alkyl–alkyl Negishi reaction 
However, a significantly different phenomenon was observed in the reaction system of 
arylzinc compounds.23 Diarylzinc reagents were found to have the ability of transmetallation 
in low dielectric solvent (such as THF) without the aid of salt, whereas ArZnX compounds 
behaved differently, requiring either a high dielectric solvent or a lower polarity solvent aided 
with enough salt. Moreover, unlike the alkylzinc systems for which higher-order zincates are 
needed to facilitate the transmetallation step, there is no evidence of a similar requirement in 
the cross-coupling of arylzinc reagents. 
3. Site-selectivity issues in palladium-catalyzed Negishi cross-couplings of 
secondary alkylzinc reagents 
The palladium-catalyzed Negishi cross-couplings involving secondary alkylzincs remain 
challenging. A major limitation arises from the competitive β-hydride elimination and 
migratory reinsertion that resultes in the formation of undesired isomers.18 A simplified 
mechanism for the reaction of an iso-propyl organozinc with an aryl halide is shown below 
(Scheme 1.10). The reaction is initiated by oxidative addition of a palladium(0) complex with 
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an aryl halide, which is then followed by transmetallation with a secondary alkylzinc, 
producing intermediate 1-26. At this stage, direct reductive elimination would afford the 
branched product 1-27 and regenerate the palladium(0) complex for the next catalytic cycle. 
Alternatively, the competitive β-H elimination can occur reversibly to form intermediate 1-28. 
It then undergoes a migratory insertion step to produce the linear palladium (II) complex 1-29, 
which can then reductively eliminate to give the isomerized product n-PrAr 1-30. 
 
Scheme 1.10. Mechanism for the palladium(0)-catalyzed Negishi cross coupling of iso-propylzinc halide with an 
aryl halide 
From the mechanism, it is clear that controlling the rate of direct reductive elimination 
relative to β-H elimination is an important factor to achieve a better site-selectivity. Previous 
studies have shown that the structure of ligands has a great effect on this competition. Over 
the last decades, various ligands and catalyst systems have been developed to supress the 
migration pathway and favour direct cross-couplings. In the meantime, the Baudoin group has 
a long-standing interest in migrative cross-couplings, which provide a new catalytic approach 
to functionalize unactivated C-H bonds at remote positions of alkyl chains.24 
3.1 Direct cross-couplings 
3.1.1 Development of phosphine ligands 
To address the issue of β-H elimination during the reaction pathway, studies from several 
groups demonstrated that the β-H elimination and migratory pathway can be limited by 
employing catalysts containing bulky phosphine ligands that increase the steric bulk around 
palladium, which can then favour the reductive elimination. 
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In 1972, Kumada/Tamao reported that nickel-diphosphine complexes could couple secondary 
alkyl Grignard reagents with a limited number of aryl halides.25 They discovered that the 
extent of isomerization strongly depends on the electronic nature of the phosphine ligand in 
the catalyst (Table 1.1). While dppe and dppp gave the direct coupling product in good yield 
and excellent selectivity (entry 1& entry 2), changing of diphosphine ligand to dmpe afforded 
mainly the migrated linear product (entry 3).  
Table 1.1. Ligand effect in nickel-catalyzed cross-coupling of secondary alkyl Grignard reagents with aryl 
halides 
 














84% 9 84 7 
 
Later, in 1984, [1,1 '-bis(diphenylphosphino)ferrocene] palladium(II) [PdCl2(dppf)] was 
found to be an active and selective catalyst for the cross-coupling of secondary and primary 
alkyl Grignard and alkylzinc reagents with organic halides (Scheme 1.11).26 
 
Scheme 1.11. Grignard and Negishi couplings of secondary alkyl organometallics catalyzed by PdCl2(dppf) 
Further studies showed that the selectivity and activity of the palladium complexes with 
bidentate phosphine ligands are strongly dependent upon the molecular framework lying 
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between the two diphenylphosphino groups in the ligand. As shown in Table 1.2, the values 
of the P-Pd-P and Cl-Pd-Cl angles in the complexes may well correlate with the activity and 
selectivity of the palladium complexes: the larger P-Pd-P and smaller Cl-Pd-Cl angles, the 
faster is the reductive elimination to form the direct cross-coupling product. 
Table 1.2. P-Pd-P and Cl-Pd-Cl angles in PdCl2L2 complexes and their activities in the cross-coupling 
 
  Angle, deg. Yield, % 
Entry PdCl2L2 P-Pd-P Cl-Pd-Cl 1-37a 1-37b 1-37c 1-38a 
1 PdCl2(dppf) 99.07 87.8 95 97 75 92 
2 PdCl2(dppp) 90.6 90.8 43 76 4 12 
3 PdCl2(dppe) 85.8 94.2 0-4 3 - 3 
 
Because of the important role of ligands in controlling the selectivity, different types of 
phosphine ligands were developed and applied to the coupling of secondary alkyl 
organometallics, such as the bulky monodentate phosphine ligands tri-tert-butylphosphine 
P(t-Bu)3
27 and cataCXium A nBuPAd2
28. In addition, an elegant work reported by the 
Buchwald group detailed the palladium-catalyzed Negishi coupling of secondary alkylzinc 
halides with aryl bromides, activated aryl chlorides and heteroaryl halides using bulky 
CPhos-type ligands. Under their optimal conditions, good to excellent ratios of direct to 





Scheme 1.12. C(sp2)-C(sp3) Negishi cross-couplings with CPhos-type ligands developed by the Buchwald group 
To have a better understanding of the unique activity and selectivity of palladium-based 
catalyst system featuring CPhos-type ligands, an air-stable oxidative addition complex 
[L·ArPdBr] (Ar = 4-cyanophenyl) 1-43 was prepared and studied (Scheme 1.13). First of all, 
catalytic amount (1 mol%) of complex 1-43 was engaged in the reaction of 
methyl-4-chlorobenzoate and iso-propylzinc bromide, giving the same ratio of direct and 
migrative products as when a palladacycle precatalyst featuring CPhos was used. They 
believe that this demonstrated the catalytic competence of 1-43 for the coupling of secondary 
alkylzinc halides. 
 
Scheme 1.13. Preparation of oxidative addition complex featuring CPhos 
The X-ray structure of 1-43 (Figure 1.1) showed a nearly square-planar Pd(II) center featuring 
k2 bound CPhos ligand through P atom and ipso-C moiety of the bottom aromatic ring 
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(ipso-C-Pd bond length = 2.478(3) Å). In addition, the solid-state structure of 1-43 indicates 
the monodentate nature of CPhos, since neither of the two dimethylamino substituents 
coordinates to the Pd(II) center. Further examination of complex 1-43 suggests that neither of 
the two dimethylamino groups lies in the plane of the bottom ring of CPhos. This probably 
discloses that the lone pair of the Me2N- group is not conjugated with the lower ring of CPhos 
and the two Me2N- group could probably act as electron-withdrawing substituents, thereby 
rendering the bottom ring of CPhos less electron-donating. Based on these results, they 
believed that the use of CPhos-type ligand in the coupling of secondary alkylzincs may 
facilitate the reductive elimination and that carefully balancing the electron-donating ability of 
P-bound substituents and the biaryl backbone is critical to obtain good selectivities. 
 
Figure 1.1. X-ray structure of 1-43 
3.1.2 Development of N-heterocyclic carbene ligands 
Besides phosphine ligands, the search for different cross-coupling catalyst systems turned 
chemists’ attention to the use of N-heterocyclic carbene (NHC) ligands.30 NHC ligands have 
shown many different interesting characters compared to phosphine ligands. The thermal 
stability of Pd-NHC bonds is relatively high. In addition, NHC ligands usually provide a 
longer catalyst lifetime and a consistent reactivity throughout the course of the transformation, 
since the strong binding of the electron-rich carbene to the metal center helps the palladium 
retain its ligand. 
Therefore, numerous monoligated palladium NHC complexes have been designed and applied 
to cross-coupling reactions (Scheme 1.14). In general, the bulkier the NHC catalysts, the 
higher is the catalytic activity.41 Of note, Pd-PEPPSI type complexes (PEPPSI is an acronym 
for pyridine-enhanced precatalyst preparation, stabilization, and initiation) developed by 
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Organ and co-workers showed comparable activity and selectivity and established them as 
successful alternatives to palladium phosphine complexes in cross-coupling reactions.30a, 30d 
 
 
Scheme 1.14. Selection of monoligated palladium NHC-complexes used in palladium-catalyzed cross-couplings 
Pd-PEPPSI-series complexes have found great applications in not only carbon-carbon bond 
formation, but also carbon-heteroatom bond formation. Particularly, some of these NHC 
ligands could suppress the β-hydride elimination process efficiently and afford the desired, 
direct coupling products in good to excellent selectivities (Scheme 1.15). DFT studies suggest 
that the relative energy barrier difference between reductive elimination and β-hydride 
elimination correlates very well with the observed selectivities. In addition, the effect 
imparted to the NHC substituents is primarily due to sterics.41b, 42 Therefore, bulky Pd-NHC 
catalysts, like Pd-PEPPSI-IPent39b, Pd-PEPPSI-IPentCl 39c and Pd-PEPPSI-IHepCl 39d were 
designed, showing great selectivity for the reactions of a wide range of secondary alkylzincs 




Scheme 1.15. Pd-PEPPSI catalyzed Negishi couplings of secondary alkylzincs 
3.2 Migrative cross-couplings developed in the Baudoin group 
3.2.1 Initial discovery and mechanistic understanding  
In 2010, the Baudoin group studied the Pd-catalyzed arylation of isobutyric esters.43 Initial 
attempts showed that ligands have a great effect on the selectivity for the α- or β-product 
(Table 1.3). Whereas the bulky phosphine ligands P(t-Bu)3 gave rise to the direct coupling 
product (entry 1), more flexible ligands afforded a completely reversed selectivity, generating 
β-arylated product 1-58a (entries 3-8). 
Table 1.3. Effect of the ligands on the Pd-catalyzed arylation of isobutyric esters 
 
Entry Ligand Conversion (%)a α/βa Yield (%)a 
1 P(t-Bu)3·HBF4 
 
100 85/15 55%, α 
2 PCy3·HBF4 6 n.d. <1 
3 PCy3·HBF4, 110 oC 100 <1/99 71%, β 
4 SPhos 100 3/97 >95%, β 
5 RuPhos 100 1/99 >95%, β 
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6 CyJohnPhos 100 1/99 >95%, β 
7 DavePhos 100 <1/99 >95%, β 
8 DavePhos, 28 oC 100 <1/99 >95%, β 
a Determined by GC-MS. 
 
However, only aryl halides with ortho-electron withdrawing substituents (1-58a, 1-58b VS. 
1-58c) or a heteroatom (O, S) at the adjacent position (1-58d) to the C-X bond gave a high 
selectivity for the β-products. A wide range of ester groups (1-58e to 1-58h) were well 
tolerated under the optimal conditions. Finally, the asymmetric version of this transformation 
was also investigated, albeit with moderate enantioselectivities in most cases (1-58i to 1-58l). 
 
Scheme 1.16. Scope and limitations of Pd-catalyzed arylation of isobutyric esters 
The unexpected β-arylation under the current catalytic conditions attracts our attention. To the 
best of our knowledge, only two examples of similar observations have been reported before. 
In 1996, Meijere group observed an unexpected palladium-catalyzed substitution on the 
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triquinanedione system (Scheme 1.17a).44 Since the oxidation of ketones and diketones to α, 
β-unsaturated compounds by palladium acetate is a known reaction, they assumed that α, 
β-unsaturated 1,3-diketone was formed as an intermediate, which was then followed by 
palladium reinsertion, generating the β-functionalized product. Another example was reported 
by the Hartwig group in 2002 (Scheme 1.17b).45 While studying the palladium-catalyzed 
arylation of α, α-disubstituted esters, a 2:1 mixture of α- and β-arylated products was obtained 
in the reaction of methyl isobutyrate with 2-bromothiophene. Since this phenomenon was 
only observed with bromothiophene, they proposed that the reductive elimination from 
electron-rich thiophenylpalladium enolate intermediate is slower compared to the analogous 
intermediates formed from aryl or other heteroaryl bromides. Due to the slower reductive 
elimination, the transformation of the hindered palladium enolate to a less hindered 
homoenolate occurred, which then afforded the β-arylated product after subsequent reductive 
elimination. 
 
Scheme 1.17. Overview of previously reported unexpected β-functionalization 
To gain further insight into the unexpected β-selectivity, our group conducted in-depth 
mechanistic studies in collaboration with the group of Prof. Eric Clot (University of 
Montpellier).46 DFT calculations were performed in order to give insights into the selectivity 
resulting from the presence of different ligands. It was found computationally that with PCy3, 
the reductive elimination leading to α-arylated product was disfavoured (∆G≠ = 23.5 kcal. 
mol-1 with 1-bromo-2-fluorobenzene) over the β-arylation pathway (∆G≠ = 19.8 kcal. mol-1). 
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Based on these studies, the mechanism described in Scheme 1.18 was proposed. The 
mechanistic cycle starts with oxidative addition between aryl bromide and catalytic palladium 
(0) species, forming palladium (II) species 1-59, which then undergoes ligand substitution to 
give intermediate 1-60. At this point, two possible pathways could occur depending on the 
catalytic system and also on the substrate. Direct reductive elimination affords the classical 
α-arylated product 1-57. In the meantime, with a suitable ligand, the palladium homoenolate 
intermediate 1-63 could be formed via a sequence of β-H elimination/bond 
rotation/reinsertion. Subsequent reductive elimination would result in the formation of 
β-product 1-58 and regeneration of the active palladium (0) species for the next catalytic 
cycle. 
 
Scheme 1.18. Mechanistic cycle for β–arylation of methyl isobutyrate 
3.2.2 Developments of migrative cross-couplings in other enolate systems 
In addition to isobutyrates, this migrative cross-coupling strategy was also extended to the 
long range C-H arylation of α-amino esters, which occurred selectively at the terminal 
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position of the alkyl chain thanks to a fine-tuning of the ligand structure, giving rise to a broad 
scope of synthetically useful (hetero)arylalanines and homologues (Scheme 1.19). 47 
 
Scheme 1.19. Migrative arylation of α-amino esters 
To further extend the scope of migrative cross-couplings, silyl ketene acetals (SKAs) were 
chosen as competent nucleophiles.48 SKAs are believed to be stable and isolable surrogates of 
ester enolates and they are less reactive than the corresponding lithium enolates. The 
β-arylation of SKAs furnished a milder protocol, thus allowing the possibility of synthesizing 
more functionalized compounds with sensitive groups. The synthetic value of this 
methodology was further demonstrated by the easy transformation of the products into 





Scheme 1.20. Migrative cross-couplings of silyl ketene acetals 
3.2.3 Developments of migrative cross-couplings in Negishi reactions 
β-hydride elimination is still a challenging issue in palladium-catalyzed C(sp2)-C(sp3) Negishi 
cross-couplings. As stated before, previous studies were mainly focused on suppressing this 
process. On the other hand, taking advantage of β-hydride elimination step and the migratory 
pathway to realize remote functionalization is less developed.24 
In 2010, while studying the diastereoselective arylation of substituted Boc-piperidines, 
Knochel and co-workers discovered that unexpected β-arylated products were obtained when 
2-methyl piperidine was used (Scheme 1.21a).49 They assumed that the reaction proceeds 
through β-hydride elimination and the Pd 1,2-migration/cross-coupling sequence seems to be 
affected by the nature and stoichiometry of the phosphine ligand, since no migration occurred 
in Coldham’s catalyst system (Pd(OAc)2/t-Bu3P with a ratio of 1:2) (Scheme 1.21b).
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Scheme 1.21. Studies on arylation of N-Boc-piperidines by Knochel and Coldham groups 
In line with previous efforts to develop migratory cross-couplings and the in-depth 
mechanistic analysis in this field, the Baudoin group developed an elegant work on 
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ligand-controlled selective arylation of α-zincated cyclic51 and acyclic N-Boc-amines52 
(Scheme 1.22), giving rise to a variety of synthetically useful β-arylated amines, such as the 
drug candidate preclamol (Scheme 1.23). The selectivity for α- VS. β-arylation was controlled 
by the ligand, with bulky and rigid phosphine ligands providing  normal α-arylated product, 
whereas more flexible N-phenylazole-based phosphine ligands induced majorly β-arylation. 
 
Scheme 1.22. Direct & migrative Negishi couplings of cyclic and acyclic N-Boc-amines 
 
Scheme 1.23. Formal synthesis of preclamol using migrative Negishi couplings 
4. Research aim and challenges 
Palladium-catalyzed C(sp2)-C(sp3) cross-couplings are particularly valuable tools in synthetic 
chemistry and hence a great deal of interest has emerged in this area. Although great progress 
has been made over the last decades, challenges still exist in this regard, e.g. preformation of 
organometallic species, site-selectivity due to β-H elimination. The aim of this Ph.D. thesis 
was to further study the selectivity control in the palladium(0)-catalyzed cross-couplings of 
secondary alkylzinc reagents and apply this strategy to prepare synthetically useful organic 
intermediates. 
In the first part, we extended the migrative cross-couplings to simple and easily accessible 




In the second part, based on previous studies, a series of azole-based bulky and rigid 
phosphine ligands was designed and applied to direct C(sp2)-C(sp3) Negishi cross-couplings. 
Finally, based on the “ligand-controlled selectivity” strategy, an enantioselective divergent 
arylation of N-Boc-1,3-oxazinanes was successfully developed. The application potential of 
this methodology has been further demonstrated in the divergent synthesis of enantioriched 



































































1. Introduction and research plan 
1.1 Remote functionalization strategies 
The direct and selective functionalization of hydrocarbon chains at the remote positions 
provides a step-economic strategy to make functionalized molecules from easily accessed 
feedstocks.4a Consequently, tremendous efforts have been made towards the direct 
functionalization of C-H bonds to useful C-X (X = C, O, N, etc.) bonds. Site-selectivity is a 
particularly challenging issue within this research field. To solve this problem, different 
strategies have been developed over the past decades.53 Among them, employing a directing 
group (Scheme 2.1) is greatly pursued,54 and therefore, numerous monodentate and bidentate 
directing groups were designed and developed, and found many applications in organic 
synthesis. Despite the impressive number of contributions and the achievements obtained, 
there are still significant demand and great limitations in this area. One of the disadvantages is 
that this method is only limited to the formation of small palladacycles (usually four- to six- 
membered).  
 
Scheme 2.1. Remote C-H functionalization by installing a directing group 
On the other hand, the Baudoin group developed a new strategy of remote C-H 
functionalization based on the migration of an organopalladium species along an alkyl chain 
(Scheme 2.2).24 This type of reaction is initiated by α-palladation via the sequence of 
deprotonation at the acidic α C-H bond/oxidative addition with R-X, forming the intermediate 
2-5. At this stage, reductive elimination directly affords α-functionalized product 2-6. 
Alternatively, Baudoin group discovered that a suitable ligand or substrate could force the 
branched intermediate 2-5 to form the terminal palladium complex 2-7 via a β-H 
elimination/rotation/insertion sequence, which then undergoes reductive elimination to 
provide β- or even long-range functionalized molecules. As mentioned in bibliographic part, 
based on this ligand-controlled strategy, our group has successfully realized a series of β- or 





Scheme 2.2. Remote C-H functionalization by migrative cross-coupling reactions 
1.2 Barbier-type reactions 
The Barbier reaction is an organic reaction between an alkyl halide and a carbonyl group as 
an electrophilic substrate in the presence of a metal, such as magnesium, aluminium, zinc, 
indium, tin, or its salts.55 The reaction is similar to the Grignard reaction but the crucial 
difference is that the Barbier reaction is a one-pot synthesis, since the organometallic species 
used in this reaction are generated in-situ. This method provides a simple and step-economy 
way for cross-coupling reactions, avoiding the handle of air- or moisture-sensitive 
organometallic species. 
In 2009, von Wangelin and co-workers reported a new, operationally simple and one-pot 
iron-catalyzed C(sp2)-C(sp3) cross-coupling with in-situ generated Grignard reagent (Scheme 
2.3).56 Due to the nature of Grignard reagents, however, there is limited tolerance of 
functional groups in either coupling partners. 
 
Scheme 2.3.  Domino iron catalysis enables direct aryl–alkyl cross-coupling 
Later, the direct Barbier-Negishi cross-couplings were reported by the Lipshutz group, which 
utilized water as the solvent and a diamine as an additive, either in the presence of a surfactant 
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(2-10a, 2-10b) or under ‘‘on water’’ (2-10c) conditions (Scheme 2.4).57 Nevertheless, one 
drawback of this approach is that competitive reduction of the aryl halides often occurred and 
a significant excess of the alkyl halide was required to suppress this side reaction. 
 
Scheme 2.4. Barbier-Negishi cross-couplings developed by the Lipshutz group 
An improved catalytic system developed by Buchwald and co-workers enables the rapid 
construction of a broad range of cyclic alkylated scaffolds from alkylzinc reagents generated 
in-situ (Scheme 2.5).58 They found that the simple combination of octanoic acid/sodium 
octanoate is an efficient surfactant system for this micelle-enhanced Negishi cross-coupling, 
allowing the C(sp3)-C(sp2) cross-coupling reactions to occur with a broad spectrum of 
electronically differentiated (hetero)aryl halides and as little as 1.5 equivalents of a variety of 
aliphatic heterocyclic bromides. 
 
Scheme 2.5. An improved Barbier-Negishi coupling developed by the Buchwald group 
1.3 Research plan 
Secondary alkyl bromides are simple and readily available motifs, which can be easily 
generated by the bromination of abundant feedstocks, such as alkenes, alcohols or even 
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alkanes.59 Therefore, in this part, we would like to extend the migrative cross-couplings to 
either pure or non-useful mixtures of secondary alkyl bromides, expecting to achieve 
terminal-selective functionalization of alkyl chains regioconvergently (Scheme 2.6). In 
addition, Barbier conditions with organozincs generated in-situ will be utilized to maximize 
the overall step economy. 
 
Scheme 2.6. Overview of research plan  
2. Migrative Barbier-Negishi cross-couplings 
2.1 Optimization of the reaction conditions 
2.1.1 Ligands effect 
Preliminary work on this topic in our group was reported by Dr. Anne-Sophie Goutierre in her 
Ph.D. thesis.60 With the aid of a flexible phosphine ligand, the proposed reaction was 
demonstrated to be feasible to achieve the terminal functionalization of alkyl chains using 
preformed secondary alkylzincs as the coupling partners. Nevertheless, the developed reaction 
was limited to a narrow scope and the preparation of organozincs from alkyl bromides met 
with difficulties due to the zinc insertion problems in some cases. Therefore, at the outset of 
our studies, we wanted to seek for suitable and practical conditions for the generation and 
cross-coupling of alkylzinc compounds. After extensive investigations, Dr. Stéphanie Dupuy 
developed the Barbier conditions to achieve that goal. 
To avoid competitive metal insertion, aryl triflates were chosen as electrophiles, and therefore 
they should show orthogonal reactivity to alkyl halides.61 Previous studies demonstrated that 
ligands play an important role in controlling the site-selectivity, hence, we started to 
investigate the reaction of 2-Br propane with a library of in-house ligands under Barbier 
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conditions where the organozinc reagent was generated in-situ by magnesium insertion and 
transmetallation with ZnCl2 (Table 2.1).
62 
Table 2.1. Effect of ligands in migrative Barbier-Negishi couplings 
 
Entry Ligand Conversion (%)a l/ba 
Yield of 2-14a 
(%)a 
1 L2 35 42/58 12 
2 L3 - - <10 
3 L4 93 78/22 41 
4 L5 - - <10 
5 L6 100 92/8 52 
6 L7 97 93/7 47 
7 L8 100 95/5 32 
8 L9 96 33/67 28 
9 L10 46 22/78 12 
10 L11 74 88/12 22 
11 L12 100 92/8 42 
12 CPhos 100 <2/98 84b 
13 DavePhos 100 4/96 83b 
a Measured by GC-MS with tetradecane as an internal standard; b Isolated yield of branched product 2-15a. 
 
As depicted in Table 2.1, ligands indeed have a remarkable influence on the selectivity and 
reactivity. Among these ligands, the phenyl-pyrrole-based phosphine ligand L6 gave the best 
result in terms of both linear selectivity and yield (entry 5). The unique property of L6 could 
be explained by the high level of flexibility of this ligand due to the phenyl-pyrrole backbone 
and also the linear group n-Bu at the phosphorus atom. On the contrary, rigid and bulky 
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ligands, such as CPhos29a and DavePhos63, gave a completely inversed selectivity, affording 
the branched product 2-15a in good yields (entry 12 & entry 13). These results highly 
correlate with the ‘‘ligands effect’’ in the cross-coupling reactions discussed in Chapter 1. 
2.1.2 Optimization of other reaction parameters 
With the best ligand in hand, we next further optimized the other reaction parameters.  
Changing 2-bromo propane 2-13a to 2-chloro propane 2-13b resulted in similar results in the 
presence or absence of ZnCl2 (entry 1 VS. entry 2, entry 3 VS. entry 4). A control experiment 
with commercially available Grignard reagent 2-13c also gave a similar linear selectivity and 
comparable yield of 2-14a (entry 5). Further control experiments disclosed that ZnCl2 is 
crucial to achieve a better result, especially for substrates with functional groups like ester 
(entry 6 VS. entry 7). Organozinc reagent generated in-situ from the mixture of Mg, LiCl and 
ZnCl2 is more efficient than from the mixture of zinc dust and LiCl, since a low yield was 
obtained when zinc dust was engaged in the reaction mixture (entry 9).64 Final optimization 
showed that the organozinc reagent generated in-situ could be reduced to 2.0 equiv. (entry 8) 
and the reaction worked well even with 2.5 mol% palladium catalysts (entry 10), but a lower 
yield was obtained with 1.25 mol% (entry 11). In the end, the optimal condition is: 2-13a/ 
Mg/LiCl/ZnCl2 (2 equiv.), 1.25 mol% Pd2dba3 and 2.5 mol% L6, 60 
oC, 16 h, giving rise to 
the linear product 2-14a in 92% selectivity and 80% isolated yield of mixture of 
linear/branched products. 





l/ba Yield of 2-14a (%)a 
1 2-13a/Mg/LiCl/ZnCl2 (4) 92/8 52 
2 2-13b/Mg/LiCl/ZnCl2 (4) 92/8 45 
3 2-13a/Mg/LiCl (4) 87/13 52 
4 2-13b/Mg/LiCl (4) 89/11 62 
5 2-13c/LiCl (1.3) 88/12 72 
6b 2-13a/Mg/LiCl (4) 63/37 <10 
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7b 2-13a/Mg/LiCl/ZnCl2 (4) 87/13 (76)c 
8 2-13a/Mg/LiCl/ZnCl2 (2) 92/8 82 (83)c 
9 2-13a/Zn/LiCl (2) 90/10 18 
10d 2-13a/Mg/LiCl/ZnCl2 (2) 92/8 76 (80)c 
11e 2-13a/Mg/LiCl/ZnCl2 (2) 92/8 66 (64)c 
a Measured by GC-MS with tetradecane as an internal standard; b 4-CO2EtC6H4OTf was used; 
c isolated yield of mixture; d Catalyst 
loading: 1.25 mol% Pd2dba3/2.5 mol% L
6; e 0.625 mol% Pd2dba3/1.25 mol% L
6. 
2.2 Scope and limitations of migrative Barbier-Negishi couplings 
2.2.1 Coupling of aryl/alkenyl triflates with 3-bromopentane 
Under the optimal reaction conditions, the scope and limitations of this migrative 
Barbier-Negishi cross-coupling reaction with regard to different triflates were then 
investigated by Dr. Stéphanie Dupuy. In general, the reaction was found to be compatible 
with a wide range of triflates, giving rise to the corresponding linear products in good yields 
and selectivities (Scheme 2.7). Functional groups, such as ester (2-14f), nitrile (2-14k) and 
even more electrophilic aldehyde (2-14g) were well tolerated due to the nature of Negishi 
cross-couplings. As expected, ortho-substituted aromatic triflates gave exclusively the linear 
products, which is consistent with our previous studies (2-14l to 2-14o).43, 46-48, 51-52 A control 
experiment with the substrate 2-12o was conducted using CPhos as the ligand, showing that 
the selectivity is controlled by both the ligand and substrate (the selectivity for 2-14o: 
l/b >99/1 with L6 and 73/27 with CPhos). 
Heteroaromatic triflate (2-12r) is also possible under the established conditions, albeit with a 
relatively lower linear selectivity. Cyclic alkene triflate is another interesting example, since 
the desired linear product (2-14t) was obtained in 98% yield and 93% selectivity. We were 
pleased to find that the double migrative cross-coupling also gave a good result (2-14u, 71% 
yield, l/b 85/15). Moreover, the developed conditions could be even applied to a more 
complex example-estrone derived triflate with a free ketone (2-12v), thus further 
demonstrating the generality of our protocol. Of note, simply combination of a triflate and a 
secondary alkyl bromide enabled the synthesis of η-amino acid 2-16 in 55% yield over a 





Scheme 2.7. Scope and limitations with respect to aryl/alkenyl triflates 
 
Scheme 2.8. Application of migrative Barbier-Negishi coupling to the synthesis of η-amino acid  
2.2.2 Coupling of 4-methoxyphenyl trifluoromethanesulfonate with secondary alkyl 
bromides 
Next, the coupling of 4-methoxyphenyl trifluoromethanesulfonate 2-12a with various 
secondary alkyl bromides was studied. Due to the nature of organozinc reagent, various 
functional groups, such as esters (2-13g, 2-13h), TBS-protected alcohols (2-13i, 2-13m), 
protected amine (2-13n) and acetal (2-13o), were all well tolerated under the Barbier 
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conditions. In addition, we were pleased to find that the reaction regioconvergently afforded 
mainly the linear product in all cases, no matter where the bromine atom is on the alkyl chain. 
Nevertheless, this is not the same case for the isomeric bromides containing a phenyl group, 
since significantly different selectivities for the linear product were observed and bromide 
2-13l did not give any coupling product. These results could be attributed to the presence of a 
benzyl position, which disfavours the palladium migration and C-C reductive elimination. 
Interestingly, when bromide 2-13p was engaged in the current Barbier conditions, compound 
2-14ad was obtained as the only linear product. No trace of the other possible linear product 
was observed from GC-MS, suggesting that branched motif could block palladium migration 
along the alkyl chain. 
 
Scheme 2.9. Scope and limitations with respect to secondary alkyl bromides 
2.2.3 Coupling of 4-methoxyphenyl trifluoromethanesulfonate with tertiary alkyl 
substrates 
Besides the secondary alkyl bromides, tertiary alkyl halides were also examined to see the 
generality of this reaction. Unfortunately, the desired product was not obtained in all cases 
(Scheme 2.10a). We assumed that the lack of reactivity might originate from the magnesium 
insertion step, which is known to be quite slow to tertiary halides.65 Therefore, the 
commercially available tert-butylmagnesium chloride was engaged in the reaction instead, 
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and we were delighted to find that the reaction worked quite well, affording the desired linear 
product in 63% isolated yield with 100% linear selectivity (Scheme 2.10b). Control 
experiment with CPhos was conducted, leading to the complete linear product as well. 
However, the only difference between L6 and CPhos is that significant amount of reduction 
product anisole was produced when CPhos was used, which is difficult for the purification by 
column chromatography (Scheme 2.10b). Consequently, L6 continued to be the best ligand 
for the tertiary substrates. 
 
Scheme 2.10. Coupling with tertiary halides 
2.3 Two-step linear-selective functionalization of alkanes 
2.3.1 Proof-of-concept 
As observed from the scope study with different secondary alkyl bromides, linear products 
were mainly obtained in a regioconvergent manner despite of the position of bromine atom on 
the alkyl chain. To further examine the possibility of regioconvergent cross-coupling with 
mixtures of alkyl bromides prepared from the non-selective bromination of simple alkanes, a 
proof-of-concept experiment was firstly performed using an equimolar mixture of 
bromopentanes. As expected, the reaction gave a similar result in terms of both yield and 
selectivity, compared to the results with isolated bromopentanes (Scheme 2.11). This result 
suggested that the same principle could be applied to the regioconvergent coupling of 




Scheme 2.11. A proof-of-concept experiment on the regioconvergent cross-coupling 
2.3.2 Radical bromination of alkanes 
At the beginning of this project, we aimed to find a practical method to prepare the mixtures 
of secondary alkyl bromides. In 2014, Alexanian group developed a site-selective, 
intermolecular bromination of unactivated, aliphatic C−H bonds using N-bromoamides and 
visible light (Scheme 2.12a).66 While this radical-mediated process allows the utility of 
hydrocarbons as limiting reagent in all examples, limitations still exists, especially when we 
want to prepare the mixtures of alkyl bromides on large scale. Although great efforts were 
made on this part for a long time, we still could not get satisfying result. After extensive 
exploring work, in the end, the desired mixtures could be obtained using the method 
developed by Li and co-workers,67 which is operationally simple and could be performed well 
even on large scale. Nevertheless, the only problem is that this methodology was limited to 
simple alkanes. With this approach, we were able to obtain the following three mixtures of 
alkyl bromides starting from n-pentane, n-hexane and n-dodecane (Scheme 2.12b). 
 
Scheme 2.12. Radical bromination of alkanes 
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2.3.3 Linear-selective functionalization of alkanes from mixtures of secondary alkyl 
bromides 
With the mixtures of alkyl bromides in hand, we then examined the regioconvergent 
cross-couplings with various electrophiles. As shown in Scheme 2.13, excellent results were 
observed with these three mixtures, furnishing the linear products with good to excellent 
selectivities, depending on the aryl triflates used. Moreover, the regioconvergent coupling 
could be performed on a 10 mmol scale without a significant decrease in efficiency, which 
further demonstrated the practicality of our protocol. Therefore, the terminal-selective 
functionalization of simple alkanes could be achieved with a sequence of non-selective 
bromination/migrative Barbier-Negishi cross-couplings. 
 
Scheme 2.13. Regioconvergent cross-coupling with mixtures of bromoalkanes 
2.4 Deuterium labelling experiments 
In order to gain a better understanding of the reaction pathway, deuterated 1- and 
2-bromopropane were engaged in this Barbier-Negishi cross-coupling reaction (Scheme 2.14). 
The pronounced deuterium scrambling observed with 2-13r shows that the palladium 
migration is reversible along the alkyl chain. Additionally, the unequal deuterium distribution 
on the three carbons of the propyl chain observed from both deuterated 1- and 
2-bromopropane likely reflects the intramolecular isotope effect associated with the faster β-H 




Scheme 2.14. Experiments with deuterated substrates.  
3. Conclusion 
To conclude, we have extended the ligand-controlled palladium migration to simple and 
commercially available secondary alkyl bromides. Under practical Barbier-type conditions 
involving magnesium insertion and transmetallation with ZnCl2, a series of linear arylated 
alkanes could be obtained in a regioconvergent manner with good to excellent linear/branched 
selectivities, thanks to the use of a suitable phosphine ligand. Moreover, this strategy could be 
coupled to a non-selective radical monobromination process, which allowed the 
terminal-selective functionalization of simple alkanes in just two steps.  
 
Scheme 2.15. Overview of the palladium-catalyzed migrative Barbier-Negishi cross-coupling reaction 
After our work was published, the migrative coupling of alkyl bromides has witnessed 
significant developments. These include using cheap and abundant nickel catalysis69 and also 
photocatalysis70. We believe that these unconventional methodologies will represent powerful 
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1. Introduction and research plan 
Alkyl groups, especially secondary alkyl ones, are important and ubiquitous motifs found in 
numerous pharmaceuticals and natural products, such as the top ten selling drugs Lipitor and 
Crestor (Scheme 3.1).72 Consequently, extensive studies have been devoted to the direct and 
rapid construction of C(sp2)-C(sp3) bonds in both laboratory and industry. Among all the 
methods established, direct Negishi cross-coupling reaction has been demonstrated to be a 
reliable and practical approach to form C(sp2)-C(sp3) bonds. Although great achievements 
have been made in this area, two main challenges still exist: the requirement of preformed 
organozinc compounds and most importantly the site-selectivity issue due to β-hydride 
elimination. 
 
Scheme 3.1. Examples of pharmaceuticals containing a secondary alkyl group 
To overcome the site-selectivity problem in C(sp2)-C(sp3) cross-couplings, the development 
of catalyst system to speed reductive elimination (from 3-3 to 3-4) while suppressing the 
competitive β-hydride elimination (from 3-3 to 3-5) is the most important task. In this regard, 
various ligands and catalyst systems have been developed to inhibit the migratory pathway 
(from 3-3 to 3-7) and facilitate the formation of direct cross-coupling product 3-4. However, 
in all these cases, the moisture-sensitive organozinc reagents have to be prepared prior to the 
coupling step. On the other hand, as described in the introduction part of Chapter 2, 
Lipshutz57 and Buchwald58 groups independently reported the Barbier-Negishi coupling 
conditions, which avoid the preformation of organozinc species. Recently, our group applied 
the water-free Barbier conditions to the terminal-selective functionalization of alkyl chains 
based on the migrative cross-coupling strategy.73 Following the interests in the field of 
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‘‘ligand-controlled selectivity’’ in palladium-mediated cross-coupling reactions, in this part, 
we would like to favour the direct coupling product 3-4 by examining and designing bulky 
ligands, expecting to develop a mild and highly selective C(sp2)-C(sp3) Negishi 
cross-coupling. 
 
Scheme 3.2. Barbier-Negishi coupling of secondary alkyl bromides 
2. Direct Barbier-Negishi coupling of secondary alkyl bromides with aryl 
and alkenyl triflates and nonaflates 
2.1 Optimization of the reaction conditions 
2.1.1 Initial results using commercially available and previously reported ligands 
Our initial efforts to achieve the more challenging direct Barbier-Negishi cross-couplings 
using various reported or commercially available ligands under palladium catalysis did not 
give satisfying results. All the tested phosphine ligands gave low to moderate selectivities in 
the Barbier-Negishi reaction of aryl triflate 2-12a and 3-bromopentane (Scheme 3.3a). 
CPhos,29 which was shown to be completely selective formation of the direct coupling 
product in our previously studied Barbier conditions with 2-bromopropane,73 led to only 77% 
selectivity in the system of 3-bromopentane. Other types of Buchwald ligands were further 
examined. Whereas RuPhos74 afforded a slightly higher direct selectivity (83/17) and a better 
yield (88%), t-Bu XPhos75 mainly delivered the homocoupling product of 2-12a. The use of 
PdCl2(dppf)
26 provided low conversion and poor selectivity for the direct product. 
In addition, various types of tri-tert-butylphosphine27, 76 were examined. To our surprise, the 
reactions failed to give any coupling product with these ligands (Scheme 3.3b). The 
unexpected result could be attributed to the problem of triflates used as the coupling partner.77 
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Control experiment was then conducted with the preformed organozinc compound. No 
products were observed when triflate was used in the presence of Pd(PtBu3)2, however, the 
reaction gave the desired ipso-product in 82% GC yield and 89% selectivity when 
4-methoxyphenyl bromide was engaged in(Scheme 3.4). 
 




Scheme 3.4. Control experiments with Pd(PtBu3)2 as the catalyst system 
Another very important type of ligands-N-heterocyclic carbenes (NHCs) were not compatible 
with Barbier conditions. In all cases, no coupling products were observed no matter what type 
of NHC was used (Scheme 3.3c). The PEPPSI-type complexes developed by the Organ 
group,39 which have found great applications in the cross-coupling reactions, also failed under 
the Barbier conditions. However, the control experiment with the corresponding preformed 
organozinc reagent showed a restored activity and moderate selectivity (84/16) (Scheme 3.5). 
 
Scheme 3.5. Control experiment with the preformed organozinc species in the presence of Pd-PEPPSITM-IPent 
2.1.2 Design and development of new phosphine ligands 
Since no satisfying results were obtained, we aimed to design a series of sterically demanding, 
azole-based phosphine ligands based on the previous studies from our and other research 
groups. Azole-based phosphine ligands were firstly introduced by Beller and co-workers and 
have found a wide range of applications in different cross-coupling reactions.78 Moreover, 
these azole-based analogues performed better than the conventional biaryl phosphine ligands 
in some cases. On the other hand, Buchwald group has demonstrated that the modification on 
the lower aromatic ring with electron-rich substituents, such as OMe, OiPr and NMe2, has a 
profound effect on both activity and selectivity.79 
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With these considerations in mind, two different families of rigid and bulky azole-based 
phosphine ligands were designed and synthesized from commercially available and easily 
accessed starting materials. The synthetic routes are shown below (Scheme 3.6).  
 
Scheme 3.6. Proposed synthetic routes for bulky azole-based phosphine ligands 
The Master student Fadri Christoffel, supervised by Dr. Stéphanie Dupuy, initiated the project 
and contributed to some of the ligands synthesis.80 According to these routes, totally eleven 
new azole-based bulky phosphine ligands were obtained (Scheme 3.7). However, efforts to 
make the corresponding pyrrole-based bulky phosphines failed, although different procedures 
were tried. 
 
Scheme 3.7. List of newly synthesized bulky azole-based phosphine ligands 
2.1.3 Test of new ligands in the direct Barbier-Negishi coupling 





Entry L Yield (%) a Selectivityb 
1 L13 83 93/7 
2 L14 <5 - 
3 L15 41 93/7 
4 L16 20 64/36 
5 L17 11 90/10 
6 L18 <5 - 
7 L19 73 93/7 
8 L20 61 94/6 
9 L21 61 77/23 
10 L22 18 81/19 
11 L23 56 92/8 
12c L13 76 95/5 
a Yields of 3-10a were determined by GC analysis using dodecane as an internal standard; b GC ratios of 3-10a/sum of the C1 & C2 isomers; 
c Performed using the preformed organozinc halide under otherwise identical reaction conditions. 
With the newly synthesized azole-based phosphine ligands in hand, their reactivities and 
selectivities were then examined in the direct Barbier-Negishi coupling of 4-methoxyphenyl 
trifluoromethanesulfonate 2-12a with 3-bromo pentane 2-13d. The CPhos analogues 
containing an imidazole or a pyrazole only gave a moderate reactivity, but the selectivity for 
the direct coupling product was greatly improved when the phosphorus atom has a 
di-substituted t-Bu group (entries 2-5). Delightedly, the RuPhos analogues showed superior 
results considering both reactivity and selectivity (entries 6-11). As seen from Table 3.1, 
tert-butyl substitutents on the phosphorus atom provided optimal reactivity and selectivity 
compared to cyclohexyl and adamantly groups (entries 6-8). The imidazole ring is better than 
the corresponding pyrazole (entries 19 & 22). In addition, the cyclohexyloxy group on the 
ortho-positions of lower aromatic ring gave rise to the desired branched product in a higher 
yield than the corresponding methoxy and isopropoxy groups (entries 1, 7 & 11). We were 
quite surprised to observe that the reaction failed to give any products when the substituents 
on the phosphorus atom were replaced by two cyclohexyl groups (entry 2 VS. entry 3, entry 6 
VS. entry 7). So far, no satisfying explanation could be given on the huge difference between 
cyclohexyl and tert-butyl groups. A control experiment using L13 and the prepared organozinc 
halide showed that this ligand works equally well under both normal conditions and Barbier 
conditions (entry 12). 
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2.1.4 Optimization of other reaction parameters 
Table 3.2. Optimization of other reaction parameters 
 
 
entry Temp. (oC) X Y Z Yield (%)a Selectivityb 
1 60 2.0 2.5 5.0 83 93/7 
2 60 2.0 1.25 2.5 56 93/7 
3 60 1.5 2.5 5.0 82 94/6 
4c 25 1.5 2.5 5.0 (90)d 94/6 
a Yields of 3-10a were determined by GC analysis using dodecane as an internal standard; b GC ratios of 3-10a/sum of the C1 & C2 isomers; 
c The corresponding nonaflate was used instead of triflate; d Yield refer to the isolated mixture of cross-coupling products on 1.0 mmol scale. 
Further refinement was then conducted using the optimal ligand. Decreasing the catalyst 
loading from 5.0 mol% to 2.5 mol% resulted in a lower yield but the selectivity was 
maintained (entry 1 VS. entry 2). Comparable yield and selectivity was obtained when 1.5 
equiv. organozinc species was used (entry 1 VS. entry 3). Interestingly, the reaction could be 
performed even at room temperature (25 oC) with similar results (entry 4). Compared to aryl 
triflates, the corresponding nonaflates were believed to be less expensive and more reactive.81 
Therefore, the nonaflate was utilized as the coupling partner in the reaction, affording the 
coupling products in 90% yield and 94% selectivity for the direct coupling product (entry 4). 
2.2 Scope and limitations 
2.2.1 Variation of triflates and nonaflates 
Under the established reaction conditions, various triflates and nonaflates were then 
investigated with 3-bromopentane. In general, electron-rich and withdrawing groups at the 
para- and meta-positions of aryl nonaflates were well tolerated, delivering the ipso-products 
in good to excellent yields and selectivities (3-10a to 3-10j). Interesting groups, such as a 
chloride (3-10b) and a boronate (3-10d), were also tolerated under the current reaction 
conditions, which could be used for further functionalization. A naphthyl ring was also a 
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suitable substrate (3-10k). Surprisingly, a nonaflate bearing an ethyl ester group gave mainly 
the migrative product (10:90) in quite a low yield. A control experiment with the preformed 
organozinc compound resulted in 85% selectivity for the direct coupling product 3-10e. This 
further illustrates the huge difference between Negishi couplings performed under normal and 
Barbier conditions. Fortunately, the corresponding triflate provided a solution to this problem, 
and compound 3-10e was obtained with a same selectivity as in the normal Negishi coupling. 
In general, our newly developed phosphine ligand L13 showed superior selectivities compared 
to CPhos, especially for some challenging cases. This could be further demonstrated by the 
reaction with the ortho-substituted aryl nonaflate and triflate (2-12l, 3-19l) and as well as the 
pyridine nonaflate (3-19m). Although moderate selectivities were observed for these two 
cases with our ligand, CPhos afforded a reversed selectivity. The other tested heteroaryl 
nonaflates proceeded smoothly, giving very good selectivities for the desired products (3-10n 
& 3-10o) under the established reaction conditions. In addition, alkenyl nonaflates were also 
suitable in the optimal Barbier conditions, giving the products in good yields and selectivities 
(3-10p & 3-10q). To our delight, the developed direct Barbier-Negishi couplings could be 
used for late-stage modification of a structurally complex compound, estrone-derived 
nonaflate, affording product 3-10r in 81% yield and 98% ipso-selectivity. Of note, enolate 
formation and subsequent nucleophilic addition to the free ketone was not observed in this 





[a] With 2.0 equiv. of 3-bromopentane, Mg, LiCl and ZnCl2. 
Scheme 3.8. Scope and limitations with respect to triflates and nonaflates 
2.2.2 Variation of secondary alkyl bromides 
Variation of secondary alkyl bromides was next studied using 4-methoxyphenyl nonaflate 
3-19a as the coupling partner. As shown in Scheme 3.9, reactions of secondary alkyl 
bromides with various functional groups proceeded smoothly, giving the desired direct 
coupling products in good yields and excellent selectivities. In this part, comparable 
selectivities in several cases were also observed when CPhos was used as the ligand. The 
superior selectivity obtained in the reaction of alkyl bromides with functional groups is still 
unclear so far. 
Acyclic secondary bromides 3-20aa with a 1:1 diastereomeric mixture also reacted well with 
4-methoxyphenyl nonaflate 3-19a, albeit with a low diastereoselectivity.82 Same results were 
obtained with isolated pure syn- and anti- diastereomers of 3-20aa. On the contrary, the 
reaction of cyclic bromide 3-20ab furnished product 3-21k with excellent diastereoselectivity, 
which is in agreement with the work of Knochel and co-workers.83 
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Moreover, due to the mild and easily operational reaction conditions, the reaction could be 
scaled-up to 10 mmol easily, giving rise to 2.2 g arylated product 3-21l in 75% yield at a 
reduced catalyst loading (2.5 mol% Pd/L). 
 
[a] With 2.0 equiv. of the bromoalkane, Mg, LiCl and ZnCl2, 5.0 mol%Pd2dba3, and 10 mol% L
13 at 60 oC; [b] With 2.0 equiv. of the 
bromoalkane, Mg, LiCl and ZnCl2 at 40 
oC; [c] With 1.25 mol%Pd2dba3, and 2.5 mol% L
13. 
Scheme 3.9. Scope and limitations with respect to secondary alkyl bromides 
Optical enriched secondary alkyl bromide 3-20ac was prepared according to the literature84 
and subsequently engaged in the direct Barbier-Negishi coupling under the established 
conditions. After deprotection, 3-22 was obtained as a racemic product. Combining this result 
and the reaction with 3-20aa, it is still difficult to control the stereoselectivity in this 
Barbier-Negishi coupling for the acyclic system. We envisaged that the radical magnesium 
insertion process probably induced the loss of stereoselectivity. 
 
Scheme 3.10. Optical enriched alkyl bromide engaged in the direct Barbier-Negishi coupling 
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3. Direct Barbier-Negishi coupling of primary alkyl bromides with aryl 
nonaflates 
3.1 Optimization of the reaction conditions 
To further investigate the generality of the reaction, primary alkyl bromides were then tested 
in the Barbier conditions. To our surprise, only trace amount of the desired coupling product 
was observed from GC-MS in the reaction of 1-bromopentane with aryl triflate 2-12a. Major 
homocoupling product 3-25 was observed in the reaction mixture (entry 1). Then, more 
attention was turned to the screening of other newly synthesized phosphine ligands (Table 
3.3). Fortunately, less electron-rich pyrazole-based phosphines afforded a solution to this 
problem (entries 4 & 5). In particular, using L21 as the ligand gave the best result in the 
coupling of 1-bromopentane with 4-methoxyphenyl triflate (entry 4). Changing the leaving 
group from triflate to nonaflate gave the same result (entry 6). Increasing the catalyst loading 
to 10 mol% achieved full conversion (entry 7). Further refinement showed that the reaction 
could also be run at 25 oC without decreased efficiency (entry 9), giving the desired coupling 
product 3-24a in 90% yield. 
Table 3.3. Optimization of Barbier-Negishi coupling of triflates and nonaflates with 1-bromopentane 
 




01 OTf L13 2.5 5.0 60 6/19/75 
02 OTf L18 2.5 5.0 60 86/14/<1 
03 OTf L14 2.5 5.0 60 84/15/<1 
04 OTf L21 2.5 5.0 60 13/84/3 
05 OTf L22 2.5 5.0 60 17/63/20 
06 ONf L21 2.5 5.0 60 12/86/2 
07 ONf L21 5.0 10.0 60 1/94/5 
08 ONf L21 5.0 10.0 40 3/93/4 
09 ONf L21 5.0 10.0 25 1/96/3 (90%)b 




3.2 Extended examples 
Under the optimal reaction conditions, other primary alkyl bromides were further examined. 
In general, the reactions proceeded smoothly with different primary alkyl bromides, 
delivering the desired coupling products in >90% yield (Scheme 3.11: 3-24b, 3-24c, 3-24d). 
The couplings with short-chain primary alkyl halides were challenging under the current 
reaction conditions, since low conversions were observed in the cases of bromoethane and 
methyl iodide even under harsh reaction conditions (4.0 equiv. organozinc species, high 
concentration of reaction mixture, high reaction temperature). For the methylation, 
commercially available methylmagnesium bromide solution was used directly as a control 
experiment, however, no significant improvement was obtained (Scheme 3.11). 
 
a The ratio was estimated by GC-MS;  
Condition b: alkyl halide/Mg/LiCl/ZnCl2 (4.0 eq.), Pd2dba3 (5.0 mol%), L
21 (10 mol%), THF (0.4 M), 60 oC, 24 h. 
Scheme 3.11. Scope and limitations of Barbier-Negishi coupling with primary alkyl halides 
4. Conclusion 
In summary, a mild and practical Barbier-Negishi cross-coupling reaction has been developed. 
This one-pot reaction is easily operational, avoiding handle of the moisture-sensitive 
organozinc compounds. Based on previous studies, a series of rigid and steric bulk, 
azole-based phosphine ligands were designed and applied to the coupling of secondary alkyl 
67 
 
bromides with triflates and nonaflates. We were pleased to find that part of the newly 
synthesized ligands furnished better selectivities than the reported ones. Of note, the 
imidazole-based phosphine with t-butyl substituents on the phosphorus atom and two 
cyclohexyloxy groups on the 2’,6’-positions (highlighted in green) provided the best results, 
leading to the desired ipso-products in good yields, chemo-, and site selectivities. Meanwhile, 
the established Barbier conditions could be applied to the primary alkyl bromides in excellent 
yields by using an analogous pyrazole-based ligand. 
 
Scheme 3.12. Overview of direct Barbier-Negishi couplings of secondary alkyl bromides 
During the preparation of this Ph.D. manuscript, Browne and co-workers reported 
mechanochemical methods to achieve the direct generation and consumption of organozinc 
reagents in a Negishi coupling process, allowing the formation of both C(sp2)-C(sp2) and 
C(sp2)-C(sp3) bonds in one-pot.85 
 
Scheme 3.13. Overview of mechanochemical activation of zinc and application to Negishi cross-coupling 
In addition, a palladium-catalyzed carbonylative Barbier-Negishi coupling of aryl iodide with 
unactivated primary and secondary alkyl bromides was developed by Wu and co-workers. 
The present method provides a mild procedure for the preparation of aryl alkyl ketones.86 
 
































Enantioselective divergent functionalization of N-Boc- 
1,3-oxazinanes: Application to the synthesis of 









































1. Introduction and research plan 
1.1 Enantiopure β2- and β3-amino acids: importance and preparation  
β-amino acids, especially β2- and β3-amino acids, not only exhibit broad biological activity 
but also are important and unique building blocks of natural products and peptides.87 
(S)-Nakinadine B has been shown to possess significant cytotoxicity against a variety of 
tumour cell lines including L1210 murine leukaemia and KB human epidermoid carcinoma 
cells.88 Another example bearing a β3-amino acid motif shown here is RWJ-53033, a potent 
nonpeptide integrin antagonist (Scheme 4.1).89,90 
 
Scheme 4.1. Selected β2-, β3-amino acids motifs found in natural products 
Due to the special properties and significance of β2- and β3-amino acids, it is not surprising 
that developing new methodologies to effeciently and enantioselectively construct these 
motifs has become an important and challenging endeavour for synthetic chemists.  
α-amino acids are believed to be ideal starting materials for the preparation of β-amino acids. 
This is due to the fact that a variety of methods for their synthesis are available.91 Another 
important reason is that the stereogenic center present in these compounds is retained without 
significant racemization in the homologated β-amino acids when suitable methods are utilized. 
Among all the developed methods, the Arndt-Eistert homologation sequence is superior in 
effectiveness (Scheme 4.2).92 The α-amino acid is first activated and then reacted with 
diazomethane to form a diazoketone. After a Wolff rearrangement,93 the desired β-amino 
acids can be generated efficiently. However, compared to β3-amino acids, the β2-anolugues 




Scheme 4.2. Arndt-Eistert homologation sequence with α-amino acids 
From the retrosynthetic analysis of β2-amino acid derivatives, different synthetic routes could 
be designed as outlined in Figure 4.1.95 The Mannich reaction provides a mild and easy 
synthetic pathway to build the C(2)-C(3) bond (path a).96 The C(2)-R bond can be formed 
either by α-alkylation of chiral enolates or nucleophilic addition and substitution (path b).97 
β2-amino acid derivatives can also be synthesized by asymmetric hydrogenation (path c)98 
and asymmetric conjugate addition is usually utilized to construct the C(2)-C(1) bond (path 
d)99. 
 
Figure 4.1. Overview of disconnections to synthesize β2-amino acids 
Although various methodologies have been developed for the preparation of β2- or β3-amino 
acids, a general method to efficiently synthesize both enantiopure β2- and β3-amino acids 
needs to be developed. 
1.2 Chemistry of N-Boc-1,3-oxazinanes 
N-Boc-1,3-oxazinanes were firstly studied by Beak and co-workers, as α-metalo amine 
synthetic equivalents of unactivated primary amines.100 Upon trapping of the organolithium 
intermediate with a variety of electrophiles followed by hydrolysis, useful amino alcohols and 




Scheme 4.3. Lithiation chemistry of N-Boc-tetrahydro-1,3-oxazine 
1.3 Research plan 
Since N-Boc-1,3-oxazinanes can be regarded as synthetic equivalent of amino alcohol 
derivatives, in this part, we would like to take advantage of these substrates to achieve the 
enantiodivergent synthesis of a series of both β2- and β3-amino acids. Based on our previous 
studies, we envisaged that both α- and β-functionalized products could be generated by using 
the ‘‘ligand-controlled selectivity’’ strategy.24 Moreover, depending on the configuration of 
the used chiral diamines, both enantiomers could be accessed. After ring-opening and further 
oxidation, divergent β-amino acid derivatives could be reached. 
 
Scheme 4.4. Overview of research plan 
2. Research part  
2.1 Initial study 
Together with Dr. Weilong Lin, we firstly studied on the arylation of the organozinc species, 
generated in-situ by a sequence of α-lithiation of N-Boc-1,3-oxazinane 4-2a and 
transmetalation with ZnCl2, with phenyl bromide (Scheme 4.5). By using the same catalytic 
system as for the β-arylation of N-Boc piperidines developed by our group in 2013,51 we were 
delighted to find that the β-arylated product was obtained as the only isomer. In addition, an 
inspiring enantioselectivity (77.5:22.5) was observed when (+)-sparteine was engaged in the 
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lithiation step. Switching of the ligand to the bulky phosphine ligand L13,101 a completely 
reversed selectivity was obtained as expected. With these promising results in hand, we next 
further investigated both α- and β-C(sp3)-H functionalization of N-Boc-1,3-oxazinanes and 
applied this methodology to the synthesis of β-amino acids. 
 
Scheme 4.5. Initial results obtained by Dr. Weilong Lin 
2.2 Enantioselective β-C(sp3)-H functionalization of N-Boc-1,3-oxazinanes 
2.2.1 Effect of chiral diamines 
Later, we discovered that when two ethyl groups were installed instead of the methyl groups, 
the enantioselectivity was greatly improved to 3:97 even though the yield remained moderate 
in the presence of (+)-sparteine (Table 4.1, entry 1). Therefore, the reaction conditions were 
further optimized using substrate 4-2b. 
First of all, the effect of different chiral diamines was examined. Although (+)-sparteine gave 
a low reactivity, the other types of chiral diamines furnished the expected β-arylated product 
in good yields with different e.r. (entry 2-5). Noteworthy, the (+)-sparteine surrogate 
developed by the group of O’Brien102 affored the β-product with 81% yield and 6:94 e.r. 
(entry 5). Due to its high reactivity, the (+)-sparteine surrogate, has to be stored in the freezer 
of the glovebox after distillation or distilled prior to use (entry 4 VS. entry 5). Since 
(+)-sparteine gave a higher enantioselectivity but a lower yield, whereas the (+)-sparteine 
surrogate was highly reactive but induced a lower enantioselectivity, at this stage, two 
different strategies can be proposed: improving e.r. using the (+)-sparteine surrogate or trying 
to increase the yield in the presence of (+)-sparteine. 
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Table 4.1. Effect of chiral diamines 
 
Entry Chiral diamine Yielda e.r.b 
1 A 48% 3:97 
2 B 70% 48:52 
3 C 76% 91:9 
4c D 78% 8:92 
5d D 81% 6:94 
a Isolated yield; b Determined by chiral HPLC; c (+) sparteine surrogate was distillated and stored in the freezer outside of the glovebox; d (+) 
sparteine surrogate was distillated and stored in the freezer of the glovebox. 
 
2.2.2 Effect of zinc sources 
Previous studies showed that zinc source has an important impact on the enantioselectivity. 
Therefore, representative zinc salts were tested in combination of the (+)-sparteine surrogate. 
Good yields were obtained in all cases. Nevertheless, comparable enantioselectivities were 
observed in these cases (entries 1-4). Among all the zinc salts examined, zinc chloride gave 
the best results (entry 1). 
Table 4.2. Effect of zinc sources 
 
Entry ZnX2 Yield (%)a e.r.b 
1 ZnCl2 81 6:94 
2 Zn(OAc)2 83 9:91 
3 ZnBr2 73 8:92 
4 Zn(OPiv)2 81 9:91 
a Isolated yield; b Determined by chiral HPLC. 
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2.2.3 Effect of asymmetric lithiation time 
Table 4.3. Effect of asymmetric lithiation time with (+)-sparteine surrogate 
 
Entry Time Yield (%)a e.r.b 
1 8.0 h 89 6:94 
2 5.0 h 80 6:94 
3 3.0 h 77 6:94 
4 1.0 h 54 5.5:94.5 
a The yield was determined by crude 1H-NMR using dibromomethane as the internal standard; b Determined by chiral HPLC. 
The lithiation time was next studied when (+)-sparteine surrogate was engaged in the 
lithiation step. Previous studies in our group showed that the racemization could occur if the 
lithiation was performed for too long. Since (+)-sparteine surrogate is reported to be more 
reactive than the other chiral diamines,103 we envisaged that we could reduce the lithiation 
time, expecting to achieve a higher enantioselectivity. The lithiation step was performed in 
8.0 h, 5.0 h, 3.0 h and 1.0 h respectively and the results are shown in Table 4.3. Decreasing 
the lithiation time resulted in a lower yield while the enantioselectivity was maintained.  
On the other hand, the effect of asymmetric lithiation time was also examined when 
(+)-sparteine was used at -60 oC.104 But unfortunately no better results were achieved (Table 
4.4). Meantime, increasing the lithiation temperature from -78 oC to -60 oC only gave a 
decreased e.r.. 
Table 4.4. Effect of asymmetric lithiation time with (+)-sparteine  
 
Entry Time Yielda e.r.b 
1 8.0 h 52% 5:95 
2 5.0 h 51% 5:95 
a Isolated yield; b Determined by chiral HPLC. 
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2.2.4 Effect of R group 
Although various reaction parameters were investigated, we could not achieve this reaction 
with good yield and excellent enantioselectivity. Due to the fact that substrate 4-2b with two 
ethyl groups gave better results than substrate 4-2a with two methyl groups, we next turned 
our attention to study the effect of different R groups. 
Table 4.5. Effect of R group 
 
Entry R Yield (%)a e.r.b 
1 Me (4-2a) 51 22.5:77.5 
2 Et (4-2b) 48 3:97 
3 n-Pr (4-2c) 72 3.5:96.5 
4 Cyclohexyl (4-2d) 8 11:89 
5 Cyclopentyl (4-2e) 23 15:85 
6c n-Pr (4-2c) 63 96.5:3.5 
7d n-Pr (4-2c) 72 3:97 
8d Et (4-2b) 49 3.5:96.5 
a Isolated yield; b Determined by chiral HPLC; c (-)-sparteine was used; d 4-bromoanisole was tested instead. 
As it can be seen from Table 4.5, the gem-substituents were found to have a pronounced 
impact on the yield, as well as the enantioselectivity. While two methyl groups gave a 
moderate yield and enantioselectivity (entry 1), a remarkably enhanced enantioselectivity was 
obtained when two ethyl and n-propyl groups were installed in the N-Boc-1,3-oxazinanes 
(entries 2-3), with the two n-propyl groups as the optimal substrate (entry 3). This could be 
further demonstrated when 4-bromoanisole was used as the coupling partner (entries 7-8). On 
the contrary, the reactivities with cyclic substituents, such as cyclohexyl and cyclopentyl 
groups, developed by Dr. Weilong Lin, were found to be quite low, although the 
enantioselectivities were improved compared to the two methyl groups (entries 4-5 VS. entry 
1). As expected, (-)-sparteine gave the opposite enantiomer with similar results (entry 6). 




Scheme 4.6. Optimal reaction conditions 
2.2.6 Scope and limitations  
Under the established reaction conditions, the scope and limitations of the enantioslective 
β-C(sp3)-H functionalization of N-Boc-1,3-oxazinanes were next evaluated.  
In general, good yields and high enantioselectivities were obtained regardless of the electron 
properties and substituents positions of aryl bromides. The developed reaction conditions 
were found to tolerate a range of mono- and di-substituted bromobenzenes. Moreover, 
2-bromonaphthalene was successfully engaged in the reaction, giving rise to the 
corresponding product in 60% yield with 4.5:95.5 e.r. (4-3co). (-)-sparteine was also tested 
under the current reaction conditions, showing that both enantiomers could be easily 
generated. 
Interestingly, when the heteroaryl bromides are electron-withdrawing, a mixture of two 
isomers was observed (desired β/new isomer 80:20, observed from GC-MS). According to a 
preliminary inspection of 1H-NMR of the isolated mixture, we suspected that the other isomer 
observed could be the γ-arylated product. However, due to the similar Rf, it was not possible 
to isolated the pure γ-product. Further efforts will be conducted in order to confirm the 
structure of the new isomer. 
To show the generality of our developed reaction, the use of alkenyl bromides and alkenyl 





a With (-)-sparteine; b Yield refers to the yield of mixture of β- and γ-products (GC-MS ratio: around 80:20), and the value in parenthesis is 
e.r. of γ-product; c The e.r. was determined by ring-opening to form the corresponding amino alcohols; d No good conditions found for the 
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separation on chiral HPLC; e DavePhos was used; f The e.r. has to be checked, since one peak is partially overlapped with another minor 
peak on chiral HPLC; g ROTf was used. 
Reactions performed by myself are highlighted in blue. 
Scheme 4.7. Scope and limitations of enantioselective β-C(sp3)-H functionalization of N-Boc-1,3-oxazinanes 
2.3 Enantioselective α-C(sp3)-H functionalization of N-Boc-1,3-oxazinanes 
2.3.1 Optimization of the reaction conditions 
Enantioselective α-C(sp3)-H functionalization of N-Boc-1,3-oxazinanes was also studied 
based on the ‘‘ligand-controlled selectivity’’ strategy.24 According to our previous studies, 
representative bulky phosphine ligands were examined. Among all the tested bulky ligands, 
our newly designed bulky phosphine ligand L13 was again found to give the best results 
(entries 1-3 and entries 5-9).101 When (+)-sparteine was used as the chiral source, a high 
enantioselectivity (5:95) was obtained (entry 5). In this case, the more reactive (+)-sparteine 
surrogate gave a similar yield but a lower enantioselectivity (entry 11). In addition, we found 
that shorter alkyl chains on the substrate afforded the α-arylated product in a higher yield, 
with the diethyl group as the optimal one (entry 5 VS. entry 10). Zinc source were found to 
have an effect on the enantioselectivty, since slightly higher enantioselectivities were obtained 
when Zn(OAc)2 and Zn(OPiv)2 were used (entries 12-13). Further optimization showed that 
the use of the corresponding nonaflate or triflate resulted in a higher yield at 80 oC (entries 
14-16). Since Zn(OAc)2 is commercially available, it will be used for the scope study. 
Table 4.6. Optimization of enantioselective α-C(sp3)-H arylation 
 
Entry R diamine L α/βa 




1 Me TMEDA PtBu3·HBF4 27/73 26 - 
2 Me TMEDA CPhos >98/2 20 - 
3 Me TMEDA L13 >98/2 54 - 
4 Me (+)-sparteine L13 >98/2 53 25 :75 
5 Et (+)-sparteine L13 >98/2 51 5:95 
6 Et (+)-sparteine RuPhos 34/66 20 N.D. 
7 Et (+)-sparteine L14 88/12 43 N.D. 
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8 Et (+)-sparteine L19 >98/2 45 N.D. 
9 Et (+)-sparteine L22 >98/2 38 N.D. 




L13 >98/2 46 8:91 
12d,h Et (+)-sparteine L13 >98/2 48 3:97 
13e,h Et (+)-sparteine L13 >98/2 51 3:97 
14f,h Et (+)-sparteine L13 >98/2 58 3:97 
15d,g,h Et (+)-sparteine L13 >98/2 61 3:97 
16e,g,h Et (-)-sparteine L13 >98/2 56 3:97 
a The ratio of α/β is determined by GC-MS or 1H-NMR of the crude mixture; b Isolated yield; c Determined by chiral HPLC; d Zn(OAc)2 was 
used instead of ZnCl2; 
e Zn(OPiv)2 was used instead of ZnCl2; 
f PhOTf was used; g PhONf was used; h 80 oC. 
 
2.3.2 Optimal reaction conditions  
 
Scheme 4.8. Optimal reaction conditions 
2.4 Catalytic asymmetric deprotonation using a ligand exchange approach 
2.4.1 Proposed concept  
Enantiopure sparteine is a widely utilized chiral diamine in asymmetric synthesis. In most 
cases, stoichiometric amount of sparteine has to be used to achieve high yields and 
enantioselectivities. However, reports of catalytic applications are rare. In 2005, O’Brien and 
co-workers made a significant breakthrough in this field. They proposed a conceptually 
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different catalytic approach to achieve that goal.105 Their ligand exchange approach is 
outlined in Scheme 4.9 for N-Boc pyrrolidine 4-5. They proposed that stoichiometric achiral 
diamine 4-9 would replace catalytic amount of (-)-sparteine from 4-7, generating a new 
organolithium/diamine complex 4-11 and at the same time regenerating the active 
s-BuLi/(-)-sparteine complex 4-6, which could then enter the next catalytic cycle. Complex 
4-11 would then trap Me3SiCl to afford the product (S)-4-8.  
To achieve that goal, a suitable achiral diamine 4-9 needs to be well designed. In principle, 
several criteria must be met regarding the achiral diamine: (1) ligand exchange must occur; (2) 
organolithium/diamine complex 4-7 and 4-11 must be configurationally stable during the 
ligand exchange step; (3) deprotonation of 4-5 using s-BuLi/diamine complex 4-10 must be 
slower than that using s-BuLi/(-)-sparteine complex 4-6. 
After evaluating different stoichiometric achiral ligands, bispidine 4-12 gave the best results 
in terms of both yield and enantioselectivity.106 With this method, each enantiomer of useful 
products was accessed in the presence of catalytic (-)-sparteine or (+)-sparteine surrogate.105, 
107 Moreover, later research showed that this catalytic protocol was also compatible with 
Negishi coupling conditions.108 
 
Scheme 4.9. Proposed ligand exchange strategy for the catalytic asymmetric deprotonation of N-Boc pyrrolidine 
2.4.2 Proof-of-concept 
Based on O’Brien’s elegant work, we then followed a similar protocol using our system. 
s-BuLi/bispidine was used with three catalytic chiral diamines (0.3 equiv.): (+)-sparteine, 
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(+)-sparteine surrogate and as well as chiral diamine C, all of which had achieved good 
results in the asymmetric deprotonation of N-Boc-1,3-oxazinanes. Although catalytic 
(+)-sparteine gave the highest e.r., a disappointing yield was obtained probably due to its low 
reactivity (entry 1). Changing of the gem-substituents for less bulky ethyl groups resulted in 
almost the same yield and enantioselectivity (entry 2). Chiral diamine C, which was found to 
be reactive in the stoichiometric deprotonation, gave a slightly improved yield (entry 3). To 
our delight, the most reactive (+)-sparteine surrogate worked well in the catalytic asymmetric 
deprotonation, furnishing the coupling product 4-3cb in 68% yield and 7:93 e.r. (entry 4). 
These results clearly demonstrated that the catalytic asymmetric lithiation using the ligand 
exchange approach is feasible in our system. 
Table 4.7. Preliminary results on catalytic asymmetric deprotonation 
 
Entry Chiral diamine Yield (%)a e.r.b 
1 A 18 5:95 
2c A 12 5:95 
3 C 38 94:6 
4 D 68% 7:93 
a Isolated yield; b Determined by chiral HPLC; c substrate 4.2b with two ethyl groups was used. 
 
2.4.3 Extended examples 
This catalytic asymmetric deprotonation was then further examined with different coupling 
partners. In general, good yields and more than 90:10 e.r. were obtained with electron-rich 
and electron-withdrawing substituents at the ortho-, meta- and para-positions. A low yield 




Scheme 4.10. Representative examples of catalytic asymmetric deprotonation 
2.5 Application to the synthesis of enantiopure β2- and β3-amino acids 
Finally, to showcase our developed methodology, we applied it to the synthesis of 
enantioenriched β-amino acid derivatives. After a simple two-steps sequence of 
ring-opening/oxidation, the desired enantioriched β2-amino acids could be afforded 
efficiently.109 Moreover, we were pleased to find that the enantiomeric ratio was not eroded at 
all during these two steps. The configuration of the obtained β2-amino acid was determined by 
comparing the reported specific optical rotations ([α]D20). Similarly, we could envisage that 
the enantiopure β3-amino acids could also be prepared using the same sequence. Further 
examination on this part is ongoing. In a word, our methodology provides a general route to 




* Ee of the final amino acid derivatives were determined by the corresponding methylation product. 
Scheme 4.11. Preliminary study on the application  
3. Conclusion and outlook 
To conclude, a versatile and highly enantiodivergent functionalization of 
N-Boc-1,3-oxazinanes was developed by combining the asymmetric deprotonation chemistry 
and our developed ‘‘ligand-controlled selectivity’’ strategy. The power of this methodology 
was preliminarily demonstrated by the efficient and divergent synthesis of enantioriched β2- 
and β3-amino acids. Moreover, preliminary study showed the feasibility of a catalytic version 
of the asymmetric lithiation step. Future work includes the further study of enantioselective 
α-C(sp3)-H functionalization of N-Boc-1,3-oxazinanes and the application to the synthesis of 
enantiopure β2- and β3-amino acids. Mechanistic studies will be conducted to have a deeper 

































Over the past decades, transition metal-catalyzed cross-coupling reactions have emerged as a 
powerful method to construct carbon-carbon bonds, and even carbon-heterocarbon bonds. 
Therefore, numerous research and applications have been devoted in this field and the 
research on cross-coupling reactions continue to be the hot topic in both academic and 
industrial communities. 
Although great process has been achieved in palladium-catalyzed C(sp2)-C(sp3) 
cross-couplings, limitations and challenges still exist. Since most of the organometallics are 
air or/and moisture sensitive, the pre-formation of these reagents prior to the cross-couplings 
is normally required. Another challenging issue arises from the competitive β-hydride 
elimination relative to the direct reductive elimination.  
In this Ph.D thesis, we aimed to solve the two limitations in palladium-catalyzed 
cross-coupling reactions, trying to find and develop suitable ligands to control the 
site-selectivity when secondary alkylzinc reagents were used as the nucleophiles. 
In the first part, based on our previous studies on migrative cross-coupling reactions, we 
extended the scope to the secondary alkyl bromides under easily operational Barbier 
conditions, where the organozincs were generated in-situ by magnesium insertion and 
transmetallation with ZnCl2, and then do the cross-coupling in one-pot. Thanks to the utility 
of a suitable flexible phosphine ligand, a broad range of linear arylated products could be 
afforded with good to excellent selectivity in a regioconvergent manner. In addition, the 
developed strategy could be even coupled to a non-selective monobromination process, thus 
allowing the functionalization of simple alkanes in just two-steps. 
 
Due to the interests and challenges in the direct cross-couplings of alkyl nucleophiles 
containing β-hydogen(s), we continued the study on direct Barbier-Negishi cross-coupling of 
88 
 
secondary alkylzincs. Given the fact that reported or commercially available ligands did not 
achieve satisfying results, we designed and synthesized a series of azole-based bulky 
phosphine ligands. Under the mild conditions, good to excellent selectivities for direct 
cross-coupling products were obtained in the presence of palladium catalysis featuring one of 
our newly developed ligands (labelled green as shown below). Additionally, the Barbier 
conditions could be applied to the primary alkyl bromides. 
 
In the last part of this thesis, the ‘‘ligand-controlled selectivity’’ strategy was applied to the 
enantiodivergent functionalization of N-Boc-1,3-oxazinanes. This powerful and useful 
methodology provided a general approach to the access of enantiopure β2- and β3 -amino acid 
derivatives. Moreover, both enantiomers of amino acids could be obtained depending on the 
configuration of the chiral diamines engaged in the deprotonation system. Preliminary studies 
showed that the asymmetric catalytic deprotonation is feasible by using the reported ligand 
























































1. General information 
Techniques:  
All reactions involving air-sensitive material were carried out in a pre-dried glassware under 
an argon atmosphere by using Schlenk techniques employing double-line argon-vacuum lines 
and working in an argon-filled glove box. Analytical thin layer chromatography (TLC) was 
performed using pre-coated Merck silica gel 60 F254 plates (0.25 mm). Visualization of the 
developed chromatogram was performed by UV absorbance (254 nm) or TLC stains (KMnO4 
and Phosphomolybdic acid). Flash chromatography was performed using Silicycle SiliaFlash 
P60 (230-400 mesh) with the indicated solvent system, using gradients of increasing polarity 
in most cases. 
Chemicals:  
Anhydrous solvents were obtained by distillation over calcium hydride or by distillation over 
sodium. Tetrahydrofuran (THF) and toluene were purchased from VWR (HiPerSolv 
CHROMANORM®, HPLC grade). Dichloromethane (for HPLC, unstabilized) was purchased 
from Fischer Chemical. Et2O (Spectrophotometric Grade, 99+%, inhibitor free) was 
purchased from Alfa Aesar. The solvents were predried unter nitrogen over activated 
molecular sieve for a week. Then they were transferred under nitrogen into the storrage kegs 
of a PureSolve MD5 solvent purification system from inert®. In this system the solvents were 
then purified by passing them under nitrogen pressure through two packed columns of 
acitvated basic alumina. Zinc chloride was dried under vacuum at 140 oC for overnight and 
stored in the glovebox. Magnesium powder and anhydrous lithium chloride were stored in the 
glovebox when received. Commercially available reagents were used without further 
purification unless otherwise stated. Phosphines and palladium sources were stored in the 
glovebox. 
Instrumentation:  
HPLC analyses were performed using a Shimadzu Prominence system with SIL-20A auto 
sample, CTO-20AC column oven, LC-20AD pump system, DGU-20A3 degasser and SPD 
M20A Diode Array or UV/VIS detector. The following chiral columns from Daicel Chemical 
Industries were used: OJ-H (chiralcel), IC (chiralpak), AD-H (chiralpak) and IA (chiralpak) in 
4.6 x 250 mm size.  
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GC-MS analyses were performed on a Shimadzu QP2010 apparatus using a RTx®-5ms 
column lined with a mass (EI 0.86 kV) detection system. All GC analyses were performed on 
an Shimadzu GC-2010 with a FID detector using an achiral column (Restek, Rtx-1701, 30 m, 
0.25 mm, 0.25 μm, 14% Cyanopropylphenyl-86% dimethylpolysiloxane, Tmax = 250 
oC).  
1H, 13C , 19F and 31P NMR spectra were recorded on BrukerAvance III (500 MHz) and 
BrukerAvance III (400 MHz) spectrometers at 298 K in CDCl3 (residual peaks 
1H δ 7.26 ppm, 
13C δ 77.16 ppm) or Acetone-d6 (
1H δ 2.05 ppm, 13C δ 206.26 ppm). 19F NMR spectra were 
referenced to external CFCl3. All 
31P NMR spectra were reported in ppm relative to H3PO4 (0 
ppm – external standard). Chemical shifts (δ) are reported in ppm relative to tetramethylsilane 
(0.00 ppm). Data is reported as follows: chemical shift in parts per million (ppm), multiplicity 
(s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, and brs = broad), integration 
value, coupling constant in Hz if applicable.  
High resolution mass spectrometry was recorded by Dr. H. Nadig and Dr. M. Pfeffer of the 
University of Basel on a Bruker maXis 4G QTOF ESI mass spectrometer.  
Infrared spectra were measured on a ATR Varian Scimitar 800 FT-IR spectrometer and 
reported in cm–1.  
Optical rotations were measured on a Perkin Elmer 341 Polarimeter in a 1 mL micro cuvette 













2. Chapter 2: Terminal-selective functionalization of alkyl chains by 
regioconvergent cross-coupling 
Synthesis of Aryl triflates 
 




Prepared according to literature procedure.111 A mixture of 2-aminophenol (1.09 g, 10 mmol), 
benzyl bromide (3.42 g, 20 mmol, 2 equiv.) and sodium bicarbonate (3.36 g, 40 mmol, 4 
equiv.) in acetonitrile (150 mL) was stirred at 40 °C for 6 h. After cooling to room 
temperature, the reaction mixture was filtered and the filtrate was evaporated under reduced 
pressure. Water (100 mL) and ethyl acetate (100 mL) were added to the residue. Organic layer 
was separated, washed with water, dried over Na2SO4, and the solvent was removed under 
reduced pressure. The residue was passed through a plug of silica (pentane/CH2Cl2 60:40) to 
give 2-(dibenzylamino)phenol as a thick pale yellow oil (2.7 g, 93%). 
1H NMR (CDCl3, 400 MHz) δ 7.33 – 7.22 (m, 5H), 7.22 – 7.16 (m, 4H), 7.16 – 7.11 (m, 1H), 
7.08 – 6.98 (m, 2H), 6.87 – 6.78 (m, 2H), 4.02 (s, 4H);  
13C-{1H} NMR (CDCl3, 100 MHz) δ 152.5, 137.6, 136.9, 129.3, 128.5, 127.6, 126.9, 124.0, 
119.8, 114.1, 59.0; 
IR (neat): ν (cm-1) 3345, 3027, 1491, 1250, 758; 
HRMS (ESI): Calcd for C20H20NO ([M+H]
+): 290.1545, found 290.1540. 
 
Prepared according to literature.110 A solution of trifluoromethanesulfonic anhydride (0.82 
mL, 4.84 mmol) in CH2Cl2 (3.0 mL) was added dropwise to a solution of pyridine (0.56 mL, 
6.92 mmol) and the corresponding phenol (1 g, 3.46 mmol) in anhydrous CH2Cl2 (10 mL) at 0 
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°C. After complete addition, the mixture was warmed to room temperature and allowed to stir 
for 1 h. The mixture was then diluted with Et2O (30 mL), quenched with 10 % aq. HCl and 
washed successively with sat. NaHCO3 and brine. After drying over MgSO4, the solvent was 
removed under reduced pressure and the residue was passed through a plug of silica 
(pentane/CH2Cl2 80:20) to give the desired aryl triflate  2-12o as a colourless oil (1.5 g, 
quant.). 
1H NMR (400 MHz, CDCl3) δ 7.33 – 7.25 (m, 6H), 7.25 – 7.15 (m, 6H), 7.07 (td, J = 7.8, 1.6 
Hz, 1H), 6.92 (dd, J = 7.9, 1.5 Hz, 1H), 4.16 (s, 4H);  
13C-{1H} NMR (CDCl3, 100 MHz) δ 144.8, 143.8, 136.6, 129.4, 128.8, 128.4, 127.5, 124.2, 
123.7, 122.2, 55.1;  
19F-{1H} NMR (CDCl3, 376 MHz) δ -74.51; 
IR (neat): ν (cm-1) 2956, 1415, 1194, 1135, 884, 755, 701, 628;  
HRMS (ESI): Calcd for C21H19F3NO3S ([M+H]
+): 422.1038, found 422.1032. 
Synthesis of alkyl bromides 
Ethyl 5-bromohexanoate 2-13g 
 
This compound was synthesized by a modified literature procedure.112 
δ-Hexalactone (1.0 g, 8.76 mmol) was added to a flask containing a solution of 33% HBr in 
AcOH (3 mL) and fitted with a reflux condenser. The reaction was heated to 75 °C for 4 
hours then cooled to room temperature, at which point ethanol (8.0 mL) was added and the 
mixture was stirred at room temperature overnight. The reaction was then partially 
concentrated under reduced pressure, taken up in EtOAc, washed three times with a saturated 
aqueous solution of sodium bicarbonate, brine, and the organic layer was dried with 
magnesium sulfate and concentrated under reduced pressure. The crude product was passed 
through a plug of silica (10% Et2O/Pentane) to isolate methyl 5-bromohexanoate 2-13g as a 
colourless liquid (1.5 g, 78% yield). 
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1H NMR (400 MHz, CDCl3) δ 4.30 – 3.90 (m, 3H), 2.50 – 2.12 (m, 2H), 1.93 – 1.74 (m, 4H), 
1.71 (d, J = 6.7 Hz, 3H), 1.26 (t, J = 7.1 Hz, 3H). The spectral data is consistent with that 
reported in the literature (4). 
Ethyl 4-bromohexanoate 2-13h  
 
This compound was synthesized from γ-caprolactone via lactone opening with HBr using a 
method identical to the one described for ethyl 5-bromohexanoate above to give the desired 
product 2-13h as a colourless liquid (1.16 g, 59%). 
1H NMR (400 MHz, CDCl3) δ 4.13 (q, J = 7.1 Hz, 2H), 4.05 – 3.96 (m, 1H), 2.64 – 2.41 (m, 
2H), 2.25 – 2.12 (m, 1H), 2.11 – 1.99 (m, 1H), 1.94 – 1.81 (m, 2H), 1.25 (t, J = 7.1 Hz, 3H), 
1.05 (t, J = 7.3 Hz, 3H). The spectral data is consistent with that reported in the literature.111 
(3-Bromobutyl)benzene 2-13k  
 
This compound was prepared according to the procedure of Denmark et al..84 
Bromine (1.92 g, 0.62 mL, 12.0 mmol, 1.2 equiv) was added dropwise to a stirred suspension 
of triphenylphosphine (3.15 g, 12.0 mmol, 1.2 equiv) in CH2Cl2 (30 mL) in a round-bottomed 
flask equipped with a stirrer bar and cooled in an ice/water bath (open to air). The flask was 
then sealed with a rubber septum and purged with argon via an inlet needle. After stirring the 
resultant pale-yellow suspension for 15 min, a solution of 4-phenyl-2-butanol (1.5 g, 10.0 
mmol, 1.0 equiv) and imidazole (0.82 g, 12.0 mmol, 1.2 equiv) in CH2Cl2 (20 mL) was added 
dropwise. The cooling bath was removed, and the reaction mixture was allowed to warm to rt 
for 17 h. The mixture was then filtered on celite and concentrated in vacuo to leave a yellow 
oil residue. The latter was finally passed through a plug of silica (pentane) to give 
(3-bromobutyl)benzene 2-13k as a colourless oil (1.9 g, 89%). 
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1H NMR (400 MHz, CDCl3) δ 7.33 – 7.27 (m, 2H), 7.24 – 7.17 (m, 3H), 4.20 – 3.96 (m, 1H), 
2.94 – 2.81 (m, 1H), 2.81 – 2.66 (m, 1H), 2.26 – 1.98 (m, 2H), 1.73 (d, J = 6.7 Hz, 3H). The 
spectral data is consistent with that reported in the literature.84 
(2-Bromobutyl)benzene 2-13j  
 
This compound was synthesized from 1-phenylbutan-2-ol using the same procedure as the 
one described above to give the desired compound 2-13j as clear colourless oil (1.05 g, 75%). 
1H NMR (400 MHz, CDCl3) δ 7.36 – 7.29 (m, 2H), 7.29 – 7.25 (m, 1H), 7.24 – 7.19 (m, 2H), 
4.28 – 4.09 (m, 1H), 3.29 – 3.08 (m, 2H), 1.99 – 1.85 (m, 1H), 1.85 – 1.70 (m, 1H), 1.08 (t, J 
= 7.2 Hz, 3H). The spectral data are consistent with those reported in the literature.113 
(1-Bromobutyl)benzene 2-13l  
 
This compound was synthesized using the procedure of Li et al..67 
Butylbenzene (1.34g, 10 mmol, 2.0 equiv.) and bromine (0.26 mL, 0.8 g, 5.0 mmol, 1.0 equiv.) 
were added to a round-bottom flask containing MnO2 (85%, 1.02 g, 20 mmol, 2.0 equiv.) and 
dichloromethane (10 mL). The reaction mixture was then allowed to stir at room temperature 
until the disappearance of bromine color. The mixture was filtered and the filtrate was washed 
with water. The combined organic phases were dried over MgSO4. The residue was then 
distilled to afford the pure (1-bromobutyl)benzene 2-13l as a colourless oil (1.0 g, 93%). 
1H NMR (400 MHz, CDCl3) δ 7.36 – 7.29 (m, 2H), 7.29 – 7.24 (m, 2H), 7.23 – 7.17 (m, 1H), 
4.94 – 4.87 (m, 1H), 2.28 – 1.98 (m, 2H), 1.49 – 1.38 (m, 1H), 1.32 – 1.22 (m, 1H), 0.87 (t, J 
= 7.4 Hz, 3H). The spectral data is consistent with that reported in the literature.67 
3-(Bromobutoxy)-tert-butyldimethylsilane 2-13i  
 
The above compound was prepared according to a literature procedure.114 
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1,3-Butanediol (1.35 g, 15 mmol, 1 equiv.) and imidazole (2.25 g, 33 mmol, 2.2 equiv.) were 
stirred in DMF (7.5 mL) for 1 h at 0 °C. TBSCl (2.25 g, 15 mmol, 1 equiv.) was then added 
and the reaction mixture was allowed to warm to room temperature over 18 h. The reaction 
mixture was quenched with water and extracted with diethyl ether. The combined organic 
layers were washed with brine, dried over MgSO4 and concentrated under reduced pressure. 
Purification of the crude product on silica gel (elution using Pentane/EtOAc: 85:15) furnished 
4-(tert-butyldimethylsiloxy)butan-2-ol as a colourless oil (2.35 g, 77%). 
1H NMR (400 MHz, CDCl3) δ 4.07 – 3.98 (m, 1H), 3.93 – 3.77 (m, 2H), 3.39 (brs, 1H), 1.69 
– 1.59 (m, 2H), 1.18 (d, J = 6.3 Hz, 3H), 0.89 (s, 9H), 0.07 (s, 6H). The spectral data is 
consistent with that reported in the literature.114 
 
The desired 3-(bromobutoxy)-tert-butyldimethylsilane 2-13i was finally obtained, using the 
same procedure as for 2-13k, as a colourless oil (1.83 g, 70%).  
1H NMR (400 MHz, CDCl3) δ 4.40 – 4.24 (m, 1H), 3.75 (t, J = 5.8 Hz, 2H), 2.01 – 1.92 (m, 
2H), 1.74 (d, J = 6.7 Hz, 3H), 0.89 (s, 9H), 0.07 (s, 3H), 0.06 (s, 3H);  
13C NMR (100 MHz, CDCl3) δ 61.1, 48.5, 44.0, 26.8, 26.1, 18.4, -5.2; 
IR (neat): ν (cm-1) 2954, 2929, 2857, 1678, 1418, 1254, 1183, 899, 832, 775, 704, 665, 536; 
GCMS (EI) m/z for C10H23BrOSi  ([M]
+•): 266. 
((4-bromohexyl)oxy)(tert-butyl)dimethylsilane 2-13m  
 
This compound was synthesized via lactone opening with HBr using a method identical to the 
one described for ethyl 5-bromohexanoate 2-13g to furnish methyl 4-bromohexanoate as a 
clear liquid (4.50 g, 61%). 
1H NMR (400 MHz, CDCl3) δ 4.08 - 3.93 (m, 1H), 3.68 (s, 3H), 2.66 - 2.45 (m, 2H), 2.23 
- 1.99 (m, 2H), 1.93 - 1.80 (m, 2H), 1.05 (t, J = 7.3 Hz, 3H). The spectral data are consistent 




A solution of lithium aluminum hydride (22.5 mL, 22.5 mmol, 1.0 M in Et2O) was added 
dropwise to a 0 oC solution of methyl 4-bromohexanoate (3.01g, 14.4 mmol) in Et2O (60 mL). 
The reaction was allowed to reach room temperature and stirred for 7 hours until TLC showed 
complete consumption of the starting material. The reaction was quenched by the sequential 
slow addition of water, 2.5M NaOH solution, and water. The insoluble salts were removed via 
suction filtration. The mixture was extracted with Et2O. The organic phase was separated and 
dried and then evaporated to give the product which was used for the next step without further 
purification.66 
 
The above alcohol (1.81g, 10 mmol) and imidazole (1.50g, 22 mmol) were stirred in DMF 
(5.0 mL) for 1 h at 0 oC. TBSCl (1.51g, 10 mmol) was then added and the reaction mixture 
was allowed to r.t. over 18 h. The reaction mixture was quenched with water and extracted 
with Et2O. The combined organic layers were washed with brine, dried over MgSO4 and 
concentrated under reduced pressure. The residue was purified by column chromatography on 
silica gel (elution with Pentane) to afford 2-13m as a pale yellow oil (1.59 g, 54% yield). 
1H NMR (400 MHz, CDCl3) δ 4.07 - 3.97 (m, 1H), 3.68 - 3.59 (m, 2H), 1.99 - 1.75 (m, 5H), 
1.70 - 1.58 (m, 1H), 1.04 (t, J = 7.3 Hz, 3H), 0.89 (s, 9H), 0.05 (s, 6H);  
13C NMR (100 MHz, CDCl3) δ 62.5, 60.5, 35.4, 32.4, 30.9, 26.1, 18.5, 12.2, -5.2; 
IR (neat): ν (cm-1) 2953, 2928, 2885, 2856, 1471, 1462, 1405, 1383, 1254, 1097, 961, 836, 
776, 715, 661; 
HRMS (ESI): Calcd for C12H27BrNaOSi ([M+Na]
+): 317.0912, found 317.0903. 
tert-Butyl (3-bromobutyl)(methyl)carbamate 2-13n  
 
The above compound was prepared according to literature procedure.116 
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To a solution of but-3-en-2-one (4.2 g, 60 mmol) in absolute MeOH (30 mL) at 0 °C, was 
added N-methyl-1-phenylmethanamine (6.61 g, 54.5 mmol) dropwise via syringe. The 
mixture was warmed to room temperature and was stirred for 2 h until complete consumption 
of the starting material. The solvent was removed under reduced pressure to give a brown oil. 
Purification by flash chromatography on silica gel (elution Pentane/EtOAc: 2/1) provided the 
desired product as a light brown oil (9.37 g, 90%). 
1H NMR (400 MHz, CDCl3) δ 7.33 – 7.18 (m, 5H), 3.45 (s, 2H), 2.70 – 2.65 (m, 2H), 2.62 – 
2.56 (m, 2H), 2.15 (s, 3H), 2.10 (s, 3H). The spectral data is consistent with that reported in 
the literature.116 
 
The above compound was prepared according to literature procedure.116 
To a solution of 4-(benzyl(methyl)amino)butan-2-one (3.06 g, 16.0 mmol) in absolute MeOH 
(80 mL) at 0 °C, was added formic acid (8.0 mL) and palladium black (231 mg, 5%). The 
resulting suspension was heated to reflux under argon for 1 h until complete consumption of 
the starting material. The catalyst was filtered through Celite and washed with methanol (2×5 
mL). To the filtrate at 0 °C, was added sodium carbonate (5.09 g, 48 mmol) and Boc2O (6.29 
g, 28.0 mmol) and the stirred reaction mixture was warmed to room temperature. After 1 h, 
MeOH was removed under reduced pressure and the residue was extracted with ethyl acetate 
(3×50 mL). The combined organic layers were washed with brine, dried over anhydrous 
MgSO4 and concentrated to provide a colourless oil. Purification by flash chromatography on 
silica gel (elution Pentane/EtOAc: 4/1) provided the desired product as a colourless oil (2.57 g, 
80% for 2 steps). 
1H NMR (400 MHz, CDCl3) δ 3.44 (t, J = 6.5 Hz, 2H), 2.83 (s, 3H), 2.66 (brs, 2H), 2.15 (s, 
3H), 1.43 (s, 9H). The spectral data is consistent with that reported in the literature.116 
 
NaBH4 (1.8 g, 47.5 mmol) was added to a solution of tert-butyl methyl(3-oxobutyl)carbamate 
(2.9 g, 14.4 mmol) in MeOH (80 mL) under an argon atmosphere and the reaction mixture 
was allowed to stir at 0 oC for 2 h. The solvent was removed under reduced pressure and the 
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residue was dissolved in Et2O. The mixture was washed with water and brine, dried over 
Na2SO4, filtered and concentrated under reduced pressure. The crude residue was used 
directly in the next step. 
 
PPh3 (7.4 g, 28.2 mmol) was added to a solution of tert-butyl 
(3-hydroxybutyl)(methyl)carbamate (1.83 g, 9 mmol) and CBr4 (9.34g, 28.2 mmol) in 100 
mL of dry THF. The reaction mixture was stirred under argon overnight. THF was removed 
under reduced pressure and the residue was purified by flash chromatography on silica gel 
(elution from Pentane to Pentane/Et2O 6/1) to afford the desired product 2-13n as a yellow oil 
(1.19 g, 50%). 
1H NMR (400 MHz, CDCl3) δ 4.24 – 3.97 (m, 1H), 3.46 – 3.25 (m, 2H), 2.86 (s, 3H), 2.10 – 
1.93 (m, 2H), 1.74 (d, J = 6.7 Hz, 3H), 1.45 (s, 9H);  
13C NMR (100 MHz, CDCl3) δ 155.8, 79.7, 48.6, 47.6, 39.3, 34.8, 28.6, 26.7; 
IR (neat): ν (cm-1) 2972, 2926, 1691, 1455, 1392, 1365, 1243, 1158, 878, 772; 
HRMS (ESI): Calcd for C10H20BrNaNO2 ([M+Na]
+): 288.0575, found 288.0571. 
2-(4-bromopentyl)-2-methyl-1,3-dioxolane 2-13o 
 
The above compound was prepared according to literature procedure.117 
Under Argon, to a -78 oC solution of delt-hexanolactone (2.28g, 20 mmol) in Et2O (50 mL) 
was added a solution of MeLi (13.8 mL, 22 mmol, 1.6 M in Et2O). The mixture was stirred at 
-78 oC for 1 h. The reaction mixture was quenched by sat. NH4Cl solution. After warming the 
mixture to room temperature, NaCl was added to saturate the solution. The product was 
extracted from the aqueous layer with copious amounts of Et2O (Note: the product is 
extremely soluble in water phase). The combined organic layers were dried over MgSO4 and 
concentrated under reduced pressure to give a colourless oil. The residue was used directly for 




The above compound was synthesized using the same procedure as the one described for 
2-13k and gave 6-bromoheptan-2-one as clear oil (1.2 g, 31% yield over two steps). 
 
To a solution of 6-bromoheptan-2-one (1.2 g, 6.21 mmol) in toluene (15.0 mL) was added 
ethylene glycol (0.77 g, 0.70 mL, 12.4 mmol) and a catalytic amount of p-toluenesulfonic 
acid monohydrate (118 mg, 0.621 mmol). The reaction mixture was then stirred at reflux with 
a Dean-Stark over 48 h. The reaction mixture was cooled to room temperature, quenched by 
sat. sodium bicarbonate solution (10 mL) and then extracted with Et2O (3 x 10 mL). The 
combined organic layers were washed with brine, dried over MgSO4 and concentrated under 
reduced pressure. Purification of the crude by column chromatography on silica gel (elution 
from pentane to pentane/Et2O: 90/10) afforded 2-13o as a colourless oil (1.2 g, 82% yield). 
1H NMR (400 MHz, CDCl3) δ 4.17 - 4.07 (m, 1H), 3.99 - 3.88 (m, 4H), 1.90 - 1.73 (m, 2H), 
1.70 (d, J = 6.7 Hz, 3H), 1.67 - 1.56 (m, 3H), 1.55 - 1.46 (m, 1H), 1.31 (s, 3H); 
13C NMR (100 MHz, CDCl3) δ 110.0, 64.8, 64.8, 51.6, 41.3, 38.5, 26.6, 23.9, 22.5; 
IR (neat): ν (cm-1) 2982, 2952, 2877, 1447, 1376, 1196, 1148, 1045, 947, 871, 592, 533; 
HRMS (ESI): Calcd for C9H18BrO2 ([M+H]
+): 237.0490, found 237.0484. 
2-Bromo-4-methylpentane 2-13p  
 
This compound was prepared from 4-methylpentan-2-ol using an identical procedure as for 
2-13k. The desired product 2-13p was obtained as a colourless oil (2.0 g, 40%). 
1H NMR (400 MHz, CDCl3) δ 4.23 – 4.12 (m, 1H), 1.89 – 1.77 (m, 2H), 1.70 (d, J = 6.6 Hz, 
3H), 1.56 – 1.43 (m, 1H), 0.92 (d, J = 6.5 Hz, 3H), 0.89 (d, J = 6.6 Hz, 3H). The spectral data 
is consistent with that reported in the literature.118 
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General procedure for the direct arylation of 2-bromopropane 
In an argon-filled glove box, a Pyrex glass tube with stir bar was charged with LiCl (85 mg, 2 
mmol, 4 equiv.), Mg (49 mg, 2 mmol, 4 equiv.), ZnCl2 (273 mg, 2 mmol, 4 equiv.), Pd2dba3 
(11.4 mg, 0.0125 mmol, 2.5 mol%) and CPhos (16.4 mg, 0.0375 mmol, 7.5 mol%). The tube 
was sealed with a septum and paraffin, and was taken out of the glove box. Under an argon 
atmosphere, THF (2.5 mL), p-methoxyphenyl trifluoromethanesulfonate (0.5 mmol) and 
2-bromopropane (2 mmol, 4 equiv.) were subsequently added; the septum was quickly 
removed and replaced with a phenolic screw cap and the tube was heated at 60 °C for 16 h in 
an aluminum block. After this time, an aliquot of the crude mixture was diluted with Et2O and 
the ratio of linear/branched regioisomers was measured by GCMS. Then, the reaction mixture 
was diluted with NH4Cl sat. aq. solution (5 mL) and Et2O (5 mL). The organic layer was 
removed and the aqueous fraction was extracted with Et2O (2 x 5 mL). The combined organic 
fractions were dried over MgSO4, filtered and concentrated. The residue was subjected to 
column chromatography to yield the product as a mixture of linear/branched regioisomers 
(which could not be separated by column chromatography). 
1-isopropyl-4-methoxybenzene 2-15a 
 
The above compound was obtained according to the general procedure from 
4-methoxyphenyl trifluoromethanesulfonate and 2-bromopropane. The ratio between the 
regioisomers was determined by GCMS (branched/linear >99:1). Purification by column 
chromatography on silica gel (elution from pentane to pentane/CH2Cl2 90:10) gave 61.5 mg 
(82%) of product as a colourless oil. 




1H NMR (400 MHz, CDCl3) δ 7.17 (d, J = 8.4 Hz, 2H), 6.86 (d, J = 8.7 Hz, 2H), 3.81 (s, 3H), 
2.95 – 2.83 (m, 1H), 1.25 (d, J = 6.9 Hz, 6H). The spectral data is consistent with that 
reported in the literature.119 
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General procedure for the migrative cross-coupling reaction of aryl triflates 
and alkyl bromides 
 
In an argon-filled glove box, a Pyrex glass tube with stir bar was charged with LiCl (85 mg, 2 
mmol, 2 equiv.), Mg (49 mg, 2 mmol, 2 equiv.), ZnCl2 (273 mg, 2 mmol, 2 equiv.), Pd2dba3 
(11.4 mg, 0.0125 mmol, 1.25 mol%) and phosphine L6 (7.2 mg, 0.025 mmol, 2.5 mol%). The 
tube was sealed with a septum and paraffin, and was taken out of the glove box. Under an 
argon atmosphere, THF (2.5 mL), the aryltriflate (1 mmol) and alkylbromide (2 mmol, 2 
equiv.) were subsequently added; the septum was quickly removed and replaced with a 
phenolic screw cap and the tube was heated at 60 °C for 16 h in an aluminum block. After this 
time, an aliquot of the crude mixture was diluted with Et2O and the ratio of linear/branched 
regioisomers was measured by GCMS. Then, the reaction mixture was diluted with NH4Cl sat. 
aq. solution (5 mL) and Et2O (5 mL). The organic layer was removed and the aqueous 
fraction was extracted with Et2O (2 x 5 mL). The combined organic fractions were dried over 
MgSO4, filtered through silica and concentrated. The residue was subjected to column 
chromatography to yield the product as a mixture of linear/branched regioisomers (which 
could not be separated by column chromatography). 
Characterization data for the linear products 
1-Methoxy-4-propylbenzene 2-14a 
 
The above compound was obtained according to the general procedure from 
4-methoxyphenyl trifluoromethanesulfonate and 2-bromopropane. After completion, 
tetradecane was added to the crude mixture. The yield and ratio between the regioisomers was 
determined by GCMS (linear/branched 92:8). Purification by column chromatography on 
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silica gel (elution from pentane to pentane/CH2Cl2 89:11) gave 60 mg (80%) of the mixture of 
regioisomers as yellow oil.119, 120 
GCMS chromatogram of the crude mixture 
 
1H NMR (CDCl3, 400 MHz) δ 7.13-7.06 (m, 2H), 6.86-6.80 (m, 2H), 3.79 (s, 3H), 2.53 (t, J 
= 7.6 Hz, 2H), 1.57-1.67 (m, 2H), 0.93 (t, J = 7.4 Hz, 3H). The spectral data is consistent with 
that reported in the literature.120 
Ethyl 4-propylbenzoate 
 
The above compound was synthesized according to the general procedure from ethyl 
4-(trifluoromethylsulfonyloxy)benzoate and 2-bromopropane 2-13a using Mg powder (4 
equiv.), LiCl (4 equiv.), ZnCl2 (4 equiv.), Pd2dba3 (2.5 mol%) and phosphine L6 (5 mol%). 
The ratio between the regioisomers was determined by GCMS (linear/branched 87:13). 
Purification by column chromatography on silica gel (elution from pentane to pentane/CH2Cl2 
55:45) gave 146 mg (76%) of the mixture of regioisomers as a pale yellow oil.  
1H NMR (400 MHz, CDCl3) δ 7.95 (d, J = 8.3 Hz, 2H), 7.23 (d, J = 7.6 Hz, 2H), 4.36 (q, J = 
7.1 Hz, 2H), 2.64 (t, J = 7.3 Hz, 2H), 1.72 – 1.60 (m, 2H), 1.38 (t, J = 7.1 Hz, 3H), 0.94 (t, J = 
7.3 Hz, 3H). The spectral data is consistent with that reported in the literature.121 
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The above compound was synthesized according to the general procedure from 
4-methoxyphenyl trifluoromethanesulfonate (2-12a) and 1-bromopentane (2-13f). The ratio 
between the regioisomers was determined by GCMS (linear/branched 96:4). Purification by 
column chromatography on silica gel (elution from pentane to pentane/CH2Cl2 85:15) gave 
146 mg (82%) of the mixture of regioisomers as colourless oil. 
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GCMS chromatogram of the crude mixture: 
 
1H NMR (CDCl3, 400 MHz) δ 7.13-7.07 (m, 2H), 6.85-6.80 (m, 2H), 3.79 (s, 3H), 2.55 (t, J 
= 7.6 Hz, 2H), 1.63-1.53 (m, 2H), 1.39-1.27 (m, 4H), 0.89 (t, J = 7.0 Hz, 3H). The spectral 
data is consistent with that reported in the literature.122 
From 2-bromopentane (2-13e): The ratio between the regioisomers was determined by 
GCMS (linear/branched 91:9). Purification by column chromatography on silica gel (elution 




GCMS chromatogram of the crude mixture 
 
From 3-bromopentane (2-13d): The ratio between the regioisomers was determined by 
GCMS (linear/branched 90:10). Purification by column chromatography on silica gel (elution 
from pentane to pentane/CH2Cl2 85:15) gave 141 mg (79%) of the mixture of regioisomers as 
colourless oil. 





Ethyl 6-(4-methoxyphenyl)hexanoate 2-14x 
 
The above compound was synthesized according to the general procedure from 
4-methoxyphenyl trifluoromethanesulfonate (2-12a) and ethyl 5-bromohexanoate (2-13g). 
The ratio between the regioisomers was determined by GCMS (linear/branched 89:11). 
Purification by column chromatography on silica gel (elution from pentane to pentane/Et2O 
89:11) gave 185 mg (74%) of the mixture of regioisomers as colourless oil.  




1H NMR (400 MHz, CDCl3) δ 7.11 – 7.06 (m, 2H), 6.85 – 6.80 (m, 2H), 4.12 (q, J = 7.2 Hz, 
2H), 3.79 (s, 3H), 2.55 (t, J = 7.3 Hz, 2H), 2.28 (t, J = 7.8 Hz, 2H), 1.69 – 1.57 (m, 4H), 1.39 
– 1.32 (m, 2H), 1.25 (t, J = 7.1 Hz, 3H). The spectral data is consistent with that reported in 
the literature.123 
From ethyl 4-bromohexanoate (2-13h): The ratio between the regioisomers was determined 
by GCMS (linear/branched 87:13). Purification by column chromatography on silica gel 
(elution from pentane to pentane/Et2O 89:11) gave 173 mg (69%) of the mixture of 
regioisomers as colourless oil. 






The above compound was synthesized according to the general procedure from 
4-methoxyphenyl trifluoromethanesulfonate (2-13a) and 3-(bromobutyl)benzene (2-13k). The 
ratio between the regioisomers was determined by GCMS (linear/branched 70:30). 
Purification by column chromatography on silica gel (elution from pentane to pentane/ 









GCMS chromatogram of the crude mixture 
 
1H NMR (400 MHz, CDCl3) δ 7.29 – 7.24 (m, 2H), 7.20 – 7.15 (m, 3H), 7.10 – 7.06 (m, 2H), 
6.84 – 6.79 (m, 2H), 3.78 (s, 3H), 2.63 (t, J = 7.2 Hz, 2H), 2.58 (t, J = 7.1 Hz, 2H), 1.67 – 
1.61 (m, 4H). The spectral data are consistent with those reported in the literature.124 
From 2-(bromobutyl)benzene (2-13j). The ratio between the regioisomers was determined by 
GCMS (linear/branched 65:35). Purification by column chromatography on silica gel (elution 
from pentane to pentane/ CH2Cl2 65:35) gave 140 mg (58%) of the mixture of regioisomers as 
colourless oil.  






The above compound was synthesized according to the general procedure from 
4-methoxyphenyl trifluoromethanesulfonate and 3-(bromobutoxy)-tert-butyldimethylsilane 
(2-13i) using Pd2dba3 (0.025 mmol, 22.9 mg) and phosphine L6 (0.05 mmol, 14.4 mg). The 
ratio between the regioisomers was determined by GCMS (linear/branched 93:7). The 
reaction mixture was quenched with NH4Cl (3 mL) and extracted twice with Et2O (2 x 10 
mL). The organic layers were dried over MgSO4, filtered off and concentrated to dryness. The 





GCMS chromatogram of the crude mixture 
 
 
Acetyl chloride (0.1 equiv.) was added dropwise to MeOH (50 mL) at 0 °C. This solution was 
next slowly added to the crude residue in MeOH (10 mL) at 0 °C. The reaction mixture was 
stirred at room temperature for 16 h. The crude mixture was concentrated to dryness and the 
residue was filtered on silica (pentane/Et2O 60:40) to furnish 148 mg (82% for 2 steps) of 
2-14y as a thick oil. 
1H NMR (400 MHz, CDCl3) δ 7.12 – 7.08 (m, 2H), 6.85 – 6.81 (m, 2H), 3.79 (s, 3H), 3.66 (t, 
J = 6.3 Hz, 2H), 2.59 (t, J = 7.4 Hz, 2H), 1.72 – 1.56 (m, 4H);  
13C-{1H} NMR (CDCl3, 100 MHz) δ 157.9, 134.6, 129.4, 113.9, 63.0, 55.4, 34.9, 32.5, 27.9; 
IR (neat): ν (cm-1) 3335, 2918, 2850, 1511, 1492, 1244, 1035; 
HRMS (ESI): Calcd for C11H16NaO2 ([M+Na]





The above compound was synthesized according to the general procedure from 
4-methoxyphenyl trifluoromethanesulfonate (2-12a) and 
((4-bromohexyl)oxy)(tert-butyl)dimethylsilane (2-13m) using Pd2dba3 (0.025 mmol, 22.9 mg) 
and phosphine L6 (0.05 mmol, 14.4 mg). The ratio between the regioisomers was determined 
by GCMS (linear/branched 84:16). Purification by column chromatography on silica gel 
(elution from pentane to pentane/ CH2Cl2 85:15) gave 170 mg (53%) of the mixture of 
regioisomers as colourless oil. 
GCMS chromatogram of the isolated regioisomers 
 
1H NMR (400 MHz, CDCl3) δ 7.11 – 7.07 (m, 2H), 6.84 – 6.81 (m, 2H), 3.79 (s, 3H), 3.59 (t, 
J = 6.6 Hz, 2H), 2.60 – 2.49 (m, 2H), 1.60 – 1.49 (m, 4H), 1.37 – 1.31 (m, 4H), 0.90 (s, 9H), 
0.04 (s, 6H);  
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13C NMR (100 MHz, CDCl3) δ 157.8, 135.1, 129.4, 113.8, 63.4, 55.4, 35.1, 33.0, 31.9, 29.2, 
26.1, 25.8, 18.5, -5.1; 
IR (neat): ν (cm-1) 2927, 2854, 1612, 1511, 1463, 1360, 1245, 1176, 1098, 1039, 834, 775; 
HRMS (ESI): Calcd for C19H34NaO2Si ([M+Na]
+): 345.2226, found 345.2222. 
tert-Butyl (4-(4-methoxyphenyl)butyl)(methyl)carbamate 2-14ab 
 
The above compound was synthesized according to the general procedure from 
4-methoxyphenyl trifluoromethanesulfonate (2-12a) and tert-butyl 
(3-bromobutyl)(methyl)carbamate (2-13n) using Pd2dba3 (0.025 mmol, 22.9 mg) and 
phosphine L6 (0.05 mmol, 14.4 mg). The ratio between the regioisomers was determined by 
GCMS (linear/branched 80:20). Purification by column chromatography on silica gel (elution 
from pentane to pentane/Et2O 6:1) gave 139 mg (48%) of the mixture of regioisomers as 
yellow oil. 




1H NMR (400 MHz, CDCl3) δ 7.14 – 7.05 (m, 2H), 6.87 – 6.77 (m, 2H), 3.78 (s, 3H), 3.21 
(brs, 2H), 2.81 (s, 3H), 2.57 (t, J = 7.2 Hz, 2H), 1.63 – 1.49 (m, 4H), 1.44 (s, 9H);  
13C NMR (100 MHz, CDCl3) δ 157.7, 155.8, 129.2, 127.7, 113.7, 79.1, 55.2, 48.7, 48.2, 47.4, 
34.6, 34.0, 28.5; 
IR (neat): ν (cm-1) 2928, 1692, 1512, 1393, 1365, 1245, 1163; 
HRMS (ESI): Calcd for C17H27NNaO3 ([M+Na]
+): 316.1889, found 316.1885.                           
2-(5-(4-methoxyphenyl)pentyl)-2-methyl-1,3-dioxolane 2-14ac 
 
The above compound was synthesized according to the general procedure from 
4-methoxyphenyl trifluoromethanesulfonate (2-12a) and 
2-(4-bromopentyl)-2-methyl-1,3-dioxolane (2-13o). The ratio between the regioisomers was 
determined by GCMS (linear/branched 89:11). Purification by column chromatography on 
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silica gel (elution from pentane to pentane/ Et2O 90:10) gave 160 mg (61%) of the mixture of 
regioisomers as colourless oil. 
GCMS chromatogram of the crude mixture 
 
1H NMR (400 MHz, CDCl3) δ 7.14 – 7.04 (m, 2H), 6.86 – 6.79 (m, 2H), 3.98 – 3.87 (m, 4H), 
3.79 (s, 3H), 2.67 – 2.48 (m, 2H), 1.68 – 1.33 (m, 8H), 1.31 (s, 3H);  
13C NMR (100 MHz, CDCl3) δ 157.8, 135.0, 129.4, 113.8, 110.3, 64.7, 55.4, 39.3, 35.1, 31.8, 
29.6, 24.1, 23.9; 
IR (neat): ν (cm-1) 2981, 2929, 2854, 1611, 1511, 1376, 1300, 1241, 1066, 1037, 947, 828; 
HRMS (ESI): Calcd for C16H24NaO3 ([M+Na]
+): 287.1623, found 287.1621. 
1-Methoxy-4-(4-methylpentyl)benzene 2-14ad 
 
The above compound was synthesized according to the general procedure from 
4-methoxyphenyl trifluoromethanesulfonate (2-12a) and 2-bromo-4-methylpentane (2-13p). 
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The ratio between the regioisomers was determined by GCMS (linear/branched 89:11). 
Purification by column chromatography on silica gel (elution from pentane to pentane/ 
CH2Cl2 85:15) gave 156 mg (81%) of the mixture of regioisomers as colourless oil. 
GCMS chromatogram of the crude mixture 
 
 1H NMR (400 MHz, CDCl3) δ 7.13 – 7.07 (m, 2H), 6.85 – 6.81 (m, 2H), 3.80 (s, 3H), 2.56 
– 2.50 (m, 2H), 1.63 – 1.52 (m, 3H), 1.26 – 1.18 (m, 2H), 0.88 (d, J = 6.6 Hz, 6H). The 
spectral data are consistent with those reported in the literature.122 
1-Isobutyl-4-methoxybenzene 2-14ae  
 
In an argon-filled glove box, a Pyrex glass tube with a stirring bar was charged with LiCl 
(84.8 mg, 2 mmol, 2 equiv.), ZnCl2 (273 mg, 2 mmol, 2 equiv.), Pd2dba3 (23 mg, 0.025 mmol, 
2.5 mol%) and phosphine L6 (14.4 mg, 0.050 mmol, 5.0 mol%). The tube was sealed with a 
septum and paraffin, and was taken out. Under an argon atmosphere, THF (0.5 mL), 
tert-butylmagnesium chloride (2.0 mL, 2 mmol, 2 equiv., 1.0 M in THF) and 
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4-methoxyphenyl trifluoromethanesulfonate (2-12a, 256 mg, 1 mmol) were subsequently 
added; the septum was quickly removed and replaced with a phenolic screw cap and the tube 
was heated at 60 °C for 48 h in an aluminum block. After this time, a fraction of the crude 
mixture was diluted with Et2O and the ratio of linear/branched regioisomers was measured by 
GCMS (linear/branched >99:1). Then, the reaction mixture was diluted with NH4Cl sat. aq. 
solution (5 mL) and Et2O (5 mL). The organic layer was removed and the aqueous fraction 
was extracted with Et2O (2 x 5 mL). The combined organic fractions were dried over MgSO4, 
filtered and concentrated. The residue was subjected to column chromatography on silica gel 
(elution from pentane to pentane/CH2Cl2 85:15) to yield the product (104 mg, 63%).  
GCMS chromatogram of the crude mixture 
 
1H NMR (400 MHz, CDCl3) δ 7.10 – 7.05 (m, 2H), 6.87 – 6.81 (m, 2H), 3.80 (s, 3H), 2.43 (d, 
J = 7.2 Hz, 2H), 1.91 – 1.77 (m, 1H), 0.91 (d, J = 6.6 Hz, 6H). The spectral data is consistent 





The above compound was synthesized according to the general procedure from phenyl 
trifluoromethanesulfonate and 3-bromopentane. The ratio between the regioisomers was 
determined by GCMS (linear/branched 89:11). Purification by column chromatography on 
silica gel (elution with pentane) gave 130 mg (88%) of the mixture of regioisomers as 
colourless oil. 
GCMS chromatogram of the crude mixture 
 
1H NMR (400 MHz, CDCl3) δ 7.32 – 7.26 (m, 2H), 7.22 – 7.15 (m, 3H), 2.61 (t, J = 7.4 Hz, 
2H), 1.68 – 1.58 (m, 2H), 1.40 – 1.30 (m, 4H), 0.90 (t, J = 7.0 Hz, 3H). The spectral data is 
consistent with that reported in the literature.126 
1-Methyl-4-pentylbenzene 2-14c 
 
The above compound was synthesized according to the general procedure from 4-tolyl 
trifluoromethanesulfonate and 3-bromopentane. The ratio between the regioisomers was 
determined by GCMS (linear/branched 90:10). Purification by column chromatography on 
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silica gel (elution from pentane to pentane/Et2O 95:5) gave 102 mg (63%) of the mixture of 
regioisomers as colourless oil. 
GCMS chromatogram of the crude mixture 
 
1H NMR (400 MHz, CDCl3) δ 7.13 – 7.06 (m, 4H), 2.57 (t, J = 7.7 Hz, 2H), 2.33 (s, 3H), 
1.66 – 1.56 (m, 2H), 1.39 – 1.29 (m, 4H), 0.90 (t, J = 7.0 Hz, 3H). The spectral data is 
consistent with that reported in the literature.126 
1-Chloro-4-pentylbenzene 2-14d 
 
The above compound was synthesized according to the general procedure from 
4-chlorophenyl trifluoromethanesulfonate and 3-bromopentane. The ratio between the 
regioisomers was determined by GCMS (linear/branched 90:10). Purification by column 
chromatography on silica gel (elution with pentane) gave 132 mg (72%) of the mixture of 
regioisomers as colourless oil. 
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GCMS chromatogram of the crude mixture 
 
1H NMR (400 MHz, CDCl3) δ 7.25 – 7.21 (m, 2H), 7.13 – 7.08 (m, 2H), 2.57 (t, J = 7.8 Hz, 
2H), 1.64 – 1.55 (m, 2H), 1.36 – 1.28 (m, 4H), 0.89 (t, J = 7.0 Hz, 3H);  
13C NMR (100 MHz, CDCl3) δ 141.5, 131.4, 129.9, 128.4, 35.4, 31.5, 31.2, 22.7, 14.2; 
IR (neat) ν (cm-1): 3060, 3025, 2953, 2923, 2854, 1492, 1451, 742, 698; 




The above compound was synthesized according to the general procedure from 
4-(trifluoromethoxy)phenyl trifluoromethanesulfonate and 3-bromopentane. The ratio 
between the regioisomers was determined by GCMS (linear/branched 92:8). Purification by 
column chromatography on silica gel (elution with pentane) gave 143 mg (62%) of the 
mixture of regioisomers as colourless oil. 
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GCMS chromatogram of the crude mixture 
 
1H NMR (400 MHz, CDCl3) δ 7.21 – 7.16 (m, 2H), 7.15 – 7.07 (m, 2H), 2.60 (t, J = 7.5 Hz, 
2H), 1.66 – 1.56 (m, 2H), 1.38 – 1.27 (m, 4H), 0.90 (t, J = 6.9 Hz, 3H);  
19F NMR (376 MHz, CDCl3) δ -57.94;  
13C NMR (100 MHz, CDCl3) δ 147.4, 141.8, 129.7, 120.9, 35.4, 31.6, 31.3, 22.7, 14.2; 
IR (neat): ν (cm-1) 2930, 1508, 1256, 1221, 1163, 1245; 




The above compound was synthesized according to the general procedure from ethyl 
4-(trifluoromethylsulfonyloxy)benzoate and 3-bromopentane. The ratio between the 
regioisomers was determined by GCMS (linear/branched 82:18). Purification by column 
chromatography on silica gel (elution from pentane to pentane/Et2O 70:30) gave 197 mg 
(89%) of the mixture of regioisomers as colourless oil. 
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GCMS chromatogram of the crude mixture 
 
1H NMR (400 MHz, CDCl3) δ 7.97 – 7.94 (m, 2H), 7.25 – 7.22 (m, 2H), 4.36 (q, J = 7.1 Hz, 
2H), 2.65 (t, J = 7.6 Hz, 2H), 1.68 – 1.60 (m, 2H), 1.39 (t, J = 6.3 Hz, 3H), 1.36 – 1.28 (m, 
4H), 0.89 (t, J = 6.9 Hz, 3H);  
13C NMR (100 MHz, CDCl3) δ 166.9, 148.5, 129.7, 128.5, 128.1, 60.9, 36.1, 31.6, 31.0, 22.6, 
14.5, 14.1; 
IR (neat): ν (cm-1) 2929, 1715, 1270, 1103, 1021, 762; 
HRMS (ESI): Calcd for C14H20NaO2 ([M+Na]
+): 243.1361, found 243.1356. 
4-Pentylbenzaldehyde 2-14g 
 
The above compound was synthesized according to the general procedure from 
4-(formylphenyl) trifluoromethanesulfonate and 3-bromopentane (4 equiv.), Mg powder (4 
equiv.), ZnCl2 (4 equiv.) and LiCl (4 equiv.). The ratio between the regioisomers was 
determined by GCMS (linear/branched 65:35). Purification by column chromatography on 
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silica gel (elution from pentane to pentane/CH2Cl 50:50) gave 97 mg (55%) of the mixture of 
regioisomers as yellow oil. 
GCMS chromatogram of the crude mixture 
 
1H NMR (400 MHz, CDCl3) δ 9.97 (s, 1H), 7.83 – 7.77 (m, 2H), 7.36 – 7.32 (m, 2H), 2.68 (t, 
J = 7.3 Hz, 2H), 1.69 – 1.62 (m, 2H), 1.37 – 1.29 (m, 4H), 0.90 (t, J = 6.7 Hz, 3H). The 
spectral data is consistent with that reported in the literature.127 
1-Methoxy-3-pentylbenzene 2-14h 
 
The above compound was synthesized according to the general procedure from 
3-methoxyphenyl trifluoromethanesulfonate and 3-bromopentane. The ratio between the 
regioisomers was determined by GCMS (linear/branched 90:10). Purification by column 
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chromatography on silica gel (elution with pentane) gave 156 mg (89%) of the mixture of 
regioisomers as pale yellow oil. 
GCMS chromatogram of the crude mixture 
 
1H NMR (400 MHz, CDCl3) δ 7.20 (td, J = 7.4, 1.4 Hz, 1H), 6.78 (d, J = 7.7 Hz, 1H), 6.75 – 
6.71 (m, 2H), 3.81 (s, 3H), 2.58 (t, J = 7.4 Hz, 2H), 1.68 – 1.55 (m, 2H), 1.40 – 1.28 (m, 4H), 
0.90 (t, J = 6.9 Hz, 3H);  
13C NMR (100 MHz, CDCl3) δ 159.7, 144.8, 129.3, 121.0, 114.3, 110.9, 55.3, 36.1, 31.7, 
31.2, 22.7, 14.2; 
IR (neat): ν (cm-1) 2927, 2856, 1584, 1454, 1259, 1152, 1047; 




The above compound was synthesized according to the general procedure from 
3-fluorophenyl trifluoromethanesulfonate and 3-bromopentane. The ratio between the 
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regioisomers was determined by GCMS (linear/branched 91:9). Purification by column 
chromatography on silica gel (elution with pentane) gave 118 mg (71%) of the mixture of 
regioisomers as colourless oil. 
GCMS chromatogram of the crude mixture 
 
1H NMR (400 MHz, CDCl3) δ 7.26 – 7.19 (m, 1H), 6.95 (d, J = 7.6 Hz, 1H), 6.91 – 6.84 (m, 
2H), 2.60 (t, J = 7.8 Hz, 2H), 1.67 – 1.57 (m, 2H), 1.38 – 1.27 (m, 4H), 0.90 (t, J = 6.9 Hz, 
3H); 
19F NMR (376 MHz, CDCl3) δ -114.19;  
13C NMR (100 MHz, CDCl3) δ 163.0 (d, J = 244.9 Hz), 145.7 (d, J = 7.0 Hz), 129.7 (d, J = 
8.4 Hz), 124.2 (d, J = 2.6 Hz), 115.3 (d, J = 20.6 Hz), 112.5 (d, J = 21.1 Hz), 35.8, 31.6, 31.0, 
22.7, 14.2; 
IR (neat): ν (cm-1) 2927, 2858, 1590, 1488, 1448, 1253, 1140, 781; 






The above compound was synthesized according to the general procedure from 
3-(trifluoromethyl)phenyl trifluoromethanesulfonate and 3-bromopentane. The ratio between 
the regioisomers was determined by GCMS (linear/branched 90:10). Purification by column 
chromatography on silica gel (elution with pentane) gave 158 mg (73%) of the mixture of 
regioisomers as colourless oil. 
GCMS chromatogram of the crude mixture 
 
1H NMR (400 MHz, CDCl3) δ 7.46 – 7.41 (m, 2H), 7.40 – 7.33 (m, 2H), 2.66 (t, J = 7.1 Hz, 
2H), 1.68 – 1.59 (m, 2H), 1.38 – 1.30 (m, 4H), 0.90 (t, J = 7.0 Hz, 3H);  
19F NMR (376 MHz, CDCl3) δ -62.54;  
13C NMR (100 MHz, CDCl3) δ 143.9, 131.9, 130.7 (q, J = 32.0 Hz), 128.7, 125.2 (q, J = 3.7 
Hz), 124.4 (q, J = 273.2 Hz), 122.6 (q, J = 3.8 Hz), 35.9, 31.6, 31.1, 22.6, 14.1; 
IR (neat): ν (cm-1) 2958, 2928, 2858, 1325, 1162, 1123, 1073, 798, 702, 661; 






The above compound was synthesized according to the general procedure from 
3-cyanophenyl trifluoromethanesulfonate and 3-bromopentane. The ratio between the 
regioisomers was determined by GCMS (linear/branched 90:10). Purification by column 
chromatography on silica gel (elution from pentane to pentane/Et2O 80:20) gave 150 mg 
(87%) of the mixture of regioisomers as colourless oil. 
GCMS chromatogram of the crude mixture 
 
1H NMR (400 MHz, CDCl3) δ 7.51 – 7.44 (m, 2H), 7.43 – 7.34 (m, 2H), 2.63 (t, J = 7.3 Hz, 
2H), 1.66 – 1.57 (m, 2H), 1.38 – 1.29 (m, 4H), 0.89 (t, J = 6.8 Hz, 3H). The spectral data is 





The above compound was synthesized according to the general procedure from 2-tolyl 
trifluoromethanesulfonate and 3-bromopentane. The ratio between the regioisomers was 
determined by GCMS (linear/branched 98:2). Purification by column chromatography on 
silica gel (elution using pentane) gave 144 mg (89%) of the mixture of regioisomers as 
colourless oil. 
GCMS chromatogram of the crude mixture 
 
1H NMR (400 MHz, CDCl3) δ 7.17 – 7.07 (m, 4H), 2.59 (t, J = 7.7 Hz, 2H), 2.31 (s, 3H), 
1.63 – 1.55 (m, 2H), 1.41 – 1.33 (m, 4H), 0.92 (t, J = 7.1 Hz, 3H);  
13C NMR (100 MHz, CDCl3) δ 141.3, 136.0, 130.2, 128.9, 126.0, 125.8, 33.5, 32.1, 30.1, 
22.8, 19.4, 14.2; 
IR (neat): ν (cm-1) 2926, 2858, 1492, 1459, 739; 






The above compound was synthesized according to the general procedure from 
2-chlorophenyl trifluoromethanesulfonate and 3-bromopentane. The ratio between the 
regioisomers was determined by GCMS (linear/branched 99.5:0.5). Purification by column 
chromatography on silica gel (elution using pentane) gave 121 mg (66%) of the mixture of 
regioisomers as colourless oil. 
GCMS chromatogram of the crude mixture 
 
1H NMR (400 MHz, CDCl3) δ 7.33 (dd, J = 7.7, 1.4 Hz, 1H), 7.23 – 7.09 (m, 3H), 2.72 (t, J 
= 7.6 Hz, 2H), 1.68 – 1.58 (m, 2H), 1.40 – 1.32 (m, 4H), 0.91 (t, J = 6.8 Hz, 3H);  
13C NMR (100 MHz, CDCl3) δ 140.6, 134.0, 130.5, 129.5, 127.2, 126.8, 33.7, 31.8, 29.6, 
22.7, 14.2; 
IR (neat): ν (cm-1) 2926, 2858, 1473, 1442, 1051, 1033, 749; 






The above compound was synthesized according to the general procedure from 
2-fluorophenyl trifluoromethanesulfonate and 3-bromopentane. The ratio between the 
regioisomers was determined by GCMS (linear/branched 98:2). Purification by column 
chromatography on silica gel (elution using pentane) gave 101 mg (61%) of the mixture of 
regioisomers as colourless oil. 
GCMS chromatogram of the crude mixture 
 
1H NMR (400 MHz, CDCl3) δ 7.21 – 7.12 (m, 2H), 7.05 (td, J = 7.4, 1.3 Hz, 1H), 7.00 (ddd, 
J = 9.4, 8.0, 1.2 Hz, 1H), 2.63 (t, J = 7.4 Hz, 2H), 1.66 – 1.57 (m, 2H), 1.39 – 1.31 (m, 4H), 
0.90 (t, J = 6.6 Hz, 3H);  
19F NMR (376 MHz, CDCl3) δ -119.11;  
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13C NMR (100 MHz, CDCl3) δ 161.3 (d, J = 244.3 Hz), 130.7 (d, J = 5.3 Hz), 129.8 (d, J = 
16.1 Hz), 127.4 (d, J = 8.1 Hz), 123.9 (d, J = 3.5 Hz), 115.2 (d, J = 22.4 Hz), 31.7, 30.0, 29.1 
(d, J = 2.3 Hz), 22.6, 14.2; 
IR (neat): ν (cm-1) 2923, 2854, 1491, 1457, 1229, 1120, 753; 




The above compound was synthesized according to the general procedure from 
2-(dibenzylamino)phenyl trifluoromethanesulfonate and 3-bromopentane. The ratio between 
the regioisomers was determined by GCMS (linear/branched >99/1). Purification by column 
chromatography on silica gel (elution from pentane to pentane/CH2Cl2 92:8) gave 283 mg 
(82%) colourless oil. 




1H NMR (400 MHz, CDCl3) δ 7.30 – 7.18 (m, 11H), 7.10 – 6.99 (m, 3H), 4.05 (s, 4H), 2.80 
(t, J = 7.4 Hz, 2H), 1.66 – 1.56 (m, 2H), 1.43 – 1.33 (m, 4H), 0.92 (t, J = 6.7 Hz, 3H);  
13C NMR (100 MHz, CDCl3) δ 149.7, 139.2, 138.7, 129.7, 129.0, 128.2, 127.0, 126.0, 124.1, 
123.3, 58.0, 32.4, 30.7, 30.6, 22.8, 14.3; 
IR (neat): ν (cm-1) 3060, 3025, 2953, 2923, 2854, 1492, 1451, 742, 698; 
HRMS (ESI): Calcd for C25H30N ([M+H]
+): 344,2378, found 344.2377. 
6-(2-Aminophenyl)hexanoic acid 2-16 
 
The above compound was synthesized according to the general procedure from 
2-(dibenzylamino)phenyl trifluoromethanesulfonate (2-12o) and ethyl 5-bromohexanoate 
(2-13g). The ratio between the regioisomers was determined by GCMS 
(linear/branched >99/1). The reaction mixture was quenched with NH4Cl (3 mL) and 
extracted twice with Et2O (2 x 10 mL). The organic layers were dried over MgSO4, filtered 
off and concentrated to dryness. The residue was directly used in the next step.  





The crude residue was dissolved in EtOH (10 mL) and Pd/C (10 %) was added in one portion. 
The atmosphere was replaced by hydrogen (1 atm.) by three cycle of vacuum / H2. After 
overnight, the resulting mixture was filtered through a pad of celite and rinced with CH2Cl2 
(20 mL). The filtrate was concentrated in vacuo and purified by column chromatography 
(elution from CH2Cl2 to CH2Cl2/MeOH 97:3) to give 130 mg of ethyl 
6-(2-aminophenyl)hexanoate (55% for two steps) as an oil. 
 
To a solution of LiOH (1M) was added ethyl 6-(2-aminophenyl)hexanoate (120 mg, 0.51 
mmol) in THF (5 mL). The reaction mixture was stirred at room temperature for 16 h. After 
completion, the crude mixture was quenched with water (5 mL) and extracted with CH2Cl2 
(15 mL). The aqueous phase was acidified to pH = 6 and extracted twice with CH2Cl2 (2 x 10 
mL). The combined organic layers were washed with brine, dried over MgSO4, filtered off 
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and concentrated in vacuo to furnish the desired product 2-16 as a white solid (107 mg, 
quant.). 
1H NMR (500 MHz, CDCl3) δ 7.06 – 7.01 (m, 2H), 6.74 (td, J = 7.4, 1.2 Hz, 1H), 6.68 (dd, J 
= 8.2, 1.2 Hz, 1H), 2.50 (t, J = 7.8 Hz, 2H), 2.37 (t, J = 7.5 Hz, 2H), 1.74 – 1.62 (m, 4H), 1.49 
– 1.42 (m, 2H);  
13C NMR (126 MHz, CDCl3) δ 179.2, 144.0, 129.6, 127.1, 126.7, 119.0, 115.8, 34.0, 31.2, 
29.2, 28.5, 24.7; 
IR (neat): ν (cm-1) 3388, 3322, 2933, 2903, 2859, 1716, 1621, 1455, 1492, 1229, 1176, 962, 
792, 767, 732, 671, 443; 
HRMS (ESI): Calcd for C12H18NO2 ([M+H]
 +): 208.1338, found 208.1334. 
1,3-Dimethyl-2-pentylbenzene 2-14p 
 
The above compound was synthesized according to the general procedure from 
2,6-dimethylphenyl trifluoromethanesulfonate and 3-bromopentane using Pd2dba3 (2.5 mol%) 
and phosphine L6 (5 mol%). The ratio between the regioisomers was determined by GCMS 
(linear/branched >99/1). Purification by column chromatography on silica gel (elution using 
pentane) gave 72 mg (41%) of 2-14p as colourless oil. 




1H NMR (400 MHz, CDCl3) δ 6.99 (s, 3H), 2.67 – 2.51 (m, 2H), 2.32 (s, 6H), 1.52 – 1.35 (m, 
6H), 0.92 (t, J = 7.1 Hz, 3H);  
13C NMR (100 MHz, CDCl3) δ 139.9, 136.1, 128.2, 125.5, 32.6, 29.9, 29.9, 28.9, 22.7, 19.9, 
14.2; 
IR (neat): ν (cm-1) 2953, 2922, 2854, 1465, 1377, 765; 




The above compound was synthesized according to the general procedure from 
(naphthalen-2-yl trifluoromethanesulfonate) and 3-bromopentane. The ratio between the 
regioisomers was determined by GCMS (linear/branched 89:11). Purification by column 
chromatography on silica gel (elution using pentane) gave 170 mg (86%) of the mixture of 
regioisomers as colourless oil. 




1H NMR (400 MHz, CDCl3) δ 7.83 – 7.75 (m, 3H), 7.63 – 7.60 (m, 1H), 7.48 – 7.39 (m, 2H), 
7.38 – 7.32 (m, 1H), 2.78 (t, J = 7.5 Hz, 2H), 1.77 – 1.66 (m, 2H), 1.41 – 1.33 (m, 4H), 0.91 (t, 
J = 6.7 Hz, 3H);  
13C NMR (100 MHz, CDCl3) δ 140.6, 133.8, 132.1 127.8, 127.7, 127.6, 127.5, 126.4, 125.9, 
125.1, 36.3, 31.7, 31.2, 22.7, 14.2; 
IR (neat): ν (cm-1) 3050, 2957, 2925, 2854, 1600, 1508, 1457, 1377, 853, 815, 744, 476; 




The above compound was synthesized according to the general procedure from pyridin-2-yl 
trifluoromethanesulfonate and 3-bromopentane. The ratio between the regioisomers was 
determined by GCMS (linear/branched 79:21). Purification by column chromatography on 
silica gel (elution from pentane/EtOAc 90:10 to 60:40) gave 132 mg (88%) of the mixture of 
regioisomers as yellow oil. 
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1H NMR (400 MHz, CDCl3) δ 8.57 – 8.48 (m, 1H), 7.58 (tt, J = 7.6, 1.9 Hz, 1H), 7.13 (dt, J 
= 7.7, 1.2 Hz, 1H), 7.08 (ddd, J = 7.5, 4.9, 1.2 Hz, 1H), 2.77 (t, J = 7.5 Hz, 2H), 1.78 – 1.68 
(m, 2H), 1.39 – 1.31 (m, 4H), 0.89 (t, J = 7.2 Hz, 3H). The spectral data is consistent with that 
reported in the literature.129 




The above compound was synthesized according to the general procedure from quinolin-8-yl 
trifluoromethanesulfonate and 3-bromopentane. The ratio between the regioisomers could not 
be determined by GCMS (overlapping of the two peaks). Purification by column 
chromatography on silica gel (elution from pentane to pentane/Et2O 93:7) gave 102 mg (51%) 
of the pure compound 2-14s as colourless oil. 




1H NMR (400 MHz, CDCl3) δ 8.94 (dd, J = 4.1, 1.8 Hz, 1H), 8.13 (dd, J = 8.2, 1.8 Hz, 1H), 
7.66 (dd, J = 8.0, 1.5 Hz, 1H), 7.56 (ddt, J = 7.0, 1.5, 0.8 Hz, 1H), 7.46 (dd, J = 8.1, 7.1 Hz, 
1H), 7.38 (dd, J = 8.2, 4.2 Hz, 1H), 3.28 (t, J = 7.6 Hz, 2H), 1.85 – 1.76 (m, 2H), 1.48 – 1.34 
(m, 4H), 0.90 (t, J = 7.1 Hz, 3H);  
13C NMR (100 MHz, CDCl3) δ 149.4, 147.1, 141.8, 136.5, 128.8, 128.6, 126.4, 125.9, 120.9, 
32.1, 31.5, 30.5, 22.8, 14.2; 
IR (neat): ν (cm-1) 2953, 2923, 2855, 1498, 1466, 1366, 825, 794; 
HRMS (ESI): Calcd for C14H18N ([M+H]
+): 200.1439, found 200.1435; 
1-Penty-1-cyclohexene 2-14t 
 
The above compound was synthesized according to the general procedure from 
cyclohex-1-en-1-yl trifluoromethanesulfonate and 3-bromopentane. The ratio between the 
regioisomers was determined by GCMS (linear/branched 93:7). Purification by column 
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chromatography on silica gel (elution using pentane) gave 149 mg (98%) of the mixture of 
regioisomers as colourless oil. 
GCMS chromatogram of the crude mixture 
 
1H NMR (400 MHz, CDCl3) δ 5.41 – 5.35 (m, 1H), 2.02 – 1.86 (m, 6H), 1.65 – 1.52 (m, 4H), 
1.42 – 1.19 (m, 6H), 0.88 (t, J = 7.1 Hz, 3H);  
13C NMR (100 MHz, CDCl3) δ 138.3, 120.6, 38.2, 31.8, 28.5, 27.6, 25.4, 23.2, 22.8, 22.8, 
14.3; 
IR (neat): ν (cm-1) 2922, 2856, 1458, 1438, 917; 






The above compound was synthesized according to the general procedure from 
1,4-benzenebis(trifluoromethanesulfonate) and 3-bromopentane. The ratio between the 
regioisomers was determined by GCMS (linear/branched 85:15). Purification by column 
chromatography on silica gel (elution using pentane) gave 154 mg (71%) of the mixture of 
regioisomers as colourless oil. 
GCMS chromatogram of the crude mixture 
 
1H NMR (400 MHz, CDCl3) δ 7.09 (s, 4H), 2.57 (t, J = 7.5 Hz, 4H), 1.67 – 1.56 (m, 4H), 
1.38 – 1.29 (m, 8H), 0.89 (t, J = 6.8 Hz, 6H);  
13C NMR (100 MHz, CDCl3) δ 140.2, 128.4, 35.7, 31.7, 31.4, 22.7, 14.2; 
IR (neat): ν (cm-1) 2956, 2924, 2855, 1513, 1458; 
GCMS (EI) m/z for C16H26 ([M]
+•): 218. 




The above compound was synthesized according to the general procedure from estrone 
trifluoromethanesulfonate and 3-bromopentane. The ratio between the regioisomers was 
determined by GCMS (linear/branched 90:10). Purification by column chromatography on 
silica gel (elution from pentane to pentane/Et2O 70:30) gave 190 mg (59%) of the mixture of 
regioisomers as a white off solid. 
GCMS chromatogram of the crude mixture 
 
1H NMR (400 MHz, CDCl3) δ 7.22 (d, J = 7.9 Hz, 1H), 6.99 (d, J = 8.0 Hz, 1H), 6.94 (s, 1H), 
2.94 – 2.88 (m, 2H), 2.59 – 2.47 (m, 3H), 2.46 – 2.39 (m, 1H), 2.34 – 2.26 (m, 1H), 2.21 – 
1.94 (m, 4H), 1.70 – 1.42 (m, 9H), 1.38 – 1.33 (m, 3H), 0.92 (t, J = 2.9 Hz, 6H);  
13C NMR (100 MHz, CDCl3) δ 220.8, 140.4, 136.9, 136.2, 129.0, 125.9, 125.2, 50.6, 48.0, 
44.4, 38.3, 35.9, 35.5, 31.7, 31.7, 31.3, 29.5, 26.7, 25.8, 22.6, 21.6, 14.1, 14.0; 
IR (neat): ν (cm-1) 2923, 2856, 1736, 1499, 1454, 1405, 1374, 1256, 1082, 1005, 820; 
HRMS (ESI): Calcd for C23H32NaO ([M+Na]
+): 347.2351, found 347.2342. 
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General procedure for the bromination of alkanes  
 
The mixtures of alkyl bromides were prepared according to a literature procedure.67 
The alkane (50 or 100 mL), Br2 (5 or 10 mmol) and MnO2 (85%, 10 mmol or 20 mmol, 2 
equiv.) were charged in a round-bottom flask and heated at the appropriate temperature until 
the disappearance of bromine color. After completion, the reaction mixture was filtered and 
the filtrate was washed with water. The combined organic phases were dried over MgSO4. 
The residue was then distilled to afford the mixture of alkane isomer. The ratio between 
isomers was either determined by 1H NMR or GCMS. 
Bromopentane isomers 
 
This mixture was prepared according to the general procedure from pentane (36 °C, 1 h) to 
furnish mixture in 47% yield (0.7 g) as colourless oil. The ratio between isomers was 
determined by 1H NMR (2-bromopentane/3-bromopentane = 79:21) by comparison with 
commercially available compounds. 
Bromohexane isomers 
 
This mixture was prepared according to the general procedure from hexane (60 °C, 20 min) to 
furnish mixture in 45% yield (0.74 g) as brown oil. The ratio between isomers was 
determined by 1H NMR (2-bromohexane/3-bromohexane = 59:41) by comparison with 
commercially available compounds. 
Bromododecane isomers 
 
This mixture was prepared according to the general procedure (80 °C, 2 h) to furnish mixture  
in 79% yield (1.02 g) as yellow oil. The ratio between isomers was determined by GCMS 
(ratio of mixture of five secondary bromododecane isomers: 19:17:20:18:26) 
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General procedure for the cross-coupling reaction of aryl triflates and 
mixtures of alkyl bromides 
 
In an argon-filled glove box, a Pyrex glass tube with stir bar was charged with LiCl (85 mg, 2 
mmol, 2 equiv.), Mg (49 mg, 2 mmol, 2 equiv.), ZnCl2 (273 mg, 2 mmol, 2 equiv.), Pd2dba3 
(11.4 mg, 0.0125 mmol, 1.25 mol%) and phosphine L6 (7.2 mg, 0.025 mmol, 2.5 mol%). The 
tube was sealed with a septum and paraffin, and was taken out. Under an argon atmosphere, 
THF (2.5 mL), aryltriflate (1 mmol) and the mixture of alkyl bromides (2 mmol, 2 equiv.) 
were subsequently added; the septum was quickly removed and replaced with a phenolic 
screw cap and the tube was heated at 60 °C for 16 h in an aluminum block. After this time, an 
aliquot of the crude mixture was diluted with Et2O and the ratio of linear/branched 
regioisomers was measured by GCMS. Then, the reaction mixture was diluted with NH4Cl sat. 
aq. solution (5 mL) and Et2O (5 mL). The organic layer was removed and the aqueous 
fraction was extracted with Et2O (2 x 5 mL). The combined organic fractions were dried over 
MgSO4, filtered through silica, and concentrated. The residue was subjected to column 
chromatography to yield the product as a mixture of linear/branched regioisomers (which 
could not be separated by column chromatography). 
1-Pentyl-4-methoxybenzene 2-14a’ 
 
The above compound was synthesized according to the general procedure from 
4-methoxyphenyl trifluoromethanesulfonate and the mixture of bromopentane 
(2-bromopentane/3-bromopentane = 79:21 from 1H-NMR analysis). The ratio between the 
linear/branched regioisomers was determined by GCMS (linear/branched 91:9). Purification 
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by column chromatography on silica gel (elution from pentane to pentane/ CH2Cl2 89:11) 
gave 137 mg (77%) of the mixture of regioisomers as pale yellow oil. 




The above compound was synthesized according to the general procedure from 
4-methoxyphenyl trifluoromethanesulfonate and the mixture of bromohexane 
(2-bromohexane/3-bromohexane = 59:41 from 1H-NMR analysis). The ratio between the 
linear/branched regioisomers was determined by GCMS (linear/branched 88:12). Purification 
by column chromatography on silica gel (elution from pentane to pentane/ CH2Cl2 89:11) 
gave 163 mg (85%) of the mixture of regioisomers as colourless oil. 




1H NMR (400 MHz, CDCl3) δ 7.10 (d, J = 8.7 Hz, 2H), 6.83 (d, J = 8.7 Hz, 2H), 3.79 (s, 3H), 
2.55 (t, J = 7.5 Hz, 2H), 1.63 – 1.52 (m, 2H), 1.37 – 1.26 (m, 6H), 0.89 (t, J = 6.7 Hz, 3H). 
The spectral data is consistent with that reported in the literature.128 
1-Methoxy-4-undecylbenzene 2-14ag 
 
The above compound was synthesized according to the general procedure from 
4-methoxyphenyl trifluoromethanesulfonate and the mixture of bromododecane (ratio of 
mixture of five secondary bromododecane isomers: 19:17:20:18:26 by GC-MS analysis) 
using Pd2dba3 (0.025 mmol, 22.9 mg) and phosphine L6 (0.05 mmol, 14.4 mg). The ratio 
between the linear/branched regioisomers was determined by GCMS (linear/branched 89:11). 
Purification by column chromatography on silica gel (elution from pentane to pentane/CH2Cl2 
88:12) gave 198 mg (72%) of the mixture of regioisomers as colourless oil. 
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GCMS chromatogram of the crude mixture 
 
1H NMR (400 MHz, CDCl3) δ 7.09 (d, J = 8.7 Hz, 2H), 6.82 (d, J = 8.9 Hz, 2H), 3.79 (s, 3H), 
2.54 (t, J = 7.6 Hz, 2H), 1.63 – 1.53 (m, 2H), 1.33 – 1.20 (m, 18H), 0.88 (t, J = 6.9 Hz, 3H); 
13C NMR (100 MHz, CDCl3) δ 157.7, 135.2, 129.4, 113.8, 55.4, 35.2, 32.1, 31.9, 29.8, 29.8, 
29.8, 29.7, 29.7, 29.5, 29.4, 22.8, 14.3; 
IR (neat): ν (cm-1) 2922, 2852, 1511, 1464, 1245, 1176, 1039, 1082, 1005, 820; 




The above compound was synthesized according to the general procedure from o-tolyl 
trifluoromethanesulfonate and the mixture of bromododecane using Pd2dba3 (0.025 mmol, 
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22.9 mg) and phosphine L6 (0.05 mmol, 14.4 mg). The ratio between the linear/branched 
regioisomers was determined by GCMS (linear/branched 97:3). Purification by column 
chromatography on silica gel (elution using pentane) gave 169 mg (65%) of the mixture of 
regioisomers as colourless oil. 
GCMS chromatogram of the crude mixture 
 
1H NMR (400 MHz, CDCl3) δ 7.21 – 7.02 (m, 4H), 2.65 – 2.55 (m, 2H), 2.32 (s, 3H), 1.57 
(dd, J = 15.5, 7.8 Hz, 2H), 1.38 – 1.24 (m, 18H), 0.90 (t, J = 6.9 Hz, 3H);  
13C NMR (100 MHz, CDCl3) δ 141.3, 136.0, 130.2, 128.9, 126.0, 125.8, 33.5, 32.1, 30.5, 
29.9, 29.8, 29.8, 29.8, 29.8, 29.7, 29.5, 22.9, 19.4, 14.3; 
IR (neat): ν (cm-1) 2921, 2852, 1462, 739; 






The above compound was synthesized according to the general procedure from 
2-chlorophenyl trifluoromethanesulfonate and the mixture of bromododecane. The ratio 
between the linear/branched regioisomers was determined by GCMS (linear/branched >99/1). 
Purification by column chromatography on silica gel (elution using pentane) gave 198 mg 
(67%) of the mixture of regioisomers as colourless oil. 
GCMS chromatogram of the crude mixture 
 
1H NMR (400 MHz, CDCl3) δ 7.33 (dd, J = 7.8, 1.4 Hz, 1H), 7.24 – 7.08 (m, 3H), 2.77 – 
2.68 (m, 2H), 1.61 (dt, J = 15.4, 7.6 Hz, 2H), 1.38 – 1.24 (m, 18H), 0.89 (t, J = 6.9 Hz, 3H);  
13C NMR (100 MHz, CDCl3) δ 140.6, 134.1, 130.5, 129.5, 127.2, 126.8, 33.8, 32.1, 29.9, 
29.8, 29.8, 29.8, 29.7, 29.6, 29.6, 29.5, 22.9, 14.3; 
IR (neat): ν (cm-1) 2921, 2852, 1466, 1443, 1051, 749; 




2H Labeling experiments  
 
In an argon-filled glove box, Pyrex glass tube with stir bar was charged with LiCl (85 mg, 2 
mmol, 2 equiv.), Mg (49 mg, 2 mmol, 2 equiv.), ZnCl2 (273 mg, 2 mmol, 2 equiv.), Pd2dba3 
(11.4 mg, 0.0125 mmol, 1.25 mol%) and phosphine L6 (7.2 mg, 0.025 mmol, 2.5 mol%). The 
tube was sealed with a septum and paraffin, and was taken out. Under an argon atmosphere, 
THF (2.5 mL), 4-methoxyphenyl trifluoromethanesulfonate (1 mmol, 256 mg) and either 
2-bromopropane-2-d1 (98% D) (2-13q) or 1-Bromopropane-1,1-d2 (99% D) (2-13r) (2 mmol, 
2 equiv.) was subsequently added and the flask was heated at 60 °C for 16 h in an aluminum 
block. After this time, an aliquot of the crude mixture was diluted with Et2O and the ratio of 
linear/branched regioisomers was measured by GCMS. Then, the reaction mixture was 
diluted with NH4Cl sat. aq. solution (5 mL) and Et2O (5 mL). The organic layer was removed 
and the aqueous fraction was extracted with Et2O (2 x 5 mL). The combined organic fractions 
were dried over MgSO4, filtered through silica, and concentrated. The residue was subjected 
to column chromatography (elution from pentane to 88:12 pentane/CH2Cl2) to yield the 
deuterated product as a colourless oil. 
Experiments with deuterated substrates: the deuterium contents were 




From 2-bromopropane-2-d1 (2-13q) 
2H NMR (92 MHz, Chloroform-d) δ 2.52 (s, 0.05 D), 1.60 (s, 0.87 D), 0.93 (s, 0.08 D). 
From 1-Bromopropane-1,1-d2 (2-13r) 
2H NMR (92 MHz, Chloroform-d) δ 2.50 (s, 1.19 D), 1.60 (s, 0.13 D), 0.91 (s, 0.69 D).  
Gram-scale synthesis of 2-14ai 
In an argon-filled glove box, a Schlenck flask with stir bar was charged with LiCl (0.848 g, 20 
mmol, 2 equiv.), Mg (0.486 g, 20 mmol, 2 equiv.), ZnCl2 (2.73 g, 20 mmol, 2 equiv.), Pd2dba3 
(114 mg, 0.125 mmol, 1.25 mol%) and phosphine L6 (72 mg, 0.25 mmol, 2.5 mol%). The 
flask was sealed with a septum and paraffin, and was taken out. Under an argon atmosphere, 
THF (25 mL), 2-chlorophenyl trifluoromethanesulfonate (10 mmol, 2.6 g) and the mixture of 
bromododecanes (20 mmol, 5 g, 2 equiv.) were subsequently added and the flask was heated 
at 60 °C for 16 h in an aluminum block. After this time, a fraction of the crude mixture was 
diluted with Et2O and the ratio of linear/branched regioisomers was assessed by GCMS 
(linear/branched >99/1). Then, the reaction mixture was diluted with NH4Cl sat. aq. solution 
(20 mL) and Et2O (20 mL). The organic layer was removed and the aqueous fraction was 
extracted with Et2O (2 x 20 mL). The combined organic fractions were dried over MgSO4, 
filtered through silica, and concentrated. The residue was subjected to column 












3. Chapter 3: Direct Barbier-Negishi coupling of secondary alkyl bromides 
with aryl and alkenyl triflates and nonaflates 
General procedure for the screening reactions (Barbier conditions) 
In an argon-filled glove box, a Pyrex glass tube equipped with stirring bar was charged with 
LiCl (42.4 mg, 1.0 mmol, 2.0 equiv.), Mg powder (24.3 mg, 1 mmol, 2.0 equiv.), ZnCl2 (136 
mg, 1mmol, 2.0 equiv.), well-defined catalyst (5.0 mol%) or Pd2dba3 (97%) (2.5 
mol%)/lignad (5.0 mol%). The tube was sealed with a septum and paraffin, and was taken out 
of the glove box. Under an argon atmosphere, THF (2.5 mL), p-methoxyphenyl 
trifluoromethanesulfonate (0.5 mmol) and 3-bromopentane (151 mg, 1.0 mmol, 2.0 equiv.) 
were subsequently added; the septum was quickly removed and replaced with a phenolic 
screw cap and the tube was heated at 60 °C for 24 h in an aluminum block. After this time, 
dodecane was added and the reaction mixture was diluted with NH4Cl sat. aq. solution (5 mL) 
and Et2O (5 mL). An aliquot of the crude mixture was taken. The yield was determined by 
GC using dodecane as the internal standard and the ratio of direct/migrative cross-coupling 
products was also measured by GC.  
(Note: Using Zn/LiCl system instead of Mg/LiCl/ZnCl2 system resulted in low conversion 
and low yield.) 
General procedure for the screening reactions (Performed using the 
preformed organozinc halide) 
The preformed organozinc halide was prepared and titrated according to the procedures 
reported by Knochel and co-workers.130 
In an argon-filled glove box, a Pyrex glass tube equipped with stirring bar was charged with 
well-defined catalyst (5.0 mol%) or Pd2dba3 (97%) (2.5 mol%)/lignad (5.0 mol%). The tube 
was sealed with a septum and paraffin, and was taken out of the glove box. Under an argon 
atmosphere, THF (to make the final concentration of the mixture to 0.2 M), p-methoxyphenyl 
trifluoromethanesulfonate (0.5 mmol) were added followed by the addition of preformed 
organozinc halide in THF solution at 0 oC. The septum was quickly removed and replaced 
with a phenolic screw cap and the tube was heated at 60 °C for 24 h in an aluminum block. 
After this time, dodecane was added and the reaction mixture was diluted with NH4Cl sat. aq. 
solution (5 mL) and Et2O (5 mL). An aliquot of the crude mixture was taken. The yield was 
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determined by GC using dodecane as the internal standard and the ratio of direct/migrative 
cross-coupling products was also measured by GC.  
General procedure for the screening reactions (for primary alkyl bromides, 
using 1-Br pentane) 
In an argon-filled glove box, a Pyrex glass tube equipped with stirring bar was charged with 
LiCl (42.4 mg, 1.0 mmol, 2.0 equiv.), Mg powder (24.3 mg, 1 mmol, 2.0 equiv.), ZnCl2 (136 
mg, 1mmol, 2.0 equiv.), Pd2dba3 (97%) (Y mol%)/lignad (Z mol%). The tube was sealed with 
a septum and paraffin, and was taken out of the glove box. Under an argon atmosphere, THF 
(2.5 mL), triflate or nonaflate (0.5 mmol, 1.0 e.q.) and 1-bromopentane (151 mg, 1.0 mmol, 
2.0 equiv.) were subsequently added; the septum was quickly removed and replaced with a 
phenolic screw cap and the tube was heated at 60 oC or 40 oC in an aluminum block or 25 oC 
water bath for 24 h. After this time, the reaction mixture was diluted with NH4Cl sat. aq. 
solution (5 mL) and Et2O (5 mL). An aliquot of the crude mixture was measured by GC-MS 
to give an estimated ratio described in the following table. 
Synthesis of ligands 
1,3-diisopropoxybenzene 
 
The alkylation product was prepared according to a modified procedure reported by Yasuda 
and co-workers.131 
To an oven-dried argon flushed 500 mL two-necked flask was added resorcinol (22.02g, 200 
mmol) and K2CO3 (110 g, 800 mmol). The flask was flushed and backfilled with argon three 
times before the addition of 2-bromopropane (75.1 mL, 800 mmol) and dry DMF (200 mL). 
The reaction mixture was heated to 70 oC and stirred for 24 h before it was cooled to room 
temperature and quenched with demineralized water (1000 mL) and Et2O (200 mL). The 
mixture was extracted with Et2O three times. The combined organic phases were washed with 
brine, dried over Na2SO4 and concentrated in vacuo. Purification by silica gel column 
chromatography (Pentane/Et2O) gave the desired product as a colourless oil (37.23g, 96%). 
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1H NMR (400 MHz, Chloroform-d) δ 7.20 – 7.09 (m, 1H), 6.55 – 6.38 (m, 3H), 4.53 (hept, J 
= 6.1 Hz, 2H), 1.34 (d, J = 6.2 Hz, 12H). 
The NMR data for this compound was consistent with literature data. 
2-iodo-1,3-diisopropoxybenzene 
 
The iodination step was performed according to a modified procedure reported by Koning and 
co-workers.132  
To a solution of 1,3-diisopropoxybenzene (13.6 g, 70 mmol) in THF (100 mL) in an oven 
dried argon flushed two-necked flask at 0 oC was added n-BuLi solution (77 mmol). The 
reaction mixture was stirred for 1 h at room temperature before it was cooled to 0 oC. Then, a 
solution of iodine (19.5 g, 77 mmol) in THF (100 mL) was added dropwise and the mixture 
was stirred for further 4 h at room temperature. After that time, demineralized water (200 mL) 
was added and the mixture was extracted with EtOAc (4 x 100 mL). The combined organic 
phases were washed with brine, dried over Na2SO4 and concentrated in vacuo. Purification by 
silica gel column chromatography (pentane/CH2Cl2) gave the desired product as a pale yellow 
oil (17.6 g, 78%). 
1H NMR (400 MHz, Chloroform-d) δ 7.23 – 7.14 (m, 1H), 6.51 – 6.44 (m, 2H), 4.56 (hept, J 
= 6.2 Hz, 2H), 1.40 (d, J = 6.2 Hz, 12H). 
13C NMR (101 MHz, CDCl3) δ 158.5, 129.3, 107.2, 83.1, 72.1, 22.3. 
IR (neat): ν (cm-1) 2976, 2930, 1584, 1454, 1245, 1107, 1053, 762, 706.  
HRMS (ESI): Calcd for C12H17INaO2 [M+Na]





The product was synthesized according to the procedure reported by Yasuda and 
co-workers.131 
DIAD (25 g, 123 mmol, 2.72 e.q.) in toluene (37.5 mL) was added to a solution of resorcinol 
(5.0 g, 45.4 mmol, 1.0 e.q.), cyclohexanol (13.6 g, 136 mmol, 3.0 e.q.) and 
triphenylphosphine (35g, 133 mmol, 2.94 e.q.) in THF (50 mL) at 0 °C. The mixture was 
stirred for 24 h at room temperature. After that time, hydrogen peroxide (30%, around 15 mL) 
was added to the mixture to oxidize unreacted triphenylphosphine, followed by addition of 
cyclohexane resulting in precipitation of triphenylphosphine oxide, which then was removed 
by filtration. The aqueous layer was separated and extracted with cyclohexane two times. The 
combined organic layers were washed with sodium hydroxide solution (1 M, 3 times). The 
solvent was removed in vacuo and the crude product was purified by silica gel column 
chromatography, affording the desired product as a pale yellow oil (5.6 g, 45%). 
1H NMR (400 MHz, Chloroform-d) δ 7.20 – 7.07 (m, 1H), 6.55 – 6.41 (m, 3H), 4.27 – 4.13 
(m, 2H), 2.08 – 1.91 (m, 4H), 1.87 – 1.75 (m, 4H), 1.62 – 1.46 (m, 6H), 1.42 – 1.28 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ 159.2, 129.8, 108.2, 104.4, 75.5, 32.0, 25.8, 24.0. 
IR (neat): ν (cm-1) 2933, 2857, 1597, 1486, 1370, 1282, 1142, 1052, 838, 759, 688.  
HRMS (ESI): Calcd for C18H27O2 [M+H]
+: 275.2006, found: 275.2003. 
((2-iodo-1,3-phenylene)bis(oxy))dicyclohexane 
 
To a solution of 1,3-bis(cyclohexyloxy)benzene (5.49 g, 20 mmol) in THF (50 mL) in an 
oven dried argon flushed two-necked flask at 0 oC was added n-BuLi solution (22 mmol). The 
reaction mixture was stirred for 3 h at 0 oC and 1 h at room temperature before it was cooled 
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to 0 oC again. Then, a solution of iodine (5.58 g, 22 mmol) in THF (50 mL) was added 
dropwise and the mixture was stirred at room temperature overnight. After that time, saturated 
Na2S2O3 solution was added and the mixture was extracted with EtOAc (4 x 50 mL). The 
combined organic phases were washed with brine, dried over Na2SO4 and concentrated in 
vacuo. Purification by silica gel column chromatography (pentane/CH2Cl2) gave the desired 
product as a pale yellow oil (5.6 g, 70%). 
1H NMR (400 MHz, Chloroform-d) δ 7.20 – 7.07 (m, 1H), 6.51 – 6.36 (m, 2H), 4.43 – 4.25 
(m, 2H), 1.97 – 1.79 (m, 8H), 1.77 – 1.64 (m, 4H), 1.58 – 1.48 (m, 2H), 1.47 – 1.32 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ 158.3, 129.2, 106.9, 82.9, 76.6, 31.6, 25.8, 23.4. 
IR (neat): ν (cm-1) 2933, 2857, 1582, 1457, 1248, 1075, 761, 706.  
HRMS (ESI): Calcd for C18H26IO2 [M+H]
+: 401.0972, found: 401.0976. 
N1,N1,N3,N3-tetramethylbenzene-1,3-diamine 
 
In the glovebox, an oven dried argon flushed flask was charged with PdCl2 (74.1 mg, 0.418 
mmol) and JosiphosSL-J009-1 (268 mg, 0.418 mmol). Dry and degassed DME (100 mL) was 
added to the reaction mixture. The latter was then stirred for 10 min before dimethylamine 
(62.7 mL, 2.0 M in THF, 125 mmol) and 1,3-dichlorobenzene (2.40 mL, 20.9 mmol) was 
added. The mixture was cooled to 0 oC and LiHMDS (62.7 mL, 1.0 M in THF, 62.7 mmol) 
was slowly added. After the addition, the ice bath was removed and the reaction mixture was 
stirred for 16 h at room temperature. The mixture was quenched with demineralized water 
(100 mL) and extracted with EtOAc (3 x 80 mL). The combined organic phases were washed 
with brine, dried over Na2SO4 and concentrated in vacuo. Purification by silica gel column 
chromatography (Cyclohexane/Ethyl acetate) gave the product as a pale orange oil (3.45 g, 
99.9%). 
1H NMR (500 MHz, Chloroform-d) δ 7.19 – 7.13 (m, 1H), 6.27 – 6.21 (m, 2H), 6.17 – 6.13 
(m, 1H), 2.98 (s, 12H). 
13C NMR (126 MHz, CDCl3) δ 151.9, 129.6, 102.7, 98.0, 41.0. 
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The NMR data for this compound was consistent with literature datas.133 
2-iodo-N1,N1,N3,N3-tetramethylbenzene-1,3-diamine 
 
To an oven dried argon flushed flask was added a solution of 
N1,N1,N3,N3-tetramethylbenzene-1,3-diamine (164 mg, 1.0 mmol) in hexane (2.0 mL) and 
s-BuLi (1.1 mmol). The mixture was stirred for 1 h at 80 oC. The heating was turned off and 
1-chloro-2-iodoethane (0.109 mL, 1.2 mmol) was slowly added. The mixture was stirred for a 
further 30 min at 80 oC before it was cooled to room temperature and quenched with a 
saturated NH4Cl solution (8.0 mL). The mixture was extracted with EtOAc three times. The 
combined organic phases were washed with brine, dried over Na2SO4 and concentrated in 
vacuo. The crude was diluted with cyclohexane/EtOAc (1/1, 30 mL) and filtered through a 
short plug of Celite to yield the product as a brown solid (263 mg, 91%). 
1H NMR (500 MHz, Acetone-d6) δ 7.29 – 7.22 (m, 1H), 6.88 – 6.84 (m, 2H), 2.70 (s, 12H). 
13C NMR (126 MHz, Acetone-d6) δ 158.0, 130.5, 116.8, 101.6, 45.6. 
IR (neat): ν (cm-1) 2979, 2937, 2824, 2779, 1573, 1461, 1301, 1003, 791, 723.  
HRMS (ESI): Calcd for C10H16IN2 [M+H]
+: 291.0353, found: 291.0351. 
m.p.: 30-32 oC. 
General procedure A for the Ulmann coupling of azoles 
In the glovebox, an oven-dried argon flushed flask was charged with CuI (98%) (0.2 e.q.), 
Cs2CO3 (2.5 e.q.) and azoles (1.6 e.q.). Then outside the glovebox, a solution of 
2-iodo-1,3-disubstituted benzene (1.0 e.q.) in DMSO (0.5 M) was added to the flask under 
argon. The flask was sealed and stirred at 120 oC for 72 h under vigorous stirring. After that 
time, the mixture was cooled to room temperature, diluted with cyclohexane/EtOAc (1/1) and 
filtered over a plug of Celite. The mixture was extracted with ice cold brine three times and 
the aqueous phase was re-extracted with EtOAc two times. The combined organic phases 
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were dried over Na2SO4 and concentrated in vacuo. Purification by silica gel column 
chromatography (cyclohexane/EtOAc) gave the desired coupling product. 
1-(2,6-dimethoxyphenyl)-1H-imidazole 
 
Obtained according to the general procedure A on 6.0 mmol scale (0.61 g, 50% yield). 
1H NMR (400 MHz, Chloroform-d) δ (ppm) 7.60 – 7.53 (m, 1H), 7.36 – 7.29 (m, 1H), 7.21 – 
7.15 (m, 1H), 7.05 – 6.99 (m, 1H), 6.74 – 6.60 (m, 2H), 3.78 (s, 6H). 
The NMR data for this compound was consistent with literature data.134 
1-(2,6-diisopropoxyphenyl)-1H-imidazole 
 
Obtained according to the general procedure A on 2.0 mmol scale (0.418 g, 80% yield). 
1H NMR (500 MHz, Acetone-d6) δ 7.55 – 7.45 (m, 1H), 7.36 – 7.26 (m, 1H), 7.10 – 7.03 (m, 
1H), 7.02 – 6.95 (m, 1H), 6.85 – 6.75 (m, 2H), 4.54 (hept, J = 6.1 Hz, 2H), 1.19 (d, J = 6.0 Hz, 
12H). 
13C NMR (126 MHz, Acetone-d6) δ 154.8, 139.6, 130.0, 128.4, 122.1, 119.3, 108.6, 72.3, 
22.3. 
IR (neat): ν (cm-1) 2977, 2932, 1594, 1509, 1471, 1252, 1110, 1054, 777, 730. 
HRMS (ESI): Calcd for C15H21N2O2 [M+H]
+: 261.1598, found: 261.1601. 
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m.p.: 55-58 oC. 
1-(2,6-diisopropoxyphenyl)-1H-pyrazole 
 
Obtained according to the general procedure A on 2.0 mmol scale (0.278 g, 53% yield). 
1H NMR (500 MHz, Acetone-d6) δ 7.59 – 7.55 (m, 1H), 7.54 – 7.48 (m, 1H), 7.34 – 7.27 (m, 
1H), 6.79 – 6.74 (m, 2H), 6.37 – 6.29 (m, 1H), 4.45 (hept, J = 6.1 Hz, 2H), 1.14 (d, J = 6.1 Hz, 
12H). 
13C NMR (126 MHz, Acetone-d6) δ 156.5, 139.8, 133.1, 130.5, 123.9, 109.4, 105.6, 72.6, 
22.4. 
IR (neat): ν (cm-1) 2976, 2931, 1592, 1522, 1471, 1251, 1110, 1066, 779, 738. 
HRMS (ESI): Calcd for C15H20N2NaO2 [M+Na]
+: 283.1417, found: 283.1413. 
m.p.: 30-32 oC. 
1-(2,6-bis(cyclohexyloxy)phenyl)-1H-imidazole 
 
Obtained according to the general procedure A on 2.0 mmol scale (0.501 g, 73% yield). 
1H NMR (400 MHz, Chloroform-d) δ 7.63 – 7.55 (m, 1H), 7.24 – 7.17 (m, 1H), 7.14 – 7.10 
(m, 1H), 7.07 – 7.02 (m, 1H), 6.66 – 6.59 (m, 2H), 4.23 – 4.14 (m, 2H), 1.82 – 1.71 (m, 4H), 
1.63 – 1.54 (m, 4H), 1.50 – 1.39 (m, 6H), 1.31 – 1.22 (m, 6H). 
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13C NMR (101 MHz, CDCl3) δ 153.7, 139.1, 128.8, 127.6, 121.4, 118.6, 107.6, 76.6, 31.5, 
25.6, 23.2. 
IR (neat): ν (cm-1) 2933, 2858, 1594, 1511, 1470, 1251, 1079, 956, 903, 777, 730, 662.  
HRMS (ESI): Calcd for C21H29N2O2 [M+H]
+: 341.2224, found: 341.2222. 
2-(1H-imidazol-1-yl)-N1,N1,N3,N3-tetramethylbenzene-1,3-diamine 
 
In the glovebox, a 5.0 mL microwave vial equipped with a stirring bar was charged with CuI 
(99.999%) (38.1 mg, 0.2 mmol), Cs2CO3 (815 mg, 2.5 mmol) and imidazole (109 mg, 1.6 
mmol). Then outside the glovebox, a solution of 
2-iodo-N1,N1,N3,N3-tetramethylbenzene-1,3-diamine (290 mg, 1.0 mmol) in DMSO (3.0 mL) 
was added under argon. The vial was sealed and shaked before heating it in the microwave for 
9 h at 160 oC. After that time, the mixture was diluted with cyclohexane/EtOAc (1/1, 20 mL) 
and filtered through a plug of Celite. The mixture was extracted with ice cold brine twice and 
the aqueous phase was re-extracted with EtOAc twice. The combined organic phases were 
dried over MgSO4 and the solvent was removed in vacuo. Purification by silica gel column 
chromatography (Cyclohexane/EtOAc to EtOAc) gave the product as a pale yellow solid (111 
mg, 48%). 
1H NMR (500 MHz, Acetone-d6) δ 7.67 – 7.57 (m, 1H), 7.27 – 7.21 (m, 1H), 7.19 – 7.15 (m, 
1H), 7.11 – 7.04 (m, 1H), 6.90 – 6.73 (m, 2H), 2.37 (s, 12H). 
13C NMR (126 MHz, Acetone-d6) δ 151.2, 139.3, 129.7, 129.4, 124.4, 121.1, 114.0, 43.1. 
IR (neat): ν (cm-1) 3106, 2844, 2836, 2790, 1582, 1479, 1294, 1046, 1006, 798, 741.  
HRMS (ESI): Calcd for C13H19N4 [M+H]
+: 231.1604, found: 231.1602. 





In the glovebox, an oven-dried argon flushed flask was charged with CuI (98%) (57.1 mg, 0.3 
mmol), Cs2CO3 (815 mg, 2.5 mmol), LiI (268 mg, 2.0 mmol) and pyrazole (109 mg, 1.6 
mmol). Then outside the glovebox, a solution of 
2-iodo-N1,N1,N3,N3-tetramethylbenzene-1,3-diamine (1.0 mmol) in DMSO (2.0 mL) was 
added to the flask under argon. The flask was sealed and stirred at 120 oC for 72 h under 
vigorous stirring. After that time, the mixture was cooled to room temperature, diluted with 
cyclohexane/EtOAc (1/1) and filtered over a plug of Celite. The mixture was extracted with 
ice cold brine three times and the aqueous phase was re-extracted with EtOAc two times. The 
combined organic phases were dried over Na2SO4 and concentrated in vacuo. Purification by 
silica gel column chromatography (cyclohexane/EtOAc) gave the desired  product as a white 
solid (126 mg, 55%). 
1H NMR (500 MHz, Acetone-d6) δ 7.66 – 7.63 (m, 1H), 7.61 – 7.58 (m, 1H), 7.26 – 7.20 (m, 
1H), 6.74 – 6.70 (m, 2H), 6.44 – 6.41 (m, 1H), 2.38 (s, 12H). 
13C NMR (126 MHz, Acetone-d6) δ 152.2, 140.2, 133.9, 130.0, 127.3, 113.1, 106.9, 43.4. 
IR (neat): ν (cm-1) 2925, 2836, 2787, 1584, 1482, 1317, 1017, 790, 741.  
HRMS (ESI): Calcd for C13H19N4 [M+H]
+: 231.1604, found: 231.1606. 
General procedure B for the synthesis of azole-based phosphine ligands 
The phosphine ligands were prepared following a modified procedure of Beller and 
co-workers.78a 
An oven-dried argon flushed flask was charged with the corresponding aryl-1H-azole (1.0 e.q., 
0.5 M in THF). The mixture was cooled to -30 oC. Then, n-BuLi (1.0 e.q.) was added slowly 
and the mixture was stirred for 30 min at that temperature. A solution of the corresponding 
dialkylchlorophosphine (1.1 e.q.) in THF (2.0 M) was added dropwise before warming the 
mixture up to room temperature and stirring it for 1 h at 50 oC. After cooling with ice bath, 
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degassed saturated NH4Cl solution was added and the mixture was extracted with degassed 
toluene three times. The combined organic phases were dried over Na2SO4 and the solvent 
was removed in vacuo. Purification by silica gel column chromatography 
(Cyclohexane/EtOAc) provided the corresponding azole-based phosphine ligands. 
1-(2,6-bis(cyclohexyloxy)phenyl)-2-(di-tert-butylphosphaneyl)-1H-imidazole  
 
Obtained as a white solid (203.6 mg, 42% yield) according to the general procedure B on 
1.0 mmol scale. 
1H NMR (400 MHz, Chloroform-d) δ 7.40 – 7.30 (m, 1H), 7.26 – 7.19 (m, 1H), 6.91 – 6.83 
(m, 1H), 6.60 – 6.51 (m, 2H), 4.21 – 4.11 (m, 2H), 1.96 – 1.83 (m, 2H), 1.79 – 1.68 (m, 2H), 
1.67 – 1.23 (m, 16H), 1.22 (s, 9H), 1.19 (s, 9H). 
13C NMR (101 MHz, Chloroform-d) δ 155.0, 148.7 (d, J = 19.0 Hz), 129.6, 129.2, 123.9, 
119.3, 106.4, 76.8, 33.2 (d, J = 16.0 Hz), 32.2, 31.4, 30.8, 30.6, 25.6, 23.7 (d, J = 3.8 Hz). 
31P NMR (162 MHz, Chloroform-d) δ 8.3. 
IR (neat): ν (cm-1) 2935, 2857, 1594, 1469, 1363, 1254, 1080, 961, 778, 740. 
HRMS (ESI): Calcd for C29H46N2O2P [M+H]






Obtained as a white solid (210 mg, 63% yield) according to the general procedure B on 
0.782 mmol scale. 
1H NMR (500 MHz, Acetone-d6) δ 7.28 – 7.25 (m, 1H), 7.25 – 7.23 (m, 2H), 6.85 – 6.82 (m, 
2H), 2.41 (s, 12H), 2.20 – 2.07 (m, 4H), 1.80 – 1.72 (m, 2H), 1.69 – 1.61 (m, 6H), 1.28 – 1.16 
(m, 8H), 1.15 – 1.09 (m, 2H). 
13C NMR (101 MHz, Acetone-d6) δ 152.1, 149.2 (d, J = 14.0 Hz), 130.8, 129.9, 126.3, 124.8, 
114.4, 44.0, 35.4 (d, J = 10.0 Hz), 32.3 (d, J = 17.1 Hz), 28.5 (d, J = 12.2 Hz), 28.1 (d, J = 8.4 
Hz), 27.4 (d, J = 0.9 Hz). 
31P NMR (162 MHz, Acetone-d6) δ -21.9. 
IR (neat): ν (cm-1) 2921, 2848, 1584, 1480, 1447, 1016, 738. 
HRMS (ESI): Calcd for C25H40N4P [M+H]




Obtained as a white solid (114 mg, 41% yield) according to the general procedure B on 
0.738 mmol scale. 
1H NMR (500 MHz, Acetone-d6) δ 7.48 – 7.43 (m, 1H), 7.33 – 7.25 (m, 2H), 6.91 – 6.85 (m, 
2H), 2.46 (s, 12H), 1.16 (s, 9H), 1.13 (s, 9H). 
13C NMR (126 MHz, Acetone-d6) δ 152.9, 149.1 (d, J = 24.5 Hz), 130.2, 129.7, 127.3, 125.8, 
115.4, 45.2, 33.6 (d, J = 19.2 Hz), 31.0 (d, J = 15.3 Hz). 
31P NMR (202 MHz, Acetone-d6) δ 10.5. 
IR (neat): ν (cm-1) 3086, 2921, 2855, 1583, 1472, 1018, 791, 741. 
HRMS (ESI): Calcd for C21H36N4P [M+H]






Obtained as a white solid (46 mg, 13% yield) according to the general procedure B on 0.803 
mmol scale. 
1H NMR (500 MHz, Acetone-d6) δ 7.74 – 7.65 (m, 1H), 7.31 – 7.26 (m, 1H), 6.79 – 6.75 (m, 
2H), 6.60 – 6.56 (m, 1H), 2.52 (s, 12H), 1.79 – 1.65 (m, 12H), 1.27 – 1.08 (m, 10H). 
13C NMR (126 MHz, Acetone-d6) δ 153.8, 142.8 (d, J = 18.6 Hz), 139.5 (d, J = 2.3 Hz), 
130.6, 129.6, 114.0, 112.2 (d, J = 4.1 Hz), 45.0, 35.1 (d, J = 11.3 Hz), 30.8 (d, J = 11.9 Hz), 
30.7 (d, J = 15.1 Hz), 28.2 (d, J = 4.7 Hz), 28.1 (d, J = 6.4 Hz), 27.4 (d, J = 0.7 Hz). 
31P NMR (202 MHz, Acetone-d6) δ -25.8. 
IR (neat): ν (cm-1) 2923, 2850, 1574, 1481, 1016, 740. 
HRMS (ESI): Calcd for C25H40N4P [M+H]




Obtained as a white solid (80 mg, 21% yield) according to the general procedure B on 1.03 
mmol scale. 
1H NMR (500 MHz, Acetone-d6) δ 7.77 – 7.66 (m, 1H), 7.33 – 7.27 (m, 1H), 6.83 – 6.80 (m, 
2H), 6.77 – 6.75 (m, 1H), 2.51 (s, 12H), 1.13 (s, 9H), 1.11 (s, 9H). 
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13C NMR (126 MHz, Acetone-d6) δ 154.0, 142.1 (d, J = 26.3 Hz), 138.8 (d, J = 2.2 Hz), 
130.6, 130.0, 114.4, 113.8 (d, J = 4.6 Hz), 45.4, 32.8 (d, J = 20.7 Hz), 30.9 (d, J = 15.5 Hz). 
31P NMR (162 MHz, Acetone-d6) δ 6.1. 
IR (neat): ν (cm-1) 2938, 2859, 1583, 1474, 1015, 788, 740. 
HRMS (ESI): Calcd for C21H36N4P [M+H]
+: 375.2672, found: 375.2675. 
2-(dicyclohexylphosphaneyl)-1-(2,6-diisopropoxyphenyl)-1H-imidazole 
 
Obtained as a white solid (199 mg, 62% yield) according to the general procedure B on 
0.707 mmol scale. 
1H NMR (500 MHz, Acetone-d6) δ 7.34 – 7.26 (m, 1H), 7.19 – 7.15 (m, 1H), 6.96 – 6.88 (m, 
1H), 6.73 – 6.66 (m, 2H), 4.56 (hept, J = 6.0 Hz, 2H), 2.09 – 2.06 (m, 1H), 2.04 – 2.00 (m, 
1H), 1.85 – 1.78 (m, 2H), 1.76 – 1.54 (m, 9H), 1.31 – 1.25 (m, 2H), 1.24 (d, J = 6.0 Hz, 6H), 
1.22 – 1.13 (m, 6H), 1.12 (d, J = 6.0 Hz, 6H), 1.11 – 1.06 (m, 1H). 
13C NMR (101 MHz, Acetone-d6) δ 155.8, 148.9 (d, J = 12.8 Hz), 130.4, 130.3, 124.3, 119.2, 
106.8, 71.3, 35.0 (d, J = 8.5 Hz), 30.8 (d, J = 10.3 Hz), 30.7 (d, J = 4.7 Hz), 27.9 (d, J = 8.7 
Hz), 27.8 (d, J = 5.9 Hz), 27.4, 22.4, 22.3. 
31P NMR (162 MHz, Chloroform-d) δ -22.7. 
IR (neat): ν (cm-1) 2939, 2860, 1583, 1474, 1014, 786, 739.  
HRMS (ESI): Calcd for C27H42N2O2P [M+H]





Obtained as a pale yellow solid (170 mg, 45% yield) according to the general procedure B 
on 0.945 mmol scale. 
1H NMR (400 MHz, Acetone-d6) δ 7.34 – 7.27 (m, 1H), 7.23 – 7.16 (m, 1H), 7.00 – 6.91 (m, 
1H), 6.73 – 6.67 (m, 2H), 4.54 (hept, J = 6.1 Hz, 2H), 1.22 (d, J = 6.1 Hz, 6H), 1.20 (s, 9H), 
1.17 (s, 9H), 1.10 (d, J = 6.1 Hz, 6H). 
13C NMR (101 MHz, Acetone-d6) δ 156.1, 149.2 (d, J = 19.1 Hz), 130.5, 130.0, 124.8 (d, J = 
1.8 Hz), 120.0, 107.2, 72.0, 33.7 (d, J = 17.4 Hz), 31.2 (d, J = 14.9 Hz), 22.6, 22.5. 
31P NMR (162 MHz, Acetone-d6) δ 7.0. 
IR (neat): ν (cm-1) 2924, 2858, 1595, 1470, 1114, 1068, 786, 739. 
HRMS (ESI): Calcd for C23H38N2O2P [M+H]
+: 421.2665, found: 421.2669. 
2-(diadamantan-1-yl)phosphaneyl)-1-(2,6-diisopropoxyphenyl)-1H-imidazole 
 
Obtained as a white solid (127 mg, 45% yield) according to the general procedure B on 0.5 
mmol scale. 
1H NMR (400 MHz, Chloroform-d) δ 7.35 – 7.20 (m, 1H), 7.20 – 7.06 (m, 1H), 6.82 – 6.63 
(m, 1H), 6.54 – 6.28 (m, 2H), 4.48 – 4.13 (m, 2H), 1.97 (d, J = 12.4 Hz, 6H), 1.77 (s, 12H), 
1.55 (s, 12H), 1.13 (d, J = 6.1 Hz, 6H), 1.00 (d, J = 6.1 Hz, 6H). 
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13C NMR (101 MHz, Chloroform-d) δ 155.1, 146.4 (d, J = 17.7 Hz), 129.6, 129.5, 123.7, 
119.0, 105.9, 71.1, 41.2 (d, J = 11.7 Hz), 37.5 (d, J = 16.2 Hz), 37.1, 28.9 (d, J = 8.8 Hz), 22.1 
(d, J = 11.3 Hz) (observed complexity due to P–C splitting). 
31P NMR (162 MHz, Chloroform-d) δ 6.9. 
IR (neat): ν (cm-1) 2903, 2854, 1597, 1470, 1299, 1255, 1115, 1070, 972, 733. 
HRMS (ESI): Calcd for C35H50N2O2P [M+H]
+: 561.3604, found: 561.3613. 
5-(dicyclohexylphosphaneyl)-1-(2,6-diisopropoxyphenyl)-1H-pyrazole 
 
Obtained as a white solid (267 mg, 59% yield) according to the general procedure B on 1.0 
mmol scale. 
1H NMR (500 MHz, Acetone-d6) δ 7.71 – 7.54 (m, 1H), 7.35 – 7.23 (m, 1H), 6.71 – 6.66 (m, 
2H), 6.54 – 6.51 (m, 1H), 4.50 (hept, J = 6.1 Hz, 2H), 1.85 – 1.77 (m, 2H), 1.76 – 1.63 (m, 
10H), 1.33 – 1.23 (m, 4H), 1.21 (d, J = 6.1 Hz, 6H), 1.19 – 1.10 (m, 6H), 1.07 (d, J = 6.1 Hz, 
6H). 
13C NMR (126 MHz, Acetone-d6) δ 157.0, 142.2 (d, J = 17.0 Hz), 139.9 (d, J = 2.5 Hz), 
130.6, 123.1, 111.5 (d, J = 4.0 Hz), 107.9, 71.9, 35.0 (d, J = 10.2 Hz), 31.0 (d, J = 16.0 Hz), 
30.8 (d, J = 9.7 Hz), 28.0 (d, J = 11.5 Hz), 27.9 (d, J = 8.4 Hz), 27.4 (d, J = 1.1 Hz), 22.6, 
22.5. 
31P NMR (202 MHz, Acetone-d6) δ -27.3. 
IR (neat): ν (cm-1) 2975, 2851, 1591, 1472, 1114, 777, 737. 
HRMS (ESI): Calcd for C27H42N2O2P [M+H]





Obtained as a pale yellow solid (160 mg, 40% yield) according to the general procedure B 
on 1.0 mmol scale. 
1H NMR (500 MHz, Acetone-d6) δ 7.68 – 7.62 (m, 1H), 7.34 – 7.26 (m, 1H), 6.73 – 6.72 (m, 
1H), 6.71 – 6.68 (m, 2H), 4.48 (hept, J = 6.1 Hz, 2H), 1.20 (d, J = 6.0 Hz, 6H), 1.18 (s, 9H), 
1.15 (s, 9H), 1.05 (d, J = 6.0 Hz, 6H). 
13C NMR (126 MHz, Acetone-d6) δ 157.1, 142.2 (d, J = 23.0 Hz), 139.5 (d, J = 2.2 Hz), 
130.7, 123.9, 113.0 (d, J = 4.3 Hz), 108.4, 72.6, 32.9 (d, J = 19.2 Hz), 31.3 (d, J = 15.4 Hz), 
22.6, 22.6. 
31P NMR (162 MHz, Acetone-d6) δ 4.5. 
IR (neat): ν (cm-1) 2976, 2937, 2894, 1589, 1470, 1253, 1112, 1063, 782, 733. 
HRMS (ESI): Calcd for C23H38N2O2P [M+H]
+: 405.2665, found: 405.2670. 
2-(di-tert-butylphosphaneyl)-1-(2,6-dimethoxyphenyl)-1H-imidazole  
 
Obtained as a white solid (112.4 mg, 43% yield) according to the general procedure B on 
0.75 mmol scale. 
1H NMR (400 MHz, Chloroform-d) δ 7.48 – 7.38 (m, 1H), 7.38 – 7.30 (m, 1H), 7.04 – 6.88 
(m, 1H), 6.67 – 6.52 (m, 2H), 3.69 (s, 6H), 1.20 (s, 9H), 1.17 (s, 9H). 
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13C NMR (101 MHz, Chloroform-d) δ 156.1, 148.4 (d, J = 19.0 Hz), 130.2, 129.8, 123.6, 
116.5, 103.8, 55.4, 33.2 (d, J = 16.2 Hz), 30.3 (d, J = 14.4 Hz). 
31P NMR (162 MHz, Chloroform-d) δ 8.0. 
IR (neat): ν (cm-1) 2941, 2895, 1597, 1480, 1300, 1255, 1115, 777, 744, 647. 
HRMS (ESI): Calcd for C19H30N2O2P [M+H]
+: 349.2039, found: 349.2041. 
Synthesis of nonaflates 
General procedure C for synthesis of aryl nonaflates135 
A slurry of aryl alcohol (1.0 e.q.) in acetonitrile (0.5 M) with potassium carbonate (1.5 e.q.) 
was stirred vigorously with a magnetic stir bar. Then perfluorobutanesulfonyl fluoride (NfF, 
1.2 e.q.) was added in one portion, and the reaction was monitored by GC-MS. Upon 
completion of the reaction, the inorganic salts were removed by filtration and the solvent was 




Obtained according to the general procedure C as a colorless liquid (99% yield). 
1H NMR (400 MHz, Chloroform-d) δ 7.25 – 7.16 (m, 2H), 6.97 – 6.88 (m, 2H), 3.82 (s, 3H). 
The NMR data for this compound was consistent with literature data.135 
4-chlorophenyl 1,1,2,2,3,3,4,4,4-nonafluorobutane-1-sulfonate 
 
Obtained according to the general procedure C as a colorless liquid (98% yield). 
1H NMR (400 MHz, Chloroform-d) δ 7.44 – 7.39 (m, 2H), 7.26 – 7.20 (m, 2H). 
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The NMR data for this compound was consistent with literature data.135 
[1,1'-biphenyl]-4-yl 1,1,2,2,3,3,4,4,4-nonafluorobutane-1-sulfonate 
 
Obtained according to the general procedure C as a white solid (98% yield). 
1H NMR (400 MHz, Chloroform-d) δ 7.68 – 7.62 (m, 2H), 7.59 – 7.53 (m, 2H), 7.50 – 7.44 
(m, 2H), 7.43 – 7.39 (m, 1H), 7.38 – 7.34 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 149.3, 141.8, 139.5, 129.1, 129.0, 128.2, 127.3, 121.8 (carbon 
peaks of nonaflates are omitted due to complicated C-F splitting). 
19F NMR (376 MHz, Chloroform-d) δ -80.63, -108.87, -120.85, -125.81. 
IR (neat): ν (cm-1) 1597, 1485, 1431, 1353, 1197, 1138, 1007, 880, 761, 680.  
HRMS (ESI): Calcd for C16H9F9NaO3S [M+Na]
+: 475.0021, found: 475.0024. 
m.p.: 60-62 oC. 
Ethyl 4-(((perfluorobutyl)sulfonyl)oxy)benzoate 
 
Obtained according to the general procedure C as a colorless oil (95% yield). 
1H NMR (400 MHz, Chloroform-d) δ 8.20 – 8.09 (m, 2H), 7.39 – 7.29 (m, 2H), 4.38 (q, J = 
7.1 Hz, 2H), 1.38 (t, J = 7.1 Hz, 3H). 





Obtained according to the general procedure C as a white solid (95% yield). 
1H NMR (400 MHz, Chloroform-d) δ 6.51 – 6.47 (m, 2H), 3.86 (s, 6H), 3.84 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 153.9, 145.5, 138.0, 99.2, 61.1, 56.5 (carbon peaks of 
nonaflates are omitted due to complicated C-F splitting). 
19F NMR (376 MHz, Chloroform-d) δ -80.67, -108.93, -120.85, -125.84. 
IR (neat): ν (cm-1) 1608, 1503, 1469, 1420, 1354, 1196, 1121, 1033, 970, 856, 795, 732, 698. 
HRMS (ESI): Calcd for C13H11F9NaO6S [M+Na]
+: 489.0025, found: 489.0028. 
m.p.: 70-72 oC. 
benzo[d][1,3]dioxol-5-yl 1,1,2,2,3,3,4,4,4-nonafluorobutane-1-sulfonate 
 
Obtained according to the general procedure C as a pale yellow solid (91% yield). 
1H NMR (400 MHz, Chloroform-d) δ 6.85 – 6.71 (m, 3H), 6.04 (s, 2H). 
13C NMR (101 MHz, CDCl3) δ 148.7, 147.6, 143.9, 114.6, 108.3, 103.5, 102.6 (carbon peaks 
of nonaflates are omitted due to complicated C-F splitting). 
19F NMR (376 MHz, Chloroform-d) δ -80.67, -108.90, -120.89, -125.85. 
IR (neat): ν (cm-1) 1484, 1420, 1354, 1241, 1189, 1137, 1032, 936, 867, 816, 730, 694, 653. 
HRMS (ESI): Calcd for C11H5F9NaO5S [M+Na]
+: 442.9606, found: 442.9605. 





Obtained according to the general procedure C as a brown oil (90% yield). 
1H NMR (400 MHz, Chloroform-d) δ 7.25 (t, J = 8.3 Hz, 1H), 6.68 (dd, J = 8.4, 2.3 Hz, 1H), 
6.60 (dd, J = 8.1, 2.2 Hz, 1H), 6.53 (t, J = 2.4 Hz, 1H), 2.98 (s, 6H). 
13C NMR (101 MHz, CDCl3) δ 151.9, 151.2, 130.4, 111.8, 108.1, 104.7, 40.4 (carbon peaks 
of nonaflates are omitted due to complicated C-F splitting). 
19F NMR (376 MHz, Chloroform-d) δ -80.68, -109.17, -120.90, -125.85. 
IR (neat): ν (cm-1) 1617, 1568, 1509, 1421, 1354, 1198, 1141, 992, 906, 829, 791, 754, 679. 
HRMS (ESI): Calcd for C12H11F9NO3S [M+H]
+: 420.0310, found: 420.0314. 
3-(trifluoromethyl)phenyl 1,1,2,2,3,3,4,4,4-nonafluorobutane-1-sulfonate 
 
Obtained according to the general procedure as a colourless oil (93% yield). 
1H NMR (400 MHz, Chloroform-d) δ 7.68 (d, J = 7.8 Hz, 1H), 7.62 (t, J = 8.0 Hz, 1H), 7.55 
(s, 1H), 7.51 (d, J = 8.6 Hz, 1H). 





Obtained according to the general procedure C as a yellow oil (98% yield). 
1H NMR (400 MHz, Chloroform-d) δ 7.51 (t, J = 8.2 Hz, 1H), 7.43 (ddd, J = 8.3, 2.1, 1.0 Hz, 
1H), 7.32 (t, J = 2.2 Hz, 1H), 7.17 (dd, J = 8.2, 1.7 Hz, 1H), 7.09 (t, J = 2.2 Hz, 2H), 6.40 (t, J 
= 2.2 Hz, 2H). 
13C NMR (101 MHz, CDCl3) δ 150.4, 142.4, 131.3, 120.0, 119.3, 118.1, 113.6, 111.8 (carbon 
peaks of nonaflates are omitted due to complicated C-F splitting). 
19F NMR (376 MHz, Chloroform-d) δ -80.66, -108.76, -120.83, -125.81. 
IR (neat): ν (cm-1) 1616, 1512, 1419, 1353, 1197, 1141, 1031, 953, 881, 781, 732, 654.  
HRMS (ESI): Calcd for C14H9F9NO3S [M+H]
+: 442.0154, found: 442.0157. 
2-methoxyphenyl 1,1,2,2,3,3,4,4,4-nonafluorobutane-1-sulfonate 
 
Obtained according to the general procedure C as a colourless oil (98% yield). 
1H NMR (400 MHz, Chloroform-d) δ 7.33 (ddd, J = 8.2, 7.7, 1.6 Hz, 1H), 7.22 (dd, J = 8.1, 
1.5 Hz, 1H), 7.04 (dd, J = 8.3, 1.4 Hz, 1H), 6.98 (td, J = 7.9, 1.5 Hz, 1H), 3.91 (s, 3H). 





Obtained according to the general procedure C as a white solid (98% yield). 
1H NMR (400 MHz, Chloroform-d) δ 7.91 – 7.83 (m, 2H), 7.30 (dd, J = 8.8, 2.5 Hz, 1H), 
2.86 (s, 3H) 
13C NMR (101 MHz, CDCl3) δ 170.7, 154.1, 148.3, 135.8, 122.6, 118.3, 115.4, 20.5 (carbon 
peaks of nonaflates are omitted due to complicated C-F splitting). 
19F NMR (376 MHz, Chloroform-d) δ -80.64, -108.66, -120.85, -125.81. 
IR (neat): ν (cm-1) 2339, 2192, 2019, 1938, 1521, 1424, 1354, 1199, 1143, 1004, 673.  
HRMS (ESI): Calcd for C12H7F9NO3S2 [M+H]
+: 447.9718, found: 447.9720. 
m.p.: 83-85 oC. 
ESTRONE-ONf 
 
Obtained according to the general procedure C as a white solid (62% yield). 
1H NMR (400 MHz, Chloroform-d) δ 7.44 – 7.30 (m, 1H), 7.09 – 7.01 (m, 1H), 7.01 – 6.97 
(m, 1H), 2.94 (dd, J = 8.7, 4.1 Hz, 2H), 2.51 (dd, J = 18.7, 8.8 Hz, 1H), 2.43 – 2.24 (m, 2H), 
2.21 – 2.11 (m, 1H), 2.11 – 1.94 (m, 3H), 1.69 – 1.56 (m, 2H), 1.56 – 1.41 (m, 4H), 0.92 (s, 
3H). 
13C NMR (101 MHz, CDCl3) δ 220.4, 147.9, 140.4, 139.4, 127.3, 121.4, 118.4, 50.5, 48.0, 
44.2, 37.9, 35.9, 31.6, 29.5, 26.2, 25.8, 21.7, 13.9 (carbon peaks of nonaflates are omitted due 
to complicated C-F splitting). 
19F NMR (376 MHz, Chloroform-d) δ -80.70, -109.15, -120.93, -125.87. 
IR (neat): ν (cm-1) 1737, 1490, 1421, 1203, 1144, 1034, 907, 728, 650.  
HRMS (ESI): Calcd for C22H21F9NaO4S [M+Na]
+: 575.0909, found: 575.0916. 
m.p.: 55-57 oC. 
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General procedure D for synthesis of akenyl nonaflates137 
A solution of n-butyllithium in hexane (1.02 e.q.) was added at -78 °C to a solution of iPr2NH 
(1.02 e.q.) in THF. After this had remained for 1 h at -78 °C, cyclic ketone (8.0 mmol, 1.0 e.q.) 
was added, followed by stirring for a further 1 h at -78 °C. Neat NfF (3.02 g, 10.0 mmol) was 
added dropwise, and the reaction mixture was allowed to warm up to room temperature 
overnight and then poured into the saturated aq. NH4Cl. The aqueous phase was extracted 
with EtOAc, and the combined organic phase was washed consecutively with brine and water, 
dried over Na2SO4. The volatiles were removed in vacuo and the residue was subjected to 
silica gel column chromatography to furnish the desired product. 
1,2,3,6-tetrahydro-[1,1'-biphenyl]-4-yl 1,1,2,2,3,3,4,4,4-nonafluorobutane-1-sulfonate 
 
Obtained according to the general procedure D as a colourless oil (72% yield). 
1H NMR (400 MHz, Chloroform-d) δ 7.35 – 7.28 (m, 2H), 7.26 – 7.17 (m, 3H), 5.94 – 5.77 
(m, 1H), 2.94 – 2.76 (m, 1H), 2.64 – 2.25 (m, 4H), 2.16 – 2.01 (m, 1H), 2.02 – 1.89 (m, 1H). 




Obtained according to the general procedure D as a white solid (70% yield). 
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1H NMR (400 MHz, Chloroform-d) δ 5.61 (t, J = 3.8 Hz, 1H), 3.51 (q, J = 11.4 Hz, 4H), 2.51 
(s, 2H), 2.42 (s, 2H), 2.09 (t, J = 6.5 Hz, 2H), 1.01 (s, 3H), 0.93 (s, 3H). 
The NMR data for this compound was consistent with literature data.138 
Pyridin-2-yl 1,1,2,2,3,3,4,4,4-nonafluorobutane-1-sulfonate 
 
This nonaflate was prepared according to the procedure reported by Ressig and co-workers.139 
Pyridin-2-ol (571 mg, 6.0 mmol, 1.0 e.q.) was dissolved in THF (60 mL) and NaH (60%, 720 
mg, 18 mmol, 3.00 e.q.) was added under an argon atmosphere. Nonafluorobutanesulfonyl 
fluoride (NfF, 4.53g, 15 mmol, 2.50 e.q.) was added dropwise at room temperature. The 
mixture was stirred at room temperature for 7 h, monitored by TLC and GC-MS, and 
quenched by slow addition of methanol and water. It was extracted with ethylacetate (3 times), 
dried with Na2SO4 and concentrated in vacuo. The residue was purified by chromatography 
on silica gel (cyclohexane/ethyl acetate) to give the corresponding nonaflate derivatives (1.44 
g, 64%). 
1H NMR (500 MHz, Chloroform-d) δ 8.45 – 8.39 (m, 1H), 7.93 – 7.88 (m, 1H), 7.42 – 7.37 
(m, 1H), 7.21 – 7.17 (m, 1H). 
13C NMR (126 MHz, Chloroform-d) δ 156.1, 148.9, 141.1, 124.4, 115.4. 
19F NMR (376 MHz, Chloroform-d) δ -80.65, -108.99, -120.93, -125.84. 
IR (neat): ν (cm-1) 1597, 1424, 1353, 1201, 1141, 1034, 892, 793, 730, 627.  
HRMS (ESI): Calcd for C9H5F9NO3S [M+H]
+: 377.9841, found: 377.9845. 
Synthesis of triflates 




To a flask with magnetic stirring bar was charged 4-BPin phenol (1 equiv, 9.1 mmol, 2.0 g) 
and N-(5-chloropyridin-2-yl)-1,1,1-trifluoro-N((trifluoromethyl)sulfonyl)methanesulfonamide 
(1.1 equiv). The solids were then suspended in CH2Cl2 (10 mL/g of phenol). To the reaction 
was added iPr2EtN (4 equiv). The reaction was mixed at room temperature, and the progress 
was monitored by GC-MS. Upon completion of the reaction, the mixture was concentrated, 
and the resulting residue was purified by flash column chromatography on silica gel using 
ethyl acetate/cyclohexane (1/10), affording the desired product as a white solid (2.21 g, 69% 
yield). 
1H NMR (400 MHz, Chloroform-d) δ 7.94 – 7.85 (m, 2H), 7.30 – 7.23 (m, 2H), 1.35 (s, 
12H). 
The NMR data for this compound was consistent with literature data.140, 141 
General procedure E for the synthesis of aryl triflates110 
A solution of trifluoromethanesulfonic anhydride (1.2 e.q.) in DCM was added dropwise to a 
solution of pyridine (2.0 e.q.) and phenols (1.0 e.q.) in DCM at 0 oC.  After complete addition, 
the mixture was warmed to R.T. and allowed to stir for 1h. The mixture was diluted with Et2O, 
quenched with aq. 10% HCl and washed successively with sat. NaHCO3 and brine. The 
combined organic phases were dried over Na2SO4 and the solvent was removed under 




Obtained according to the general procedure E as a colourless oil (98% yield). 
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1H NMR (400 MHz, Chloroform-d) δ 8.18 – 8.09 (m, 2H), 7.39 – 7.28 (m, 2H), 4.38 (q, J = 
7.1 Hz, 2H), 1.38 (t, J = 7.1 Hz, 3H). 
The NMR data for this compound was consistent with literature data.142 
3-(trifluoromethyl)phenyl trifluoromethanesulfonate 
 
Obtained according to the general procedure E as a colourless oil (81% yield). 
1H NMR (400 MHz, Chloroform-d) δ 7.69 (d, J = 7.8 Hz, 1H), 7.63 (t, J = 8.0 Hz, 1H), 7.55 
(s, 1H), 7.50 (d, J = 8.1 Hz, 1H). 
The NMR data for this compound was consistent with literature data.143 
Naphthalen-2-yl trifluoromethanesulfonate 
 
Obtained according to the general procedure E as a colourless oil (91% yield). 
1H NMR (400 MHz, Chloroform-d) δ 7.93 – 7.84 (m, 3H), 7.79 – 7.74 (m, 1H), 7.61 – 7.55 
(m, 2H), 7.43 – 7.36 (m, 1H). 
The NMR data for this compound was consistent with literature data.144 
2-methoxyphenyl trifluoromethanesulfonate 
 
Obtained according to the general procedure E as a colourless oil (98% yield). 
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1H NMR (400 MHz, Chloroform-d) δ 7.33 (ddd, J = 8.2, 7.7, 1.6 Hz, 1H), 7.22 (dd, J = 8.1, 
1.5 Hz, 1H), 7.04 (dd, J = 8.3, 1.4 Hz, 1H), 6.98 (td, J = 7.9, 1.5 Hz, 1H), 3.91 (s, 3H). 
The NMR data for this compound was consistent with literature data.145 
tert-butyl 2-(((trifluoromethyl)sulfonyl)oxy)-9H-carbazole-9-carboxylate 
 
The above triflate was prepared according to the procedure reported by Buchwald and 
co-workers.146 
1H NMR (400 MHz, Chloroform-d) δ 8.40 – 8.24 (m, 2H), 8.06 – 7.90 (m, 2H), 7.56 – 7.48 
(m, 1H), 7.43 – 7.35 (m, 1H), 7.30 – 7.25 (m, 1H), 1.77 (s, 9H). 
The NMR data for this compound was consistent with literature data.146 
Synthesis of alkyl bromides 
2-(3-bromopentyl)-1,3-dioxolane 
 
DIBAL-H in Hexane (1.0 M, 1.1 e.q., 41.8 mmol, 41.8 mL) was added dropwise to a solution 
of methyl 4-bromohexanoate (1.0 e.q., 38 mmol, 7.95 g) in DCM at -78 oC. After being 
stirred for 1 h at -78 oC, the mixture was poured onto crushed ice and 25 mL of concentrated 
HCl. The mixture was stirred until it reached 18 oC, and the organic phase was separated, 
dried and concentrated. The crude product was used directly for the next step.147 
 
To a solution of crude aldehyde (38 mmol, 6.8 g)  in toluene (100 mL) was added ethylene 
glycol (76 mmol, 4.72 g) and a catalytic amount of p-toluenesulfonic acid monohydrate (3.8 
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mmol, 0.723 g). The reaction mixture was then stirred at reflux with a Dean-Stark over 48 h. 
The reaction mixture was cooled to room temperature, quenched by sat. sodium bicarbonate 
solution  and then extracted with Et2O. The combined organic layers were washed with brine, 
dried over MgSO4 and concentrated under reduced pressure. Purification of the crude by 
column chromatography on silica gel (elution from pentane to pentane/Et2O: 95/5) afforded 
the desired product (1.88 g, 22% yield over two steps) as a colourless oil. 
 
1H NMR (400 MHz, Chloroform-d) δ 4.87 (t, J = 4.2 Hz, 1H), 4.04 – 3.97 (m, 1H), 3.97 – 
3.92 (m, 2H), 3.86 – 3.80 (m, 2H), 1.98 – 1.89 (m, 3H), 1.87 – 1.80 (m, 2H), 1.80 – 1.74 (m, 
1H), 1.02 (t, J = 7.3 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 103.9, 65.0, 65.0, 59.9, 32.9, 32.3, 32.0, 12.1. 
IR (neat): ν (cm-1) 2967, 2294, 2253, 1728, 1633, 1442, 1376, 1038, 919, 749, 665. 
tert-butyl (3-bromopentyl)(methyl)carbamate 
The substrate was prepared according to the procedures for the synthesis of tert-butyl 






1H NMR (400 MHz, Chloroform-d) δ 4.00 – 3.80 (m, 1H), 3.39 – 3.26 (m, 2H), 2.81 (s, 3H), 
2.02 – 1.91 (m, 2H), 1.88 – 1.74 (m, 2H), 1.40 (s, 9H), 0.99 (t, J = 7.2 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 155.7, 79.5, 56.5, 47.4, 32.5, 32.3, 31.0, 28.5, 12.0. 
IR (neat): ν (cm-1) 2972, 1694, 1481, 1394, 1226, 1165, 877, 772.  
HRMS (ESI): Calcd for C11H22BrNNaO2 [M+Na]
+: 302.0726, found: 302.0727. 
((4-bromopentan-2-yl)oxy)(tert-butyl)dimethylsilane 
 
The TBS-protection step was performed according to the procedure reported by Knochel and 
co-workers.148 
 
This compound was prepared according to the procedure reported by Denmark and 
co-workers.84 
Bromine (3.19 g, 1.03 mL, 20 mmol, 1.33 equiv) was added dropwise to a stirred suspension 
of triphenylphosphine (5.23 g, 20 mmol, 1.33 equiv) in CH2Cl2 (40 mL) in a round-bottomed 
flask equipped with a stirrer bar and cooled in an ice/water bath (open to air). The flask was 
then sealed with a rubber septum and purged with argon via an inlet needle. After stirring the 
resultant pale-yellow suspension for 15 min, a solution of 
4-((tert-butyldimethylsilyl)oxy)pentan-2-ol (3.28 g, 15 mmol, 1.0 equiv) and imidazole (1.36 
g, 20 mmol, 1.33 equiv) in CH2Cl2 (20 mL) was added dropwise. The cooling bath was 
removed, and the reaction mixture was allowed to warm to room temperature for 17 h. The 
mixture was then filtered on celite and concentrated in vacuo. The residue was purified by 
silica gel column chromatography to give the desired product as a colourless oil (2.95 g, 70%, 
d.r. 50:50). 





The data given below was the mixtures of diastereomers. 
1H NMR (400 MHz, Chloroform-d) δ 4.31 – 4.21 (m, 1H), 4.19 – 4.10 (m, 1H), 4.09 – 4.00 
(m, 1H), 4.00 – 3.91 (m, 1H), 2.21 – 2.07 (m, 1H), 1.84 – 1.65 (m, 9H), 1.15 (d, J = 6.0 Hz, 
6H), 0.89 (s, 18H), 0.14 – 0.02 (m, 12H). 
13C NMR (101 MHz, Chloroform-d) δ 67.2 (66.9), 51.2 (51.1), 49.5 (47.9), 27.3 (26.5), 26.1 
(26.0), 24.3 (23.3), 18.2 (18.2), -4.0 (-4.1), -4.5 (-4.6). 
IR (neat): ν (cm-1) 2957, 1462, 1376, 1254, 1146, 1057, 998, 931, 833, 774, 718, 660. 
GC-MS (EI) m/z for C7H16BrOSi ([M-
tBu]+•): 223. 
The relative configuration was assigned according to the analogies.148 
(syn-4-bromopentan-2-yl)oxy)(tert-butyl)dimethylsilane 
 
1H NMR (400 MHz, Chloroform-d) δ 4.27 (ddtd, J = 13.4, 10.4, 6.7, 3.5 Hz, 1H), 4.10 – 3.99 
(m, 1H), 1.77 (ddd, J = 8.2, 6.6, 3.2 Hz, 2H), 1.72 (d, J = 6.7 Hz, 3H), 1.16 (d, J = 6.1 Hz, 
3H), 0.89 (s, 9H), 0.12 (s, 3H), 0.09 (s, 3H). 
13C NMR (101 MHz, Chloroform-d) δ 66.9, 51.2, 49.5, 27.3, 26.1, 24.3, 18.2, -4.0, -4.5. 
(anti-4-bromopentan-2-yl)oxy)(tert-butyl)dimethylsilane 
 
1H NMR (400 MHz, Chloroform-d) δ 4.20 – 4.09 (m, 1H), 3.97 (h, J = 6.1 Hz, 1H), 2.14 
(ddd, J = 14.3, 7.9, 6.6 Hz, 1H), 1.78 (dt, J = 14.0, 6.4 Hz, 1H), 1.72 (d, J = 6.6 Hz, 3H), 1.15 
(d, J = 6.1 Hz, 3H), 0.89 (s, 9H), 0.07 (s, 3H), 0.06 (s, 3H). 





The compound was prepared according to the procedure reported by Atack and 
co-workers.149a 
A flame-dried flask equipped with a stir bar was charged with PPh3 (12.6 g, 48 mmol, 1.2 
equiv) and imidazole (3.27 g, 48 mmol, 1.2 equiv) under argon. Anhydrous DCM (200 mL, 
0.2 M) was added and the flask was cooled in an ice bath. Bromine (7.67 g, 2.47 mL, 48 
mmol, 1.2 equiv) was added dropwise at a rate such that the color dissipates, and the mixture 
was stirred for 10 minutes. DL-Menthol (6.25 g, 40 mmol, 1 equiv), diluted in 25 mL DCM, 
was added dropwise at 0 °C, and the reaction mixture was stirred at 0 °C for 1 hour.  After 
one hour, the reaction was allowed to warm to room temperature and stirred for an additional 
12 hours. The reaction was concentrated under reduced pressure and diluted with 
hexanes:EtOAc (4:1) and filtered through a plug of silica. Filtrate was concentrated under 
reduced pressure and purified by silica flash chromatography to yield the desired product as a 
colorless liquid (3.5 g, 40%). 
1H NMR (500 MHz, Chloroform-d) δ 4.74 – 4.60 (m, 1H), 2.21 – 2.13 (m, 1H), 2.02 – 1.91 
(m, 1H), 1.80 – 1.71 (m, 2H), 1.53 – 1.31 (m, 3H), 0.93 (d, J = 1.1 Hz, 3H), 0.92 (d, J = 1.2 
Hz, 3H), 0.89 (d, J = 6.6 Hz, 3H), 0.82 – 0.74 (m, 1H). 






(R)-butane-1,3-diol (1.0 g, 11.1 mmol, 1.0 e.q., from Fluorochem) and imidazole (1.66 g, 24.4 
mmol, 2.2 e.q.) were stirred in DMF (7.5 mL) for 1 h at 0 oC. TBSCl (1.67 g, 11.1 mmol, 1.0 
e.q.) were then added to the mixture, which was then allowed to warm to room temperature 
and stirred for 18 h. The mixture was quenched with water and extracted with Et2O (three 
times). The combined organic phases were then washed with brine, dried over Na2SO4 and 
concentrated in vacuo. The residue was purified by silica gel column chromatography to give 
the desired product as a colourless oil (1.94 g, 85%). 
1H NMR (400 MHz, Chloroform-d) δ 4.10 – 3.96 (m, 1H), 3.92 – 3.75 (m, 2H), 3.43 (brs, 
1H), 1.73 – 1.53 (m, 2H), 1.18 (d, J = 6.3 Hz, 3H), 0.89 (s, 9H), 0.07 (s, 6H). 
The NMR data for this compound was consistent with literature data.150 
 
This compound was prepared according to the procedure reported by Denmark and 
co-workers.84 
Bromine (1.78 g, 0.57 mL, 11.2 mmol, 1.2 equiv) was added dropwise via syringe to a stirred 
suspension of triphenylphosphine (2.93 g, 11.2 mmol, 1.2 equiv) in CH2Cl2 (25 mL) in a 
round-bottomed flask equipped with a stirrer bar and cooled in an ice/water bath (open to air). 
The ask was then sealed with a rubber septum and purged with argon. After stirring the 
resultant pale-yellow suspension for 15 min, a solution of 
(R)-4-((tert-butyldimethylsilyl)oxy)butan-2-ol (1.9 g, 9.3 mmol, 1.0 equiv) and imidazole 
(0.76 g, 11.2 mmol, 1.2 equiv) in CH2Cl2 (15 mL) was added via cannula over ca. 5 min. The 
cooling bath was removed, and the reaction mixture was allowed to warm to room 
temperature over 17 h. The mixture was then filtered through a sintered funnel under house 
vacuum and carefully concentrated in vacuo to leave a yellow oil residue (i.e., avoiding 
precipitating the phosphorus-containing residues at this point). A stirrer bar was added to the 
residue and rapid stirring was commenced. Cycolohexane (30 mL) was quickly added in one 
portion to precipitate the phosphorus-containing residues as a white solid. The mixture was 
rinsed through a pad of SiO2 using cyclohexane (3 × 15 mL) and the filtrate was concentrated 
in vacuo to give a clear, colorless oil. Purication by silica gel column chromatography gave 
(S)-product as a clear, colorless oil (731 mg, 29%). 
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1H NMR (400 MHz, Chloroform-d) δ 4.39 – 4.24 (m, 1H), 3.75 (t, J = 5.8 Hz, 2H), 2.00 – 
1.93 (m, 2H), 1.74 (d, J = 6.7 Hz, 3H), 0.89 (s, 9H), 0.07 (s, 3H), 0.06 (s, 3H). 
13C NMR (126 MHz, Chloroform-d) δ 61.1, 48.5, 44.0, 26.8, 26.1, 18.5, -5.2. 
GC-MS (EI) m/z for C6H14BrOSi ([M-
tBu]+•): 209. 
General procedure F for the direct Barbier-Negishi couplings of secondary 
alkyl bromides 
An oven-dried 10.0 – 20.0 mL Biotage microwave vial equipped with a stirring bar was taken 
into the glovebox, magnesium powder (1.5 e.q.), lithium chloride (1.5 e.q.), zinc chloride (2.0 
e.q.), Pd2dba3 (97%) (2.5 mol%) and L13 (5.0 mol%) were added to the vial. The vial was 
capped with a Biotage cap using a crimper and removed from the glovebox. Then, a solution 
of sulfonates (1.0 mmol, 1.0 e.q.) and alkyl bromides (1.5 e.q.) in THF (5.0 mL, 0.2 M) was 
added to the mixture via syringe under argon atmosphere. The vial was wrapped with tape and 
placed into a 25 oC water bath. The reaction mixture was stirred at that temperature for 24 h. 
After that time, the reaction mixture was diluted with Et2O (5.0 mL) and carefully quenched 
with saturated NH4Cl solution (5.0 mL) (An aliquot of the crude mixture was measured by 
GC or GC-MS to determine the ratio of direct coupling product and migrative coupling 
product). The organic phase was separated and the aqueous phase was extracted with Et2O (2 
X 5.0 mL). The combined organic phases were dried over Na2SO4 and the solvent was 
removed in vacuo. Purification of the residue by silica gel column chromatography gave the 
desired product as a mixture of direct/migrative coupling products (which could not be 
separated by column chromatgraphy). 
1-methoxy-4-(pentan-3-yl)benzene 3-10a  
 
Obtained as the mixture of cross-coupling products (160 mg colourless oil, 90% yield, 94:6) 
according to the general procedure F. 




1H NMR (400 MHz, Chloroform-d) δ 7.13 – 7.03 (m, 2H), 6.91 – 6.81 (m, 2H), 3.81 (s, 3H), 
2.36 – 2.19 (m, 1H), 1.76 – 1.61 (m, 2H), 1.57 – 1.47 (m, 2H), 0.78 (t, J = 7.4 Hz, 6H). 
13C NMR (101 MHz, Chloroform-d) δ 157.8, 138.0, 128.7, 113.6, 55.3, 49.0, 29.6, 12.3. 





Obtained as the mixture of cross-coupling products (135 mg colourless oil, 74% yield, 92:8) 
according to the general procedure F. 









1H NMR (400 MHz, Chloroform-d) δ 7.44 – 7.16 (m, 2H), 7.09 – 7.01 (m, 2H), 2.33 – 2.23 
(m, 1H), 1.75 – 1.60 (m, 2H), 1.57 – 1.46 (m, 2H), 0.75 (t, J = 7.4 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 144.4, 131.5, 129.3, 128.4, 49.3, 29.4, 12.2. 
IR (neat): ν (cm-1) 2962, 2927, 2874, 1493, 1091, 823.  






Obtained as the mixture of cross-coupling products (192 mg white solid, 86% yield, 93:7) 
according to the general procedure F. 





1H NMR (400 MHz, Chloroform-d) δ 7.63 – 7.58 (m, 2H), 7.55 – 7.51 (m, 2H), 7.46 – 7.40 
(m, 2H), 7.35 – 7.30 (m, 1H), 7.24 – 7.19 (m, 2H), 2.45 – 2.31 (m, 1H), 1.79 – 1.67 (m, 2H), 
1.64 – 1.55 (m, 2H), 0.82 (t, J = 7.4 Hz, 6H). 




IR (neat): ν (cm-1) 2961, 2920, 2869, 1599, 1456, 1004, 833, 758, 689.  
GC-MS (EI) m/z for C17H20 ([M]
+•): 224. 
m.p.: 57-59 oC. 
4,4,5,5-tetramethyl-2-(4-(pentan-3-yl)phenyl)-1,3,2-dioxaborolane 3-10d 
 
Obtained as the mixture of cross-coupling products (176 mg white solid, 64% yield, 98:2) 
according to the general procedure F. 





1H NMR (400 MHz, Chloroform-d) δ 7.79 – 7.70 (m, 2H), 7.19 – 7.11 (m, 2H), 2.40 – 2.26 
(m, 1H), 1.75 – 1.63 (m, 2H), 1.60 – 1.50 (m, 2H), 1.34 (s, 12H), 0.76 (t, J = 7.4 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 149.5, 134.9, 127.5, 83.7, 50.1, 29.3, 25.0, 12.3. 
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IR (neat): ν (cm-1) 2968, 2928, 1610, 1460, 1357, 1271, 1140, 1089, 1016, 962, 835, 748, 
660. 
HRMS (ESI): Calcd for C17H27BNaO2 [M+Na]
+: 297.1999, found: 297.2001. 
m.p.: 88-90 oC. 
ethyl 4-(pentan-3-yl)benzoate 3-10e 
 
Obtained as the mixture of cross-coupling products according to the general procedure F. 
From ONf: 33 mg colourless oil, 15% yield, 10:90. 
From OTf: 163 mg colourless oil, 74% yield, 85:15. 










1H NMR (400 MHz, Chloroform-d) δ 7.99 – 7.94 (m, 2H), 7.23 – 7.15 (m, 2H), 4.36 (q, J = 
7.1 Hz, 2H), 2.45 – 2.33 (m, 1H), 1.77 – 1.66 (m, 2H), 1.59 – 1.52 (m, 2H), 1.39 (t, J = 7.1 Hz, 
3H), 0.76 (t, J = 7.4 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 166.9, 151.5, 129.6, 127.9, 127.1, 60.8, 49.9, 29.3, 14.5, 12.2. 
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IR (neat): ν (cm-1) 2963, 1719, 1610, 1461, 1367, 1275, 1179, 1105, 1022, 853, 766, 708.  
HRMS (ESI): Calcd for C14H20NaO2 [M+Na]
+: 243.1356, found: 243.1355. 
1,2,3-trimethoxy-5-(pentan-3-yl)benzene 3-10f 
 
Obtained as the mixture of cross-coupling products (219 mg colourless oil, 92% yield, 94:6) 
according to the general procedure F. 









1H NMR (400 MHz, Chloroform-d) δ 6.36 – 6.32 (m, 2H), 3.85 (s, 6H), 3.83 (s, 3H), 2.29 – 
2.17 (m, 1H), 1.73 – 1.60 (m, 2H), 1.56 – 1.47 (m, 2H), 0.79 (t, J = 7.4 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 153.1, 141.9, 136.2, 104.7, 61.0, 56.2, 50.3, 29.5, 12.4. 
IR (neat): ν (cm-1) 2930, 1588, 1509, 1456, 1319, 1233, 1123, 1011, 826, 771, 662.  
HRMS (ESI): Calcd for C14H22NaO3 [M+Na]





Obtained as the mixture of cross-coupling products (155 mg colourless oil, 81% yield, 94:6) 
according to the general procedure F. 




1H NMR (400 MHz, Chloroform-d) δ 6.73 (d, J = 7.9 Hz, 1H), 6.64 (d, J = 1.7 Hz, 1H), 6.58 
(dd, J = 7.9, 1.7 Hz, 1H), 5.92 (s, 2H), 2.31 – 2.18 (m, 1H), 1.71 – 1.59 (m, 2H), 1.53 – 1.42 
(m, 2H), 0.77 (t, J = 7.4 Hz, 6H). 




The NMR data for this compound was consistent with literature data.39c 
N, N-dimethyl-3-(pentan-3-yl)aniline 3-10h 
 
Obtained as the mixture of cross-coupling products (160 mg colourless oil, 84% yield, 94:6) 
according to the general procedure F. 





1H NMR (400 MHz, Chloroform-d) δ 7.18 (t, J = 8.1 Hz, 1H), 6.64 – 6.51 (m, 3H), 2.95 (s, 
6H), 2.32 – 2.22 (m, 1H), 1.75 – 1.63 (m, 2H), 1.62 – 1.51 (m, 2H), 0.81 (t, J = 7.4 Hz, 6H). 




IR (neat): ν (cm-1) 2959, 2924, 2871, 1601, 1499, 1457, 1346, 1229, 1158, 1061, 995, 846, 
770, 698. 
HRMS (ESI): Calcd for C13H22N [M+H]
+: 192.1747, found: 192.1746. 
1-(pentan-3-yl)-3-(trifluoromethyl)benzene 3-10i  
 
Obtained as the mixture of cross-coupling products according to the general procedure F. 
From nonaflate: 133 mg colourless oil, 62% yield, 91:9. 
From triflate: 183 mg colourless oil, 85% yield, 92:8. 














1H NMR (400 MHz, Chloroform-d) δ 7.48 – 7.30 (m, 4H), 2.46 – 2.34 (m, 1H), 1.79 – 1.67 
(m, 2H), 1.62 – 1.51 (m, 2H), 0.78 (t, J = 7.4 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 146.9, 131.4 (d, J = 1.4 Hz), 130.6 (q, J = 31.6 Hz), 128.7, 
124.6 (d, J = 271.6 Hz), 124.6 (q, J = 3.8 Hz), 122.9 (d, J = 3.8 Hz), 49.8, 29.3, 12.2. 
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19F NMR (376 MHz, CDCl3) δ -62.5. 
IR (neat): ν (cm-1) 2923, 2855, 2366, 2143, 1462, 1378, 1327, 1168, 1131, 1074, 698.  




Obtained as the mixture of cross-coupling products (138 mg colourless oil, 65% yield, 89:11) 
according to the general procedure F. 





1H NMR (400 MHz, Chloroform-d) δ 7.34 (t, J = 7.8 Hz, 1H), 7.22 (ddd, J = 8.0, 2.3, 1.1 Hz, 
1H), 7.18 (t, J = 1.9 Hz, 1H), 7.13 – 7.09 (m, 2H), 7.04 (dt, J = 7.6, 1.1 Hz, 1H), 6.36 (t, J = 




13C NMR (101 MHz, CDCl3) δ 147.8, 140.9, 129.4, 125.4, 120.2, 119.5, 118.3, 110.3, 49.9, 
29.4, 12.3. 
IR (neat): ν (cm-1) 2960, 2873, 1591, 1498, 1334, 1070, 1027, 949, 874, 789, 720.  
HRMS (ESI): Calcd for C15H20N [M+H]
+: 214.1590, found: 214.1590. 
2-(pentan-3-yl)naphthalene 3-10k  
 
Obtained as the mixture of cross-coupling products (126 mg colourless oil, 64% yield, 93:7) 
according to the general procedure F. 





1H NMR (400 MHz, Chloroform-d) δ 7.84 – 7.74 (m, 3H), 7.60 – 7.55 (m, 1H), 7.49 – 7.40 
(m, 2H), 7.35 – 7.29 (m, 1H), 2.58 – 2.45 (m, 1H), 1.85 – 1.74 (m, 2H), 1.73 – 1.61 (m, 2H), 
0.81 (t, J = 7.4 Hz, 6H). 
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13C NMR (101 MHz, CDCl3) δ 143.4, 133.7, 132.4, 127.9, 127.7, 127.6, 126.6, 126.2, 125.8, 
125.1, 50.0, 29.4, 12.4. 
The NMR data for this compound was consistent with literature data.152 
1-methoxy-2-(pentan-3-yl)benzene 3-10l  
 
Obtained as the mixture of cross-coupling products according to the general procedure F. 
From nonaflate: 156 mg colourless oil, 88% yield, 87:13. 
From triflate (using 2.0 e.q. 3-bromopentane/Mg/LiCl/ZnCl2): 140 mg colourless oil, 79% 
yield, 90:10 














1H NMR (400 MHz, Chloroform-d) δ 7.19 – 7.09 (m, 2H), 6.93 (t, J = 7.4 Hz, 1H), 6.86 (d, J 
= 8.1 Hz, 1H), 3.81 (s, 3H), 3.00 – 2.88 (m, 1H), 1.72 – 1.62 (m, 2H), 1.61 – 1.53 (m, 2H), 
0.78 (t, J = 7.4 Hz, 6H). 
218 
 
13C NMR (101 MHz, CDCl3) δ 158.0, 134.3, 127.6, 126.5, 120.6, 110.7, 55.6, 41.0, 28.1, 
12.2. 
IR (neat): ν (cm-1) 2960, 2873, 1599, 1460, 1377, 1237, 1173, 1099, 1032, 748.  
GC-MS (EI) m/z for C12H18O ([M]
+•): 178. 
2-(pentan-3-yl)pyridine 3-10m  
 
Obtained as the mixture of cross-coupling products (90.8 mg colourless oil, 61% yield, 72:28) 
according to the general procedure F. 
GC trace of the crude mixture with L13 as the ligand 










1H NMR (400 MHz, Chloroform-d) δ 8.57 – 8.53 (m, 1H), 7.60 – 7.53 (m, 1H), 7.09 – 7.04 
(m, 2H), 2.59 – 2.46 (m, 1H), 1.75 – 1.65 (m, 4H), 0.77 (t, J = 7.4 Hz, 6H). 





Obtained as the mixture of cross-coupling products (148 mg colourless oil, 68% yield, 94:6) 
according to the general procedure F. 





1H NMR (400 MHz, Chloroform-d) δ (ppm) 7.79 – 7.66 (m, 2H), 7.15 (dd, J = 8.2, 1.7 Hz, 
1H), 2.82 (s, 3H), 2.51 – 2.40 (m, 1H), 1.81 – 1.69 (m, 2H), 1.66 – 1.55 (m, 2H), 0.78 (t, J = 
7.4 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ (ppm) 167.0, 153.9, 144.3, 133.1, 125.2, 121.5, 121.0, 49.8, 
29.6, 20.2, 12.3. 
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IR (neat): ν (cm-1) 2958, 2924, 2872, 1527, 1457, 1375, 1308, 1248, 1172, 1074, 938, 880, 
809, 643. 
HRMS (ESI): Calcd for C13H18NS [M+H]
+: 220.1154, found: 220.1154. 
tert-butyl 2-(pentan-3-yl)-9H-carbazole-9-carboxylate 3-10o  
 
Obtained as the mixture of cross-coupling products (323 mg colourless oil, 96% yield, 99:1) 
according to the general procedure F. 








1H NMR (400 MHz, Chloroform-d) δ 8.33 – 8.24 (m, 1H), 8.17 – 8.09 (m, 1H), 7.98 – 7.91 
(m, 1H), 7.91 – 7.84 (m, 1H), 7.46 – 7.38 (m, 1H), 7.36 – 7.29 (m, 1H), 7.20 – 7.11 (m, 1H), 
2.56 – 2.45 (m, 1H), 1.87 – 1.70 (m, 11H), 1.70 – 1.61 (m, 2H), 0.82 (t, J = 7.4 Hz, 6H). 
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13C NMR (101 MHz, CDCl3) δ 151.4, 145.6, 139.1, 138.7, 126.6, 126.1, 124.0, 123.2, 123.0, 
119.4, 119.2, 116.4, 115.7, 83.8, 50.6, 29.8, 28.6, 12.5. 
IR (neat): ν (cm-1) 2964, 2928, 1727, 1458, 1364, 1221, 1158, 767.  
HRMS (ESI): Calcd for C22H27NNaO2 [M+Na]
+: 360.1934, found: 360.1934. 
4-(pentan-3-yl)-1,2,3,6-tetrahydro-1,1'-biphenyl 3-10p  
 
Obtained as the mixture of cross-coupling products (141 mg pale yellow oil, 62% yield, 93:7) 
according to the general procedure F. 










1H NMR (400 MHz, Chloroform-d) δ 7.39 – 7.18 (m, 5H), 5.55 – 5.41 (m, 1H), 2.86 – 2.70 
(m, 1H), 2.40 – 2.14 (m, 2H), 2.05 – 1.90 (m, 3H), 1.81 – 1.68 (m, 2H), 1.43 – 1.29 (m, 4H), 
0.89 – 0.77 (m, 6H). 
13C NMR (101 MHz, Chloroform-d) δ 147.6, 139.3, 128.4, 127.1, 126.0, 122.1, 51.2, 40.7, 
33.7, 30.3, 26.4, 26.2, 24.7, 12.4. 
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IR (neat): ν (cm-1) 2960, 2927, 2874, 2363, 2126, 1494, 1454, 757, 698, 654. 
GC-MS (EI) m/z for C17H24 ([M]
+•): 228. 
3,3-dimethyl-9-(pentan-3-yl)-1,5-dioxaspiro[5.5]undec-8-ene 3-10q  
 
Obtained as the mixture of cross-coupling products (138 mg pale yellow oil, 55% yield, 94:6) 
according to the general procedure F. 





1H NMR (400 MHz, Chloroform-d) δ 5.22 (t, J = 3.7 Hz, 1H), 3.60 – 3.47 (m, 4H), 2.46 – 
2.30 (m, 2H), 1.98 – 1.87 (m, 4H), 1.79 – 1.67 (m, 1H), 1.38 – 1.30 (m, 2H), 1.30 – 1.24 (m, 
2H), 1.02 (s, 3H), 0.93 (s, 3H), 0.77 (t, J = 7.4 Hz, 6H). 
13C NMR (101 MHz, Chloroform-d) δ 139.0, 118.5, 97.7, 70.4, 50.7, 34.7, 30.4, 28.0, 26.2, 
23.0, 22.8, 22.2, 12.3. 
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IR (neat): ν (cm-1) 2955, 2865, 1463, 1362, 1247, 1113, 1039, 859. 





Obtained as the mixture of cross-coupling products (263 mg white solid, 81% yield, 98:2) 
according to the general procedure F. 









1H NMR (400 MHz, Chloroform-d) δ 7.25 – 7.18 (m, 1H), 6.98 – 6.91 (m, 1H), 6.90 – 6.85 
(m, 1H), 3.03 – 2.86 (m, 2H), 2.52 (dd, J = 18.5, 8.6 Hz, 1H), 2.47 – 2.41 (m, 1H), 2.38 – 
2.24 (m, 2H), 2.22 – 2.13 (m, 1H), 2.11 – 1.97 (m, 3H), 1.73 – 1.48 (m, 10H), 0.94 (s, 3H), 
0.82 (t, J = 7.4 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 220.7, 143.2, 136.9, 135.9, 128.4, 125.1, 125.0, 50.6, 49.1, 
48.0, 44.4, 38.3, 35.9, 31.7, 29.5, 29.1, 26.7, 25.7, 21.6, 13.9, 12.3. 
IR (neat): ν (cm-1) 2928, 2870, 1737, 1455, 1264, 1007, 821, 735.  
HRMS (ESI): Calcd for C23H32NaO [M+Na]
+: 347.2345, found: 347.2347. 
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m.p.: 112-115 oC. 
1-isopropyl-4-methoxybenzene 3-21a 
 
Obtained as the mixture of cross-coupling products (82.5 mg colourless oil, 60% yield, 99:1) 
according to the general procedure F. 








1H NMR (400 MHz, Chloroform-d) δ 7.21 – 7.12 (m, 2H), 6.88 – 6.78 (m, 2H), 3.80 (s, 3H), 
2.87 (hept, J = 6.9 Hz, 1H), 1.24 (d, J = 6.9 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 157.8, 141.2, 127.4, 113.8, 55.4, 33.4, 24.4. 
The NMR data for this compound was consistent with literature data.29a 
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1-(sec-butyl)-4-methoxybenzene 3-21b  
 
Obtained as the mixture of cross-coupling products (102 mg colourless oil, 62% yield, >99:1) 
according to the general procedure F. 





1H NMR (400 MHz, Chloroform-d) δ 7.14 – 7.07 (m, 2H), 6.88 – 6.81 (m, 2H), 3.80 (s, 3H), 
2.63 – 2.49 (m, 1H), 1.61 – 1.53 (m, 2H), 1.22 (d, J = 7.0 Hz, 3H), 0.82 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 157.8, 140.0, 128.0, 113.8, 55.4, 41.0, 31.5, 22.2, 12.4. 
The NMR data for this compound was consistent with literature data.154 
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1-methoxy-4-(4-methylpentan-2-yl)benzene 3-21c  
 
Obtained as the mixture of cross-coupling products (146 mg colourless oil, 76% yield, >99:1) 
according to the general procedure F. 





1H NMR (400 MHz, Chloroform-d) δ 7.14 – 7.09 (m, 2H), 6.87 – 6.80 (m, 2H), 3.80 (s, 3H), 
2.81 – 2.68 (m, 1H), 1.51 – 1.34 (m, 3H), 1.19 (d, J = 6.9 Hz, 3H), 0.88 (d, J = 6.2 Hz, 3H), 
0.85 (d, J = 6.3 Hz, 3H). 




IR (neat): ν (cm-1) 2955, 1612, 1512, 1464, 1297, 1246, 1178, 1039, 830, 690.  
HRMS (ESI): Calcd for C13H20NaO [M+Na]
+: 215.1406, found: 215.1409. 
2-(4-(4-methoxyphenyl)pentyl)-2-methyl-1,3-dioxolane 3-21d  
 
Obtained as the mixture of cross-coupling products (152 mg colourless oil, 58% yield, >99:1) 
according to the general procedure F. 





1H NMR (400 MHz, Chloroform-d) δ 7.13 – 7.05 (m, 2H), 6.87 – 6.77 (m, 2H), 3.94 – 3.85 
(m, 4H), 3.79 (s, 3H), 2.74 – 2.54 (m, 1H), 1.64 – 1.58 (m, 2H), 1.57 – 1.50 (m, 2H), 1.39 – 
1.29 (m, 2H), 1.26 (s, 3H), 1.21 (d, J = 6.9 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 157.8, 140.0, 127.9, 113.8, 110.3, 64.7, 64.7, 55.4, 39.3, 39.2, 
39.0, 23.8, 22.5, 22.4. 
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IR (neat): ν (cm-1) 2362, 2313, 2194, 2100, 2047, 1996, 1947, 1866, 1697, 1207, 1149, 1088, 
831, 740, 680.  
HRMS (ESI): Calcd for C16H24NaO3 [M+Na]
+: 287.1618, found: 287.1620. 
1-methoxy-4-(1-phenylbutan-2-yl)benzene 3-21e 
 
Obtained as the mixture of cross-coupling products (144 mg colourless oil, 60% yield, >99:1) 
according to the general procedure F. 





1H NMR (400 MHz, Chloroform-d) δ 7.24 – 7.19 (m, 2H), 7.18 – 7.12 (m, 1H), 7.07 – 7.01 
(m, 4H), 6.85 – 6.80 (m, 2H), 3.79 (s, 3H), 2.92 – 2.82 (m, 2H), 2.74 – 2.64 (m, 1H), 1.80 – 
1.66 (m, 1H), 1.64 – 1.52 (m, 1H), 0.77 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 157.9, 141.1, 137.2, 129.3, 128.8, 128.1, 125.8, 113.7, 55.3, 
49.1, 43.8, 28.6, 12.3. 
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IR (neat): ν (cm-1) 2926, 1611, 1511, 1455, 1300, 1247, 1177, 1035, 829, 748, 699.  
HRMS (ESI): Calcd for C17H20NaO [M+Na]
+: 263.1406, found: 263.1408. 
methyl 4-(4-methoxyphenyl)hexanoate 3-21f 
 
Obtained as the mixture of cross-coupling products (195 mg colourless oil, 83% yield, >99:1) 
according to the general procedure F. 





1H NMR (400 MHz, Chloroform-d) δ 7.07 – 7.00 (m, 2H), 6.88 – 6.80 (m, 2H), 3.79 (s, 3H), 
3.61 (s, 3H), 2.42 – 2.32 (m, 1H), 2.17 – 2.10 (m, 2H), 2.05  – 1.95 (m, 1H), 1.85 – 1.74 (m, 
1H), 1.71 – 1.59 (m, 1H), 1.58 – 1.48 (m, 1H), 0.77 (t, J = 7.4 Hz, 3H). 




IR (neat): ν (cm-1) 2956, 1736, 1611, 1512, 1458, 1302, 1246, 1162, 1034, 829, 680.  
HRMS (ESI): Calcd for C14H20NaO3 [M+Na]
+: 259.1305, found: 259.1306. 
2-(3-(4-methoxyphenyl)pentyl)-1,3-dioxolane 3-21g  
 
Obtained as the mixture of cross-coupling products (185 mg colourless oil, 74% yield, 99:1) 
according to the general procedure F. 









1H NMR (400 MHz, Chloroform-d) δ 7.10 – 7.01 (m, 2H), 6.87 – 6.77 (m, 2H), 4.78 (t, J = 
4.6 Hz, 1H), 3.97 – 3.80 (m, 4H), 3.78 (s, 3H), 2.48 – 2.30 (m, 1H), 1.85 – 1.72 (m, 1H), 1.68 
– 1.61 (m, 1H), 1.59 – 1.45 (m, 4H), 0.76 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 157.9, 137.4, 128.7, 113.8, 104.8, 65.0, 64.9, 55.4, 47.0, 32.2, 
30.9, 30.0, 12.3. 
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IR (neat): ν (cm-1) 2955, 2873, 1611, 1511, 1460, 1408, 1300, 1246, 1140, 1034, 943, 909, 
830, 682. 
HRMS (ESI): Calcd for C15H22NaO3 [M+Na]
+: 273.1461, found: 273.1458. 
tert-butyl (3-(4-methoxyphenyl)pentyl)(methyl)carbamate 3-21h 
 
Obtained as the mixture of cross-coupling products (185 mg colourless oil, 60% yield, 99:1) 
according to the general procedure F with a modified conditions (Using 2.0 equiv alkyl 
bromide/Mg/LiCl,ZnCl2, 5 mol% Pd2dba3, 10 mol% L13, at 60 °C ). 




1H NMR (400 MHz, Chloroform-d) δ 7.10 – 7.02 (m, 2H), 6.87 – 6.79 (m, 2H), 3.79 (s, 3H), 
3.27 – 2.89 (m, 2H), 2.76 (s, 3H), 2.34 (s, 1H), 1.89 – 1.79 (m, 1H), 1.77 – 1.63 (m, 2H), 1.57 
– 1.46 (m, 1H), 1.42 (s, 9H), 0.76 (t, J = 7.3 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 158.0, 155.9, 137.1, 128.5, 113.9, 79.2, 55.4, 47.7, 44.6, 34.4, 
30.5, 30.1, 28.6, 12.2. 
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IR (neat): ν (cm-1) 2930, 1694, 1612, 1512, 1460, 1394, 1249, 1175, 1037, 879, 830, 772. 
HRMS (ESI): Calcd for C18H29NNaO3 [M+Na]
+: 330.2040, found: 330.2039. 
tert-butyl((4-(4-methoxyphenyl)hexyl)oxy)dimethylsilane 3-21i  
 
Obtained as the mixture of cross-coupling products (196 mg colourless oil, 63% yield, 97:3) 
according to the general procedure F. 





1H NMR (400 MHz, Chloroform-d) δ 7.10 – 7.01 (m, 2H), 6.87 – 6.79 (m, 2H), 3.79 (s, 3H), 
3.53 (t, J = 6.5 Hz, 2H), 2.42 – 2.28 (m, 1H), 1.74 – 1.60 (m, 2H), 1.55 – 1.47 (m, 2H), 1.40 – 
1.32 (m, 2H), 0.88 (s, 9H), 0.76 (t, J = 7.4 Hz, 3H), 0.01 (s, 3H), 0.01 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 157.9, 138.0, 128.7, 113.7, 63.4, 55.4, 46.9, 32.8, 31.0, 30.1, 
26.1, 18.5, 12.3, -5.1. 
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IR (neat): ν (cm-1) 2930, 2858, 1612, 1512, 1463, 1249, 1178, 1098, 1040, 833, 776.  
HRMS (ESI): Calcd for C19H35O2Si [M+H]
+: 323.2401, found: 323.2404. 
tert-butyl((4-(4-methoxyphenyl)pentan-2-yl)oxy)dimethylsilane 3-21j 
 
Obtained as a mixture of diastereoisomers (160 mg colourless oil, 52% yield, >99:1 
selectivity, 60:40 d.r.) according to the general procedure F. 





The same result (d.r. 60:40) was obtained with isolated syn and anti diastereoisomers 




The data given below was the mixtures of diastereomers. 
1H NMR (400 MHz, Chloroform-d) δ 7.15 – 7.06 (m, 2H), 6.89 – 6.79 (m, 2H), 3.79 (s, 3H), 
3.71 – 3.59 (m, 1H), 2.90 – 2.73 (m, 1H), 1.82 – 1.60 (m, 2H), 1.20 (dd, J = 6.9, 5.2 Hz, 3H), 
1.12 (d, J = 6.0 Hz, 1H), 1.08 (d, J = 6.1 Hz, 2H), 0.88 (d, J = 10.8 Hz, 9H), 0.03 – -0.10 (m, 
6H). 
13C NMR (101 MHz, Chloroform-d) δ 157.9, 157.8, 140.0, 139.8, 128.1, 127.8, 113.9, 113.8, 
67.0, 66.7, 55.4, 55.4, 48.8, 48.6, 35.8, 35.5, 26.2, 26.1, 24.5, 23.9, 23.9, 22.5, 18.3, 18.3, -3.8, 
-4.2, -4.4, -4.6. 
IR (neat): ν (cm-1) 2956, 1613, 1513, 1462, 1373, 1296, 1248, 1144, 1041, 830, 774, 720. 
HRMS (ESI): Calcd for C18H32NaO2Si [M+Na]
+: 331.2064, found: 331.2060. 




Obtained as the mixture of cross-coupling products (143 mg colourless oil, 58% yield, 
99:1selectivity, >99:1 d.r.) according to the general procedure F with a modified 
conditions (using 2.0 equiv alkyl bromide/Mg/LiCl,ZnCl2, at 40 °C). 





1H NMR (400 MHz, Chloroform-d) δ 7.12 – 7.04 (m, 2H), 6.87 – 6.78 (m, 2H), 3.79 (s, 3H), 
2.38 (td, J = 11.6, 3.5 Hz, 1H), 1.85 – 1.70 (m, 3H), 1.51 – 1.36 (m, 3H), 1.19 – 0.97 (m, 3H), 
0.89 (d, J = 6.6 Hz, 3H), 0.80 (d, J = 6.9 Hz, 3H), 0.67 (d, J = 6.8 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 157.7, 139.0, 128.4, 113.8, 55.3, 47.8, 47.2, 45.8, 35.5, 33.4, 
27.5, 24.8, 22.7, 21.7, 15.5. 
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Obtained as pale yellow oil (90 mg, 50% yield, >99:1selectivity, ee: 3%.) according to the 
general procedure F and deprotection by TBAF. 




1H NMR (400 MHz, Chloroform-d) δ 7.16 – 7.10 (m, 2H), 6.88 – 6.81 (m, 2H), 3.79 (s, 3H), 
3.63 – 3.47 (m, 2H), 2.83 (dt, J = 13.7, 6.9 Hz, 1H), 1.91 – 1.76 (m, 2H), 1.25 (d, J = 7.0 Hz, 
3H), 1.20 (brs, 1H). 
13C NMR (126 MHz, Chloroform-d) δ 158.0, 139.0, 127.9, 114.0, 61.4, 55.4, 41.3, 35.8, 22.8. 
HPLC conditions: DAICEL CHIRACEL OD-H, heptane/2-propanol = 99.5:0.5, flow rate = 
1.0 mL/min, 25 oC, λ = 221 nm. 










Procedure for scale-up reaction 
methyl 4-(3,4,5-trimethoxyphenyl)hexanoate 3-21l  
 
An oven-dried 100 mL schlenk tube equipped with a stirring bar was taken into the glovebox, 
corresponding nonaflate (solid, 4.66 g, 10 mmol), magnesium powder (365 mg, 15 mmol), 
lithium chloride (636 mg, 15 mmol), zinc chloride (2.04 g, 15 mmol), Pd2dba3 (97%) (118 mg, 
1.25 mol%) and L13 (121 mg, 2.5 mol%) were added to the schlenk tube. The tube was 
capped with a septum and paraffin, and removed from the glovebox. Then, a solution of alkyl 
bromides (3.14 g, 15 mmol) in THF (25 mL) was added to the mixture via syringe under 
argon atmosphere. The septum was wrapped with paraffin and placed into a 25 oC water bath. 
The reaction mixture was stirred at that temperature for 48 h under argon. After that time, the 
reaction mixture was diluted with Et2O (50 mL) and carefully quenched with saturated NH4Cl 
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solution (30 mL) (An aliquot of the crude mixture was measured by GC-MS to determine the 
ratio of direct coupling product and migrative coupling product). The organic phase was 
separated and the aqueous phase was extracted with Et2O (3 X 50 mL). The combined organic 
phases were dried over Na2SO4 and the solvent was removed in vacuo. Purification of the 
residue by silica gel column chromatography gave the desired product (2.2 g, 75%, >99:1) as 
a pale yellow oil. 





1H NMR (400 MHz, Chloroform-d) δ 6.32 (s, 2H), 3.84 (s, 6H), 3.82 (s, 3H), 3.62 (s, 3H), 
2.38 – 2.28 (m, 1H), 2.19 – 2.12 (m, 2H), 2.05 – 1.95 (m, 1H), 1.83 – 1.74 (m, 1H), 1.63 – 
1.49 (m, 2H), 0.80 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 174.3, 153.2, 140.4, 136.4, 104.6, 61.0, 56.2, 51.6, 47.9, 32.4, 
31.6, 29.7, 12.3. 
IR (neat): ν (cm-1) 2957, 1736, 1589, 1509, 1322, 1238, 1128, 1011, 830, 772, 664. 
HRMS (ESI): Calcd for C16H24NaO5 [M+Na]
+: 319.1516, found: 319.1519. 
General procedure G for Barbier-Negishi couplings of primary alkyl bromides 
An oven-dried 10.0 – 20.0 mL Biotage microwave vial equipped with a stirring bar was taken 
into the glovebox, magnesium powder (2.0 e.q.), lithium chloride (2.0 e.q.), zinc chloride (2.0 
e.q.), Pd2dba3 (97%) (5.0 mol%) and L21 (10.0 mol%) were added to the vial. The vial was 
capped with a Biotage cap using a crimper and removed from the glovebox. Then, a solution 
of sulfonates (1.0 mmol, 1.0 e.q.) and alkyl bromides (2.0 e.q.) in THF (5.0 mL, 0.2 M) was 
added to the mixture via syringe under argon atmosphere. The vial was wrapped with tape and 
placed into a 25 oC water bath. The reaction mixture was stirred at that temperature for 24 h. 
After that time, the reaction mixture was diluted with Et2O (5.0 mL) and carefully quenched 
with saturated NH4Cl solution (5.0 mL). The organic phase was separated and the aqueous 
phase was extracted with Et2O (2 X 5.0 mL). The combined organic phases were dried over 
Na2SO4 and the solvent was removed in vacuo. Purification of the residue by silica gel 
column chromatography gave the desired product. 
1-methoxy-4-propylbenzene 3-24b  
 
Obtained as a colourless oil (139 mg, 93% yield) according to the general procedure G. 
1H NMR (400 MHz, Chloroform-d) δ 7.16 – 7.05 (m, 2H), 6.90 – 6.76 (m, 2H), 3.80 (s, 3H), 
2.54 (t, J = 7.5 Hz, 2H), 1.70 – 1.54 (m, 2H), 0.94 (t, J = 7.3 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 157.8, 134.9, 129.4, 113.8, 55.4, 37.3, 24.9, 13.9. 
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The NMR data for this compound was consistent with literature data.73 
1-butyl-4-methoxybenzene 3-24c  
 
Obtained as a colourless oil (156 mg, 95% yield) according to the general procedure G. 
1H NMR (400 MHz, Chloroform-d) δ 7.14 – 7.06 (m, 2H), 6.88 – 6.79 (m, 2H), 3.80 (s, 3H), 
2.60 – 2.53 (m, 2H), 1.63 – 1.53 (m, 2H), 1.42 – 1.32 (m, 2H), 0.93 (t, J = 7.3 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 157.7, 135.2, 129.4, 113.8, 55.4, 34.9, 34.1, 22.5, 14.1. 
The NMR data for this compound was consistent with literature data.157 
1-methoxy-4-pentylbenzene 3-24a  
 
Obtained as a colourless oil (160 mg, 90% yield) according to the general procedure G. 
1H NMR (400 MHz, Chloroform-d) δ 7.16 – 7.04 (m, 2H), 6.89 – 6.77 (m, 2H), 3.80 (s, 3H), 
2.56 (t, J = 7.7 Hz, 2H), 1.60 (dt, J = 15.2, 7.6 Hz, 2H), 1.40 – 1.28 (m, 4H), 0.91 (t, J = 6.8 
Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 157.7, 135.2, 129.4, 113.8, 55.4, 35.2, 31.6, 31.6, 22.7, 14.2. 
The NMR data for this compound was consistent with literature data.73 
ethyl 6-(4-methoxyphenyl)hexanoate 3-24d 
 
Obtained as a pale yellow oil (235 mg, 94% yield) according to the general procedure G. 
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1H NMR (400 MHz, Chloroform-d) δ 7.14 – 7.04 (m, 2H), 6.88 – 6.75 (m, 2H), 4.12 (q, J = 
7.1 Hz, 2H), 3.79 (s, 3H), 2.62 – 2.48 (m, 2H), 2.29 (t, J = 7.6 Hz, 2H), 1.72 – 1.57 (m, 4H), 
1.41 – 1.31 (m, 2H), 1.25 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 173.9, 157.8, 134.7, 129.3, 113.8, 60.3, 55.4, 34.9, 34.4, 31.4, 
28.8, 25.0, 14.4. 






















4. Chapter 4: Enantioselective divergent arylation of 
N-Boc-tetrahydro-1,3-oxazine: Application to the synthesis of 
enantioenriched β2- and β3 -amino acids 
General procedure 
A: N-Boc-tetrahydro-1,3-oxazine synthesis 
 
To a solution of 3-aminopropan-1-ol (1.0 equiv.) in toluene (1.0 M) was added ketone (1.5 
equiv.). The mixture was then stirred under reflux for 24 hours. After cooling to room 
temperature, the mixture was filtered and concentrated, and the residue was used directly for 
the next step. 
To the solution of crude1,3-oxazinane (1.0 equiv.) and triethylamine (1.0 equiv.) in anhydrous 
THF (1.0 M), Boc2O (1.0 equiv.) was added portionwise at 0 
oC. The reaction was stirred for 
10 min at 0 oC, warmed to room temperature and then stirred overnight. The mixture was 
diluted with water and extracted with ethyl acetate twice. The combined organic layers were 
dried over Na2SO4 and then concentrated under reduced pressure. The crude product was then 
purified by column chromatography on silica gel using Cyclohexane/Ethyl acetate as eluent to 
give the desired compound. 
tert-butyl 2,2-diethyl-1,3-oxazinane-3-carboxylate 4-2b 
 
Obtained according to General procedure A as colourless oil (30% over two steps). 
1H NMR (400 MHz, Chloroform-d) δ 3.75 (t, J = 7.1 Hz, 2H), 3.62 – 3.49 (m, 2H), 2.09 (dq, 
J = 14.9, 7.5 Hz, 2H), 1.95 – 1.73 (m, 4H), 1.45 (s, 9H), 0.87 (t, J = 7.4 Hz, 6H). 




IR (neat): ν (cm-1) 2971, 2881, 2361, 1688, 1390, 1168, 1091, 1026, 887, 769, 675, 628. 
HRMS (ESI): Calcd for C13H25NNaO3 [M+Na]
+: 266.1727, found: 266.1731. 
tert-butyl 2,2-dipropyl-1,3-oxazinane-3-carboxylate 4-2c 
 
Obtained according to General procedure A as white solid (25% over two steps). 
1H NMR (400 MHz, Chloroform-d) δ 3.74 (t, J = 7.1 Hz, 2H), 3.58 – 3.48 (m, 2H), 2.04 (ddd, 
J = 14.1, 12.0, 4.6 Hz, 2H), 1.90 – 1.75 (m, 4H), 1.45 (s, 9H), 1.44 – 1.21 (m, 4H), 0.91 (t, J = 
7.4 Hz, 6H). 
13C NMR (101 MHz, Chloroform-d) δ 154.2, 91.2, 79.7, 58.4, 39.2, 38.7, 28.7, 24.3, 16.8, 
14.5. 
IR (neat): ν (cm-1) 2956, 2875, 2361, 1683, 1365, 1282, 1162, 1088, 1016, 940, 891, 824, 777, 
672. 
HRMS (ESI): Calcd for C15H29NNaO3 [M+Na]
+: 294.2040, found: 294.2038. 
B: β-Arylation of N-Boc-tetrahydro-1,3-oxazine derivatives 
 
B1: Racemic version 
In a test-tube capped with rubber septum under argon, a solution of 
N-Boc-tetrahydro-1,3-oxazine (1.0 equiv., 0.5 mmol)  and TMEDA (1.2 equiv.) in 
anhydrous THF (1.0 mL) was stirred and cooled to -78 oC (acetone/dry ice bath), and s-BuLi 
(1.6 M in hexane, 1.2 equiv.) was added slowly via syringe. The reaction was stirred for 5 h at 
this temperature before a solution of ZnCl2 in THF (0.5 M, 1.2 equiv.) was added dropwise. 
The mixture was stirred for 30 min at -78 oC and then warmed to room temperature and 
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stirred for another 1 h. Solvents were removed in vacuo. Meanwhile, a solution of 
Pd2dba3·CHCl3 (2.5 mol%) and L2 (5.0 mol%) in toluene (1.5 mL) was prepared and stirred at 
room temperature for 15 min. The catalyst solution was added to the organozinc reagent tube 
followed by the addition of aryl bromides (0.7 equiv.). The reaction mixture was then allowed 
to stir at 80 oC for 17 h. After cooling to room temperature, saturated NH4Cl solution (2.0 mL) 
was added and the mixture was extracted twice with ethyl acetate. The combined organic 
phases were dried over Na2SO4 and concentrated under reduced pressure. The residue was 
purified by column chromatography on silica gel yielding the desired product. 
B2: Stoichiometric asymmetric version 
In a test-tube capped with rubber septum under argon, a solution of 
N-Boc-tetrahydro-1,3-oxazine (1.0 equiv., 0.5 mmol)  and (+)-sparteine (1.2 equiv., 
(-)-sparteine was used in some cases) in anhydrous Et2O (1.0 mL) was stirred and cooled to 
-78 oC (acetone/dry ice bath), and s-BuLi (1.6 M in hexane, 1.2 equiv.) was added slowly via 
syringe. The reaction was stirred for 8 h at this temperature before a solution of ZnCl2 in THF 
(0.5 M, 1.2 equiv.) was added dropwise. The mixture was stirred for 30 min at -78 oC and 
then warmed to room temperature and stirred for another 1 h. Solvents were removed in 
vacuo. Meanwhile, a solution of Pd2dba3·CHCl3 (2.5 mol%) and L2 (5.0 mol%) in toluene 
(1.5 mL) was prepared and stirred at room temperature for 15 min. The catalyst solution was 
added to the organozinc reagent tube followed by the addition of aryl bromides (0.7 equiv.). 
The reaction mixture was then allowed to stir at 80 oC for 17 h. After cooling to room 
temperature, saturated NH4Cl solution (2.0 mL) was added and the mixture was extracted 
twice with ethyl acetate. The combined organic phases were dried over Na2SO4 and 
concentrated under reduced pressure. The residue was purified by column chromatography on 
silica gel yielding the desired product. 
B3: Catalytic asymmetric version 
In a test-tube capped with rubber septum under argon, s-BuLi (1.6 M in hexane, 1.2 equiv.) 
was added dropwise to a stirred solution of (+)-sparteine surrogate (0.3 equiv.) and 
di-iPr-bispidine (1.3 equiv.) in anhydrous Et2O (1.0 mL) at -78 
oC. After stirring for 15 min at 
this temperature, a solution of N-Boc-tetrahydro-1,3-oxazine (1.0 equiv.) in anhydrous Et2O 
(0.5 mL) was added dropwise. The reaction mixture was allowed to stir at -78 oC for 8 h 
before a solution of ZnCl2 in THF (0.5 M, 1.2 equiv.) was added dropwise. The reaction 
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mixture was stirred for 30 min at -78 °C and was then allowed to warm to room temperature 
and stirred for 1 hour. Solvents were removed in vaccuo. Meanwhile, a solution of 
Pd2dba3·CHCl3 (2.5 mol%) and L2 (5.0 mol%) was prepared in 1.5 mL of anhydrous toluene 
and allowed to stirred for 15 min at room temperature. The catalyst solution was added to the 
organozinc reagent tube followed by the addition of aryl bromide (0.7 equiv.). This mixture 
was conducted at 80 °C for 17 h. After cooling to room temperature, saturated NH4Cl solution 
(2 mL) was added and the aqueous layer was extracted twice with ethyl acetate. The 
combined organic layers were dried over Na2SO4 and concentrated under reduced pressure. 
The residue was purified by column chromatography on silica gel yielding the desired 
product. 
tert-butyl 5-phenyl-2,2-dipropyl-1,3-oxazinane-3-carboxylate 4-3ca 
 
Obtained as colourless oil (72% yield) according to General procedure B2 using 
(+)-sparteine. 
1H NMR (400 MHz, Chloroform-d) δ 7.37 – 7.30 (m, 2H), 7.28 – 7.21 (m, 3H), 4.15 – 3.97 
(m, 2H), 3.74 (dd, J = 11.7, 8.4 Hz, 1H), 3.32 (dd, J = 12.7, 11.1 Hz, 1H), 3.23 – 3.09 (m, 1H), 
2.23 – 2.04 (m, 3H), 1.85– 1.70 (m, 1H), 1.56 – 1.47 (m, 2H), 1.46 (s, 9H), 1.40 – 1.26 (m, 
2H), 0.94 (q, J = 7.3 Hz, 6H). 
13C NMR (101 MHz, Chloroform-d) δ 154.1, 141.7, 128.8, 127.5, 127.1, 90.9, 79.9, 65.0, 
45.8, 41.6, 39.2, 37.6, 28.6, 17.2, 16.5, 14.6, 14.5. 
IR (neat): ν (cm-1) 2961, 2362, 1688, 1455, 1365, 1246, 1163, 1107, 938, 831, 733, 660, 649. 
HRMS (ESI): Calcd for C21H33NNaO3 [M+Na]
+: 370.2353, found: 370.2354. 
[α]D20 = -22.4ᵒ (c = 0.56, CHCl3). 
HPLC separation: Chiralpak IC, n-Heptane/i-PrOH = 99.5:0.5, 1.0 mL/min, 220 nm, 









Obtained as colourless oil (72% yield) according to General procedure B2 using 
(+)-sparteine. 
1H NMR (400 MHz, Chloroform-d) δ 7.20 – 7.11 (m, 2H), 6.90 – 6.81 (m, 2H), 4.08 – 3.96 
(m, 2H), 3.79 (s, 3H), 3.69 (dd, J = 11.6, 8.5 Hz, 1H), 3.26 (dd, J = 12.7, 11.2 Hz, 1H), 3.16 – 
3.03 (m, 1H), 2.20 – 2.04 (m, 3H), 1.82 – 1.70 (m, 1H), 1.55 – 1.47 (m, 2H), 1.45 (s, 9H), 
1.39– 1.27 (m, 2H), 0.99 – 0.88 (m, 6H). 
13C NMR (101 MHz, Chloroform-d) δ 158.7, 154.1, 133.7, 128.4, 114.2, 90.8, 79.9, 65.2, 
55.4, 46.0, 40.8, 39.3, 37.5, 28.6, 17.2, 16.5, 14.6, 14.5. 
IR (neat): ν (cm-1) 2960, 2361, 1688, 1613, 1514, 1458, 1391, 1247, 1171, 1103, 940, 826, 
769, 631. 
HRMS (ESI): Calcd for C22H35NNaO4 [M+Na]
+: 400.2458, found: 400.2457. 
[α]D20 = -25.6ᵒ (c = 1.38, CHCl3). 
HPLC separation: Chiralpak IC, n-Heptane/i-PrOH = 99.5:0.5, 1.0 mL/min, 226 nm, 









Obtained as colourless oil (35% yield) according to General procedure B2 using 
(+)-sparteine. 
1H NMR (400 MHz, Chloroform-d) δ 7.65 – 7.56 (m, 2H), 7.41 – 7.30 (m, 2H), 4.10 – 3.97 
(m, 2H), 3.69 (dd, J = 11.9, 7.6 Hz, 1H), 3.37 (dd, J = 12.9, 10.1 Hz, 1H), 3.26 – 3.15 (m, 1H), 
2.18 – 1.99 (m, 3H), 1.78 (ddd, J = 14.1, 12.0, 4.5 Hz, 1H), 1.51 – 1.47 (m, 1H), 1.45 (s, 9H), 
1.41 – 1.22 (m, 3H), 0.92 (dt, J = 9.8, 7.4 Hz, 6H). 
13C NMR (101 MHz, Chloroform-d) δ 154.1, 147.4, 132.6, 128.3, 118.8, 111.1, 91.3, 80.3, 
64.3, 45.1, 41.7, 38.8, 38.0, 28.6, 17.2, 16.5, 14.5, 14.4. 
IR (neat): ν (cm-1) 2961, 2361, 2229, 1686, 1609, 1457, 1392, 1282, 1246, 1163, 1103, 938, 
826, 769. 
HRMS (ESI): Calcd for C22H32N2NaO3 [M+Na]
+: 395.2305, found: 395.2307. 
[α]D20 = -28.9ᵒ (c = 1.1, CHCl3). 
HPLC separation: Chiralpak IC, n-Heptane/i-PrOH = 95:5, 1.0 mL/min, 240 nm, tr(major) = 









4-3ch, obtained as white solid (58% yield) according to General procedure B2 using 
(+)-sparteine. 
ent-4-3ch, obtained as white solid (61% yield) according to General procedure B2 using 
(-)-sparteine. 
1H NMR (400 MHz, Chloroform-d) δ 7.61 – 7.52 (m, 4H), 7.47 – 7.40 (m, 2H), 7.37 – 7.30 
(m, 3H), 4.17 – 4.02 (m, 2H), 3.77 (dd, J = 11.7, 8.3 Hz, 1H), 3.36 (dd, J = 12.7, 11.0 Hz, 1H), 
3.28 – 3.12 (m, 1H), 2.23 – 2.06 (m, 3H), 1.79 (ddd, J = 14.0, 12.0, 4.5 Hz, 1H), 1.54 – 1.49 
(m, 2H), 1.47 (s, 9H), 1.41 – 1.29 (m, 2H), 0.95 (q, J = 7.3 Hz, 6H). 
13C NMR (101 MHz, Chloroform-d) δ 154.1, 140.9, 140.7, 140.1, 128.9, 127.9, 127.5, 127.4, 
127.1, 91.0, 80.0, 65.0, 45.8, 41.3, 39.2, 37.6, 28.6, 17.2, 16.5, 14.6, 14.5. 
IR (neat): ν (cm-1) 2961, 1685, 1455, 1364, 1267, 1165, 1109, 938, 798, 699, 631. 
HRMS (ESI): Calcd for C27H37NNaO3 [M+Na]
+: 446.2666, found: 446.2664. 
[α]D20 = -21.8ᵒ (c = 1.35, CHCl3) (from (+)-sparteine) 
[α]D20 = +46.7ᵒ (c = 0.69, CHCl3) (from (-)-sparteine) 
HPLC separation: Chiralpak IC, n-Heptane/i-PrOH = 99.5:0.5, 1.0 mL/min, 246 nm, 
tr(minor) = 9.8 min, tr(major) = 16.7 min, 3.5:96.5 e.r. (from (+)-sparteine) 
HPLC separation: Chiralpak IC, n-Heptane/i-PrOH = 99.5:0.5, 1.0 mL/min, 246 nm, 









tert-butyl 5-(3-fluorophenyl)-2,2-dipropyl-1,3-oxazinane-3-carboxylate 4-3ci 
 
Obtained as colourless oil (70% yield) according to General procedure B2 using 
(+)-sparteine. 
1H NMR (400 MHz, Chloroform-d) δ 7.33 – 7.27 (m, 1H), 7.06 – 6.90 (m, 3H), 4.10 – 4.01 
(m, 2H), 3.71 (dd, J = 11.8, 8.1 Hz, 1H), 3.34 (dd, J = 12.8, 10.7 Hz, 1H), 3.22 – 3.11 (m, 1H), 
2.19 – 2.04 (m, 3H), 1.79 (ddd, J = 14.1, 11.9, 4.6 Hz, 1H), 1.57 – 1.50 (m, 1H), 1.47 (s, 9H), 
1.45 – 1.26 (m, 3H), 0.95 (q, J = 7.3 Hz, 6H). 
13C NMR (101 MHz, Chloroform-d) δ 163.1 (d, J = 244.6 Hz), 154.1, 144.3 (d, J = 7.1 Hz), 
130.2 (d, J = 8.2 Hz), 123.1 (d, J = 2.8 Hz), 114.3 (d, J = 21.3 Hz), 114.0 (d, J = 21.0 Hz), 
91.0, 80.1, 64.7, 45.4, 41.3, 39.1, 37.7, 28.6, 17.2, 16.5, 14.5, 14.5. 
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19F NMR (376 MHz, Chloroform-d) δ -112.7. 
IR (neat): ν (cm-1) 2961, 2361, 1688, 1590, 1452, 1366, 1245, 1160, 1108, 938, 783, 695, 
629. 
HRMS (ESI): Calcd for C21H32FNNaO3 [M+Na]
+: 388.2258, found: 388.2257. 
[α]D20 = -16.9ᵒ (c = 1.23, CHCl3). 
HPLC separation: Chiralpak IC, n-Heptane/i-PrOH = 99.5:0.5, 1.0 mL/min, 211 nm, 





tert-butyl 5-(3-acetylphenyl)-2,2-dipropyl-1,3-oxazinane-3-carboxylate 4-3cj 
 
Obtained as colourless oil (46% yield) according to General procedure B2 using 
(+)-sparteine. 
1H NMR (400 MHz, Chloroform-d) δ 7.89–7.79 (m, 2H), 7.50 – 7.38 (m, 2H), 4.11 – 4.01 (m, 
2H), 3.73 (dd, J = 11.8, 8.1 Hz, 1H), 3.39 (dd, J = 12.8, 10.6 Hz, 1H), 3.27 – 3.14 (m, 1H), 
2.60 (s, 3H), 2.21 – 2.04 (m, 3H), 1.84 – 1.72 (m, 1H), 1.55 – 1.48 (m, 1H), 1.46 (s, 9H), 1.40 
– 1.22 (m, 3H), 0.94 (q, J = 7.4 Hz, 6H). 
13C NMR (101 MHz, Chloroform-d) δ 198.1, 154.1, 142.4, 137.6, 132.2, 129.1, 127.3, 127.2, 
91.1, 80.1, 64.8, 45.5, 41.5, 39.1, 37.8, 28.6, 26.8, 17.2, 16.5, 14.6, 14.5. 
IR (neat): ν (cm-1) 2961, 1685, 1455, 1364, 1267, 1165, 1109, 938, 699, 631. 
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HRMS (ESI): Calcd for C23H35NNaO4 [M+Na]
+: 412.2458, found: 412.2464. 
[α]D20 = -22.0ᵒ (c = 0.91, CHCl3). 
HPLC separation: Chiralpak IC, n-Heptane/i-PrOH = 95:5, 1.0 mL/min, 232 nm, tr(minor) = 





tert-butyl 5-(3,4-dimethoxyphenyl)-2,2-dipropyl-1,3-oxazinane-3-carboxylate 4-3cm 
 
Obtained as colourless oil (68% yield) according to General procedure B2 using 
(+)-sparteine. 
1H NMR (400 MHz, Chloroform-d) δ 6.84 – 6.72 (m, 3H), 4.08 – 3.97 (m, 2H), 3.86 (s, 3H), 
3.84 (s, 3H), 3.69 (dd, J = 11.7, 8.3 Hz, 1H), 3.30 (dd, J = 12.8, 10.9 Hz, 1H), 3.16 – 3.03 (m, 
1H), 2.21 – 2.01 (m, 3H), 1.82 – 1.69 (m, 1H), 1.56 – 1.46 (m, 2H), 1.44 (s, 9H), 1.38 – 1.24 
(m, 2H), 0.93 (q, J = 7.3 Hz, 6H). 
13C NMR (101 MHz, Chloroform-d) δ 154.1, 149.1, 148.1, 134.3, 119.3, 111.4, 110.7, 90.8, 
79.9, 65.1, 56.0, 56.0, 45.8, 41.1, 39.2, 37.7, 28.6, 17.2, 16.5, 14.5, 14.5. 




HRMS (ESI): Calcd for C23H37NNaO5 [M+Na]
+: 430.2564, found: 430.2566. 
[α]D20 = -25.0ᵒ (c = 1.0, CHCl3). 
HPLC separation: Chiralpak IC, n-Heptane/i-PrOH = 90:10, 1.0 mL/min, 220 nm, tr(minor) 







4-3cn, obtained as colourless oil (85% yield) according to General procedure B2 using 
(+)-sparteine. 
ent-4-3cn, obtained as colourless oil (82% yield) according to General procedure B2 using 
(-)-sparteine. 
1H NMR (400 MHz, Chloroform-d) δ 6.76 – 6.72 (m, 2H), 6.70 – 6.65 (m, 1H), 5.92 (s, 2H), 
4.10 – 3.91 (m, 2H), 3.65 (dd, J = 11.7, 8.3 Hz, 1H), 3.24 (dd, J = 12.7, 11.0 Hz, 1H), 3.12 – 
3.01 (m, 1H), 2.19 – 2.02 (m, 3H), 1.81 – 1.70 (m, 1H), 1.53 – 1.47 (m, 1H), 1.45 (s, 9H), 
1.44 – 1.23 (m, 3H), 0.93 (td, J = 7.4, 5.0 Hz, 6H). 
13C NMR (101 MHz, Chloroform-d) δ 154.1, 148.0, 146.6, 135.5, 120.5, 108.5, 107.7, 101.1, 
90.9, 79.9, 65.1, 45.9, 41.3, 39.2, 37.6, 28.6, 17.2, 16.4, 14.6, 14.5. 
285 
 
IR (neat): ν (cm-1) 2961, 2361, 1684, 1488, 1444, 1393, 1247, 1166, 1103, 1041, 910, 809, 
731, 647. 
HRMS (ESI): Calcd for C22H33NNaO5 [M+Na]
+: 414.2251, found: 414.2253. 
[α]D20 = -27.6ᵒ (c = 1.35, CHCl3) (from (+)-sparteine) 
[α]D20 = +25.6ᵒ (c = 0.59, CHCl3) (from (-)-sparteine) 
HPLC separation: Chiralpak IC, n-Heptane/i-PrOH = 99.5:0.5, 1.0 mL/min, 213 nm, 
tr(minor) = 16.3 min, tr(major) = 31.3 min, 4:96 e.r. (from (+)-sparteine) 
HPLC separation: Chiralpak IC, n-Heptane/i-PrOH = 99.5:0.5, 1.0 mL/min, 213 nm, 










Obtained as colourless oil (66% yield of mixture of β- and γ-products) according to General 
procedure B2 using (+)-sparteine. 
The data shown below is the characterization for the major β-product. 
1H NMR (400 MHz, Chloroform-d) δ 8.54 – 8.44 (m, 2H), 7.60 – 7.54 (m, 1H), 7.28 – 7.21 
(m, 1H), 4.08 – 3.99 (m, 2H), 3.69 (dd, J = 11.8, 7.8 Hz, 1H), 3.35 (dd, J = 12.9, 10.4 Hz, 1H), 
3.21 – 3.11 (m, 1H), 2.10 – 1.99 (m, 3H), 1.81 – 1.72 (m, 1H), 1.64 – 1.48 (m, 1H), 1.43 (s, 
9H), 1.38 – 1.22 (m, 3H), 0.98 – 0.83 (m, 6H). 
13C NMR (101 MHz, Chloroform-d) δ 154.0, 149.3, 148.6, 137.2, 134.7, 123.7, 91.1, 80.2, 
64.4, 45.3, 40.7, 39.1, 37.8, 28.5, 17.1, 16.5, 14.5, 14.4. 
IR (neat): ν (cm-1) 2960, 2361, 1687, 1457, 1365, 1241, 1162, 1105, 939, 715, 666, 628. 
HRMS (ESI): Calcd for C20H33N2O3 [M+H]
+: 349.2486, found: 349.2486. 
HPLC separation:  
β-product (major): Chiralpak IC, n-Heptane/i-PrOH = 90:10, 1.0 mL/min, 260 nm, tr(minor) 
= 11.8 min, tr(major) = 16.4 min, 5:95 e.r. 
γ-product (minor): Chiralpak IC, n-Heptane/i-PrOH = 90:10, 1.0 mL/min, 260 nm, tr(minor) 










Obtained as colourless oil (64% yield of mixture of β- and γ-products) according to General 
procedure B2 using (+)-sparteine. 
The data shown below is the characterization for the major β-product. 
1H NMR (400 MHz, Chloroform-d) δ 8.21 – 8.16 (m, 2H), 3.99 – 3.91 (m, 2H), 3.59 (dd, J = 
11.8, 8.3 Hz, 1H), 3.23 (dd, J = 12.9, 10.7 Hz, 1H), 3.14 (s, 6H), 3.00 – 2.87 (m, 1H), 2.06 – 
1.91 (m, 3H), 1.76 – 1.69 (m, 1H), 1.53 – 1.46 (m, 1H), 1.42 (s, 9H), 1.34 – 1.21 (m, 3H), 
0.94 – 0.86 (m, 6H). 
13C NMR (101 MHz, Chloroform-d) δ 161.8, 156.7, 154.0, 121.2, 91.0, 80.1, 64.5, 45.5, 40.7, 
39.1, 37.2, 37.2, 36.3, 28.5, 17.1, 16.4, 14.5, 14.4. 
IR (neat): ν (cm-1) 2960, 2361, 1689, 1605, 1537, 1388, 1161, 1106, 939, 658. 
HRMS (ESI): Calcd for C21H37N4O3 [M+H]
+: 393.2860, found: 393.2864. 
HPLC separation: did not find good conditions to separate it on chiral HPLC. 
tert-butyl 5-(prop-1-en-2-yl)-2,2-dipropyl-1,3-oxazinane-3-carboxylate 4-3cs 
 
Obtained as colourless oil (82% yield) according to General procedure B2 using 
(+)-sparteine. 
1H NMR (400 MHz, Chloroform-d) δ 4.80 – 4.77 (m, 1H), 4.75 – 4.71 (m, 1H), 3.98 – 3.78 
(m, 2H), 3.50 (dd, J = 11.5, 8.6 Hz, 1H), 3.11 (dd, J = 12.7, 10.8 Hz, 1H), 2.62 – 2.49 (m, 1H), 
2.13 – 1.94 (m, 3H), 1.72 (s, 3H), 1.70 – 1.64 (m, 1H), 1.45 (s, 9H), 1.41 – 1.19 (m, 4H), 0.93 
– 0.87 (m, 6H). 
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13C NMR (101 MHz, Chloroform-d) δ 154.1, 144.4, 111.4, 90.8, 79.8, 62.7, 43.5, 42.2, 39.2, 
37.7, 28.6, 20.9, 17.2, 16.4, 14.5, 14.5. 
IR (neat): ν (cm-1) 2962, 2361, 1684, 1456, 1377, 1166, 1110, 908, 733, 670, 629. 
HRMS (ESI): Calcd for C18H33NNaO3 [M+Na]
+: 334.2353, found: 334.2353. 
[α]D20 = -14.2ᵒ (c = 0.87, CHCl3). 
The e.r. was determined by the corresponding amino alcohol. 
tert-butyl (2-(hydroxymethyl)-3-methylbut-3-en-1-yl)carbamate 
 
1H NMR (400 MHz, Chloroform-d) δ 4.93 (s, 1H), 4.75 (s, 1H), 4.71 (brs, 1H), 3.68 – 3.52 
(m, 2H), 3.37 – 3.15 (m, 2H), 2.73 (brs, 1H), 2.38 – 2.22 (m, 1H), 1.74 (s, 3H), 1.44 (s, 9H). 
13C NMR (126 MHz, Chloroform-d) δ 157.0, 143.8, 113.0, 79.9, 61.8, 49.0, 39.8, 28.5, 21.7. 
IR (neat): ν (cm-1) 3355, 2976, 2361, 1687, 1511, 1366, 1250, 1167, 1039, 893, 670. 
HRMS (ESI): Calcd for C11H21NNaO3 [M+Na]
+: 238.1414, found: 238.1414. 
[α]D20 = +6.5ᵒ (c = 1.53, CHCl3). 
HPLC separation: Chiralpak IC, n-Heptane/i-PrOH = 95:5, 0.5 mL/min, 206 nm, tr(minor) = 









Obtained as colourless oil (68% yield) according to General procedure B2 using 
(+)-sparteine. 
1H NMR (400 MHz, Chloroform-d) δ 5.52 – 5.38 (m, 1H), 3.83 (ddd, J = 31.9, 12.1, 6.2 Hz, 
2H), 3.49 (dd, J = 11.5, 8.8 Hz, 1H), 3.07 (dd, J = 12.6, 11.1 Hz, 1H), 2.49 – 2.39 (m, 1H), 
2.13 – 1.84 (m, 7H), 1.74 – 1.52 (m, 5H), 1.45 (s, 9H), 1.43 – 1.27 (m, 4H), 0.90 (td, J = 7.4, 
5.1 Hz, 6H). 
13C NMR (101 MHz, Chloroform-d) δ 154.2, 136.7, 122.6, 90.7, 79.7, 62.9, 43.7, 42.5, 39.3, 
37.7, 28.6, 26.6, 25.3, 23.0, 22.5, 17.2, 16.4, 14.6, 14.5. 
IR (neat): ν (cm-1) 2929, 2362, 1692, 1392, 1164, 1104, 940, 786, 631. 
HRMS (ESI): Calcd for C21H37NNaO3 [M+Na]
+: 374.2666, found: 374.2664. 
[α]D20 = -10.7ᵒ (c = 1.23, CHCl3). 
The e.r. was determined by the corresponding amino alcohol. 
tert-butyl (2-(cyclohex-1-en-1-yl)-3-hydroxypropyl)carbamate 
 
1H NMR (500 MHz, Chloroform-d) δ 5.48 (s, 1H), 4.67 (brs, 1H), 3.63 – 3.48 (m, 2H), 3.32 
– 3.15 (m, 2H), 2.52 (brs, 1H), 2.22 – 2.13 (m, 1H), 2.06 – 1.97 (m, 2H), 1.96 – 1.88 (m, 2H), 
1.65 – 1.51 (m, 4H), 1.44 (s, 9H). 
13C NMR (126 MHz, Chloroform-d) δ 156.9, 135.9, 124.5, 76.9, 62.0, 49.6, 40.0, 28.5, 27.1, 
25.4, 23.0, 22.6. 
IR (neat): ν (cm-1) 3357, 2928, 2361, 1687, 1510, 1366, 1250, 1168, 1040, 919, 863, 629. 
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HRMS (ESI): Calcd for C14H25NNaO3 [M+Na]
+: 278.1727, found: 278.1723. 
[α]D20 = +8.2ᵒ (c = 1.31, CHCl3). 
HPLC separation: Chiralpak IC, n-Heptane/i-PrOH = 95:5, 0.5 mL/min, 206 nm, tr(minor) = 









Obtained as colourless oil (47% yield) according to General procedure B2 using 
(+)-sparteine (from R-OTf instead of R-Br). 
The data shown below could be the mixture of diastereoisomers. 
1H NMR (400 MHz, Chloroform-d) δ 7.33 – 7.27 (m, 2H), 7.24 – 7.17 (m, 3H), 5.57 (d, J = 
3.6 Hz, 1H), 3.98 – 3.81 (m, 2H), 3.62 – 3.47 (m, 1H), 3.20 – 3.09 (m, 1H), 2.80 – 2.69 (m, 
1H), 2.60 – 2.47 (m, 1H), 2.37 – 2.26 (m, 1H), 2.22 – 1.93 (m, 7H), 1.82 – 1.63 (m, 2H), 1.47 
(s, 9H), 1.45 – 1.23 (m, 4H), 0.98 – 0.88 (m, 6H). 
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13C NMR (101 MHz, Chloroform-d) δ 154.2/154.2, 147.0/146.9, 136.7/136.6, 128.5, 
127.0/126.9, 126.2, 122.4/122.3/122.2/122.2, 90.8/90.8, 79.8, 62.9/62.8, 43.9/43.5, 42.3/42.0, 
40.2/40.0, 39.3/39.2, 37.8/37.6, 33.6/33.5, 30.1/30.0, 28.6, 27.2/27.2, 17.2/17.2, 16.4/16.4, 
14.6, 14.5. 
IR (neat): ν (cm-1) 2960, 2361, 1690, 1392, 1163, 1103, 940, 787, 699, 631. 
HRMS (ESI): Calcd for C27H41NNaO3 [M+Na]
+: 450.2979, found: 450.2984. 
[α]D20 = -21.8ᵒ (c = 1.05, CHCl3). 
HPLC separation: Chiralpak IC, n-Heptane/i-PrOH = 99.7:0.3, 1.0 mL/min, 209 nm, 
tr(major) = 10.0 min, tr(minor) = 13.9 min (?), 96:4 e.r. 





Catalytic version of asymmetric deprotonation 
tert-butyl 5-(4-methoxyphenyl)-2,2-dipropyl-1,3-oxazinane-3-carboxylate 
 
Obtained as colourless oil (68% yield) according to General procedure B3 using catalytic 
(+)-sparteine surrogate. 
HPLC separation: Chiralpak IC, n-Heptane/i-PrOH = 99.5:0.5, 1.0 mL/min, 226 nm, 









Obtained as colourless oil (57% yield) according to General procedure B3 using catalytic 
(+)-sparteine surrogate. 
1H NMR (400 MHz, Chloroform-d) δ 8.00 – 7.95 (m, 2H), 7.34 – 7.28 (m, 2H), 4.09 – 4.00 
(m, 2H), 3.88 (s, 3H), 3.71 (dd, J = 11.8, 7.9 Hz, 1H), 3.36 (dd, J = 12.8, 10.6 Hz, 1H), 3.26 – 
3.15 (m, 1H), 2.20 – 2.02 (m, 3H), 1.82 – 1.71 (m, 1H), 1.55 – 1.47 (m, 1H), 1.44 (s, 9H), 
1.42 – 1.24 (m, 3H), 0.92 (dt, J = 8.7, 7.4 Hz, 6H). 
13C NMR (101 MHz, Chloroform-d) δ 166.9, 154.0, 147.0, 130.1, 129.0, 127.5, 91.1, 80.1, 
64.5, 52.2, 45.3, 41.6, 39.0, 37.8, 28.5, 17.2, 16.4, 14.5, 14.4. 
IR (neat): ν (cm-1) 2960, 2362, 1689, 1392, 1280, 1168, 1109, 769, 632. 
HRMS (ESI): Calcd for C23H35NNaO5 [M+Na]
+: 428.2407, found: 428.2408. 
[α]D20 = -35.9ᵒ (c = 1.27, CHCl3). 
HPLC separation: Chiralpak IC, n-Heptane/i-PrOH = 95:5, 1.0 mL/min, 236 nm, tr(major) = 









Obtained as colourless oil (73% yield) according to General procedure B3 using catalytic 
(+)-sparteine surrogate. 
HPLC separation: Chiralpak IC, n-Heptane/i-PrOH = 99.5:0.5, 1.0 mL/min, 213 nm, 







Obtained as colourless oil (26% yield) according to General procedure B3 using catalytic 
(+)-sparteine surrogate. 
HPLC separation: Chiralpak IC, n-Heptane/i-PrOH = 95:5, 1.0 mL/min, 232 nm, tr(minor) = 









Obtained as colourless oil (52% yield) according to General procedure B3 using 
(+)-sparteine surrogate. 
1H NMR (400 MHz, Chloroform-d) δ 7.31 – 7.27 (m, 1H), 7.24 – 7.12 (m, 3H), 4.10 – 3.99 
(m, 2H), 3.72 (dd, J = 11.6, 7.8 Hz, 1H), 3.44 – 3.28 (m, 2H), 2.36 (s, 3H), 2.23 – 2.09 (m, 
3H), 1.86 – 1.74 (m, 1H), 1.59 – 1.51 (m, 1H), 1.47 (s, 9H), 1.43 – 1.26 (m, 3H), 0.96 (dt, J = 
9.0, 7.4 Hz, 6H). 
13C NMR (101 MHz, Chloroform-d) δ 154.0, 140.0, 136.0, 130.6, 126.8, 126.6, 126.1, 91.0, 
79.9, 64.4, 45.2, 39.2, 37.7, 37.4, 28.6, 19.7, 17.3, 16.5, 14.6, 14.5. 
IR (neat): ν (cm-1) 2960, 2361, 1690, 1458, 1392, 1167, 1098, 938, 755, 631. 
HRMS (ESI): Calcd for C22H35NNaO3 [M+Na]
+: 384.2509, found: 384.2514. 
[α]D20 = -7.8ᵒ (c = 1.28, CHCl3). 
HPLC separation: Chiralpak IC, n-Heptane/i-PrOH = 99.5:0.5, 1.0 mL/min, 220 nm, 









C1: Racemic version 
In a test-tube capped with rubber septum under argon, a solution of 
N-Boc-tetrahydro-1,3-oxazine (1.0 equiv., 0.5 mmol)  and TMEDA (1.2 equiv.) in 
anhydrous THF (1.0 mL) was stirred and cooled to -78 oC (acetone/dry ice bath), and s-BuLi 
(1.2 equiv.) was added slowly via syringe. The reaction was stirred for 5 h at this temperature 
before a solution of ZnCl2 in THF (0.5 M, 1.2 equiv.) was added dropwise. The mixture was 
stirred for 30 min at -78 oC and then warmed to room temperature and stirred for another 1 h. 
Solvents were removed in vacuo. Meanwhile, a solution of Pd2dba3·CHCl3 (2.5 mol%) and 
L13 (5.0 mol%) in toluene (1.5 mL) was prepared and stirred at room temperature for 15 min. 
The catalyst solution was added to the organozinc reagent tube followed by the addition of 
aryl nonaflate (0.7 equiv.). The reaction mixture was then allowed to stir at 80 oC for 24 h. 
After cooling to room temperature, saturated NH4Cl solution (2.0 mL) was added and the 
mixture was extracted twice with ethyl acetate. The combined organic phases were dried over 
Na2SO4 and concentrated under reduced pressure. The residue was purified by column 
chromatography on silica gel yielding the desired product. 
C2: Stoichiometric asymmetric version 
In a test-tube capped with rubber septum under argon, a solution of 
N-Boc-tetrahydro-1,3-oxazine (1.0 equiv., 0.5 mmol)  and (+)-sparteine (1.2 equiv.) in 
anhydrous Et2O (1.0 mL) was stirred and cooled to -78 
oC (acetone/dry ice bath), and s-BuLi 
(1.2 equiv.) was added slowly via syringe. The reaction was stirred for 8 h at this temperature 
before a solution of Zn(OAc)2 in THF (0.5 M, 1.2 equiv.) was added dropwise. The mixture 
was stirred for 30 min at -78 oC and then warmed to room temperature and stirred for another 
1 h. Solvents were removed in vacuo. Meanwhile, a solution of Pd2dba3·CHCl3 (2.5 mol%) 
and L13 (5.0 mol%) in toluene (1.5 mL) was prepared and stirred at room temperature for 15 
min. The catalyst solution was added to the organozinc reagent tube followed by the addition 
of aryl nonaflate (0.7 equiv.). The reaction mixture was then allowed to stir at 80 oC for 24 h. 
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After cooling to room temperature, saturated NH4Cl solution (2.0 mL) was added and the 
mixture was extracted twice with ethyl acetate. The combined organic phases were dried over 
Na2SO4 and concentrated under reduced pressure. The residue was purified by column 
chromatography on silica gel yielding the desired product. 
tert-butyl 2,2-diethyl-4-phenyl-1,3-oxazinane-3-carboxylate 4-4ba 
 
Obtained as colourless oil (61% yield) according to General procedure C2 using 
(+)-sparteine. 
1H NMR (400 MHz, Chloroform-d) δ 7.50 – 7.45 (m, 2H), 7.33 – 7.27 (m, 2H), 7.24 – 7.18 
(m, 1H), 5.29 (dd, J = 6.3, 3.3 Hz, 1H), 3.98 – 3.83 (m, 2H), 2.43 – 2.30 (m, 1H), 2.29 – 2.15 
(m, 3H), 2.14 – 2.04 (m, 1H), 1.77 (dq, J = 14.6, 7.3 Hz, 1H), 1.38 (s, 9H), 0.94 (t, J = 7.5 Hz, 
3H), 0.64 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, Chloroform-d) δ 154.4, 144.6, 128.1, 127.4, 126.6, 92.3, 80.0, 56.4, 
53.8, 30.3, 28.9, 28.5, 28.3, 8.9, 8.3. 
IR (neat): ν (cm-1) 2958, 2361, 1686, 1455, 1366, 1254, 1168, 1098, 890, 700, 629. 
HRMS (ESI): Calcd for C19H29NNaO3 [M+Na]
+: 342.2040, found: 342.2042. 
[α]D20 = -50.2ᵒ (c = 0.85, CHCl3). 
HPLC separation: Chiralpak IA, n-Heptane/i-PrOH = 100:0, 0.4 mL/min, 224 nm, tr(minor) 





D: Synthesis of Enantiopure β2-amino acid derivatives  
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D1100: To a solution of β-arylated product in THF (0.1 M) was added 50% aqueous 
trifluoroacetic acid under ice-batch temperature. After 1 h, the reaction temperature was 
allowed to increase to room temperature and the solution was stirred until the starting material 
was not detectable (TLC). The mixture was dissolved in 10 mL of water and extracted with 
ethyl ether. The combined organic extracts were dried over anhydrous NaSO4 and 
concentrated under reduced pressure. The residue was purified by a short pad of flash column 
chromatography with ethyl acetate/hexane as an eluent. 
D2: To a solution of the amino alcohol (1.0 equiv.) in the mixture of MeCN/H2O was added 
RuCl3 hydrate (5 mol%) and NaIO4 (3.0 equiv.) at 0 
oC. The reaction mixture was then 
allowed to warm to room temperature for 3.0 h. The mixture was quenched by 5 mol% 
Na2CO3 aqueous solution and extracted with ethyl acetate. The combined organic phases were 
washed with brine, dried over anhydrous NaSO4 and concentrated under reduced pressure. 





The amino acid was obtained as white solid (57% yield over two steps). The e.r. was 
determined by the corresponding methylation product.158 
The configuration was determined to be S- by comparing the [α]D20 reported in the 
literature.158 
1H NMR (400 MHz, Chloroform-d) δ 7.39 – 7.26 (m, 5H), 6.94 (brs, 0.5H), 4.96 (brs, 0.5H), 
3.92 (brs, 0.5H), 3.80 (brs, 0.5H), 3.68 – 3.43 (m, 2H), 1.48 (brs, 4.5H), 1.42 (brs, 4.5H). 
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The 1H-NMR is consistent with the reported data.158 
[α]D20 = -63.5ᵒ (c = 0.92, CHCl3). 




HPLC separation: Chiralpak AD-H, n-Heptane/i-PrOH = 95:5, 1.0 mL/min, 218 nm, 





 (R)-3-((tert-butoxycarbonyl)amino)-2-phenylpropanoic acid 
 
 
The amino acid was obtained as white solid (61% yield over two steps). The e.r. was 
determined by the corresponding methylation product.159 
 
HPLC separation: Chiralpak AD-H, n-Heptane/i-PrOH = 95:5, 1.0 mL/min, 218 nm, 
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